Involvement of Pattern Recognition Receptors in Coxsackievirus B Infection of Human Islets by Domsgen, Erna
 
 
 
 
 
 
Involvement of Pattern Recognition Receptors 
in Coxsackievirus B Infection of Human Islets 
 
 
 
 
 
 
 Dissertation  
 
zur Erlangung des Grades eines Doktors der Naturwissenschaften  
 
im Fachbereich Biologie/Chemie  
der Universität Bremen  
 
 
 
 
vorgelegt von  
Erna Domsgen 
 
Bremen, 21.01.2013 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Gutachter: Prof. Dr. Kathrin Mädler 
2. Gutachter: Prof. Dr. Noel Morgan 
 
Erklärung gemäß §6 Abs. 5 der Promotionsordnung  
 
Ich versichere, dass ich die vorliegende Dissertation mit dem Titel „Involvement of Pattern 
Recognition Receptors in Coxsackievirus B Infection of Human Islets“ selbständig verfasst 
und keine anderen als die angegebenen Quellen und Hilfsmittel benutzt habe.  
 
Bremen, den 21.01.2013 
 
 
 
 
Erna Domsgen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I 
 
  Table of contents 
Table of contents .................................................................................................................... I 
Abbreviations ...................................................................................................................... IV 
1 Summary .........................................................................................................................1 
1     Zusammenfassung ...........................................................................................................3 
2 Introduction .....................................................................................................................5 
2.1 Islets of Langerhans ................................................................................................5 
2.2 Diabetes mellitus .....................................................................................................7 
2.2.1 Type 1 Diabetes ..................................................................................................8 
2.2.1.1 HLA class I and II ..................................................................................... 10 
2.2.1.2 Non-HLA genetic factors ........................................................................... 10 
2.2.1.3 Pattern recognition receptors (PRRs) ......................................................... 11 
2.2.1.4 Autoantibodies and immune mediated destruction of ?-cells ...................... 14 
2.3 Viruses in the etiology of T1DM ........................................................................... 17 
2.3.1 Viruses associated with T1DM .......................................................................... 17 
2.3.1.1 Human enteroviruses ................................................................................. 18 
2.3.2 Evidence for human enteroviruses as inducers of T1DM ................................... 20 
2.3.2.1 Cross-sectional and prospective studies ..................................................... 20 
2.3.2.2 Pancreas and in vitro studies ...................................................................... 21 
2.3.3 Possible mechanisms of virus triggered T1DM .................................................. 22 
3 Materials and methods ................................................................................................... 25 
3.1 Isolated human islets and cell lines ........................................................................ 25 
3.2 Viruses .................................................................................................................. 25 
3.3 Plasmids................................................................................................................ 25 
3.4 Inhibitors............................................................................................................... 26 
3.5 Human islet and cell line culture ........................................................................... 26 
3.5.1 Islet treatment and neutralization study .............................................................. 27 
3.6 Virus preparations ................................................................................................. 27 
3.6.1 Production of virus stocks ................................................................................. 27 
3.6.2 Virus purification .............................................................................................. 28 
3.6.3 Virus titration .................................................................................................... 28 
3.6.4 CM cell and human islet infections .................................................................... 29 
3.6.5 Inhibition of JNK and PKR in CM cells and human islets .................................. 29 
II 
 
3.7 Protein analysis ..................................................................................................... 30 
3.7.1 Protein extraction .............................................................................................. 30 
3.7.2 BCA Assay for quantification of proteins .......................................................... 31 
3.7.3 Co-Immunoprecipitation (Co-IP) ....................................................................... 31 
3.7.4 Western blot ...................................................................................................... 32 
3.7.5 Glucose Stimulated Insulin Secretion (GSIS) .................................................... 33 
3.7.6 Human insulin and CXCL10 ELISA ................................................................. 34 
3.8 RNA analysis ........................................................................................................ 34 
3.8.1 RNA isolation ................................................................................................... 34 
3.8.2 RT-reaction ....................................................................................................... 35 
3.8.3 Polymerase chain reaction (PCR) ...................................................................... 35 
3.8.4 Real-Time PCR (qPCR) .................................................................................... 35 
3.8.5 RNA-Immunoprecipitation (RIP) ...................................................................... 36 
3.9 Immunocyto- and histochemistry .......................................................................... 37 
3.10 Human islet transfection ........................................................................................ 38 
4 Results .......................................................................................................................... 40 
4.1 Establishment of CVB infection in isolated human islets ....................................... 40 
4.1.1 CVB3 and CVB4 infect human islet cells and induce cell death ........................ 40 
4.1.2 CVB3 and CVB4 reach high titers in isolated human islets ................................ 42 
4.1.3 ??????????????????????-cell function ............................................................ 43 
4.1.4 ????????????????????-?????????????????????????- ??????????????????????????-cells 
  .......................................................................................................................... 44 
4.1.5 ??????????????????????-cell death ................................................................ 45 
4.2 Induction of inflammation-related genes as result of CVB3 and CVB4 islet 
infections .......................................................................................................................... 48 
4.2.1 In vitro CVB3 and CVB4 infections of human islets induce transcription of 
inflammatory cytokine and chemokine genes ................................................................ 48 
4.2.2 ??????????????????????????????????????????????????????????????-cell apoptosis51 
4.2.3 PRRs are upregulated upon infection of isolated human islets ........................... 52 
4.3 Involvement of PRRs in CVB sensing ................................................................... 54 
4.3.1 CVB3 RNA is sensed by TLR3 and PKR and CVB4 RNA by TLR3, PKR, as 
well as by TLR7 ........................................................................................................... 54 
4.3.2 TLR3 and TLR7 are differentially expressed within human islets ...................... 56 
III 
 
4.3.3 TLR3 depletion decrease cytokine and chemokine gene expression in CVB3 and 
CVB4 infected human islets .......................................................................................... 57 
4.4 ?????????????-cell apoptosis is partially TLR3 and JNK dependent .................... 61 
4.4.1 TLR3 depletion protects from CVB induced apoptosis ...................................... 61 
4.4.2 pJNK as mediator of CVB induced apoptosis .................................................... 63 
4.4.3 PKR does not contribute to virus induced cell death .......................................... 66 
4.5 CVB3 infects the exocrine tissue in mice .............................................................. 68 
5 Discussion ..................................................................................................................... 69 
6 References..................................................................................................................... 78 
7 Appendix ...................................................................................................................... 91 
Acknowledgments .............................................................................................................. 109 
Abbreviations 
IV 
Abbreviations  
 
  
AP-1 Activating protein-1  
APC Antigen presenting cell 
ATF-2  Activating transcription factor 2  
CAR  Coxsackievirus and adenovirus receptor  
CD8+ T-cell T-cell receptors  
CMV Cytomegalovirus 
CPE  Cytopathic effect  
CTLA-4 T lymphocyte-associated protein 4 
CVB  Coxsackieviruses B 
DAF Decay accelerating factor  
DMEM Dulbecco’s Modified Eagle Medium 
ECIT  European Consortium for Islet Transplantation  
????? Eukaryotic translational initiation factor 2-alpha  
ELISA Enzyme-linked immunosorbent assay  
ERK  Extracellular signalregulated kinase  
EV Enterovirus 
FasL  Fas ligand  
GAD65  Glutamic acid decarboxylase 65  
GAD67 Glutamic acid decarboxylase 67 
GLP-1, GLP-2 Glucagon-like peptide-1 and -2  
GLUT2  Glucose transporter 2 
GWAS Genome wide association studies  
HAV  Hepatitis A virus 
HLA II Human leukocyte antigen II 
HSV-1  Herpes simplex virus-1 
IA- 2 Insulinoma-associated antigen 2  
ICA Islet cell antibodies  
IFIH1 Interferon-induced helicase 1  
IFNs  Interferon 
IIDP  Integrated Islet Distribution Program 
???? ???????????? 
IL-1R Interleukin receptor 1  
IL-?? ??????????????? 
Abbreviations 
V 
IL-2  Interleukin 2 
IL-2Ralpha Interleukin 2 receptor alpha 
IL-6  Interleukin 6 
IP Immunoprecipitation 
IP-10  Interferon-?-inducible protein  
IRES  Internal ribosomal entry site  
IRF3 Interferon regulatory factor 3  
ISG´s Interferon stimulated genes 
??? ????????????????? 
JNK  c-Jun N-terminal kinase  
KRB Krebs-Ringer bicarbonate buffer 
LCMV lymphocytic choriomeningitis virus 
LCMV-GP lymphocytic choriomeningitis virus glycoprotein  
LGP2 Laboratory of Genetics and Physiology 2  
LYP lymphoid protein tyrosine phosphatase 
MAVS Mitochondrial antiviral signaling 
MDA5 Melanoma differentiation associated gene-5  
MHC  Major histocompatibility   
MyD88 Differentiation primary response gene (88) 
NDRI National Disease Research Interchange 
NK-cells Natural killer cells 
OAS1  2´-5´-oligoadenylate synthetase 1  
p.i. Post infection  
PAMP  Pathogen associated molecular pattern 
PCR Polymerase chain reaction 
PKR Protein kinase regulated by RNA 
Poly I:C Polyinosine deoxycytidylic acid 
PP Pancreatic polypeptide 
PPI Preproinsulin  
PRR Pattern recognition receptor  
PVDF Polyvinylidene flouride-membrane 
RIG-I Retinoid-inducible gene I  
RIP  Rat insulin promoter  
RLR Retinoid-inducible gene I like receptors 
RT Room temperature 
RT-PCR  Reverse transcription-polymerase chain reaction  
Abbreviations 
VI 
SNP  Single-nucleotide polymorphism  
ssRNA  Single strand RNA 
ssRNA Single-stranded RNA 
T1DM Type 1 Diabetes mellitus 
T2DM Type 2 Diabetes mellitus 
TAK1  ????????????????????????????-activated protein kinase 1  
TBK1  TANK-binding kinase 1 
TCID50 Tissue culture infectious dose 50 % 
TCR  CD8+ cytotoxic T-lymphocyte  
TEDDY The Environmental Determinants of Diabetes in the Young  
TIR Toll/IL-1R 
TLR  Toll-like receptor  
TLR7 Toll-like receptor 7  
???? Tumor necrosis factors ? 
Tregs Regulatory T-cells  
TRIF TIR-domain-containing adapter-inducing interferon-?? 
VNTR´s Variable number of tandem repeats  
VP Viral protein 
VRC vanadyl ribonucleoside complexes  
WHO World Health Organization 
ZnT8 Zink transporter 8  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary 
1 
1 Summary  
 
????? ??????????? ????????????? ??????????-cells are selectively destroyed by the immune 
???????? ??? ???????????? ??? ?-cell destruction insulin levels decline resulting in elevated 
blood glucose levels. The decline ends finally in complete insulin deficiency and 
manifestation of T1DM. At this step patients with T1DM require lifelong insulin therapy. The 
disease is highly associated with genetic susceptibility. The major susceptibility locus for 
T1DM is the HLA II region on chromosome 6. Over the last decades the overall incidence is 
rising especially in children under the age of 5. This increase is too big to be explained by 
genetic factors only, suggesting that environmental factors contribute to the manifestation of 
the disease [1, 2]. T1DM is thought to result from the interaction between genetic 
predisposition, immune system and environmental factors [3]. Such environmental factors 
may be viral infections, which have been associated with T1DM for many years. So far, the 
best investigated viral environmental factors with the best documented connection to T1DM 
are human EVs [4]. Epidemiological studies and analysis of pancreatic tissue samples show 
the clear involvement of EVs and among those, coxsackievirus B (CVB) in T1DM. However, 
the molecular mechanisms of islet infection and how viruses can lead to the disease are still 
not discovered.  
In the present study isolated human islets were infected with two serotypes CVB3 and CVB4 
and molecular mechanisms of infections were investigated. Infections with both viruses 
sho???? ????? ??????? ?-cells were infected ?????? ????????? ??? ????????? ?-cell apoptosis and 
impaired ?-cell function. Gene expression analysis revealed that upon CVB3 and CVB4 
infections genes encoding pro-inflammatory proteins were highly expressed, especially those 
of CXCL10 and ????. Induction of genes encoding cytokines and chemokines is mediated by 
the interaction of PAMPs (pathogen associated molecular patterns), as dsRNA, with 
pathogen recognition receptors (PRRs). The present study showed the binding or CVB3 and 
CVB4 RNA to PKR and in addition to TLR3 and TLR7 which are members of the PRR family. 
This observation was further supported by the RNA interference analysis. TLR3 depleted 
human islets infected with CVB3 and CVB4, showed lower expression levels of cytokine and 
chemokine genes, especially of CXCL10 and IFN? genes, indicating that induction of gene 
expression was TLR3 mediated. In addition, TLR3 depleted and CVB3 and CVB4 infected 
human islets showed less apoptosis, suggesting that the TLR3 pathway was involved in 
virus-?????????-cell death. Further studies on virus mediated apoptosis induction revealed 
that JNK also was involved in cell death.  
High expression of cytokines and chemokines such as CXCL10 contribute to the activation 
???? ???? ??????????? ??? ? ????? ?????? ??? ???? ????? ??? ???? ??????????? ?????????? ?-cells can be 
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????????????????????? ???????? ??? ???????????????????? ?????? ???? ???????? ?-cell antigens. This 
results in activation of cytotoxic T-cells. Both effects can be crucial for the initialization of 
autoimmunity in genetically susceptible individuals. 
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1   Zusammenfassung 
 
Typ 1 Diabetes Mellitus (T1DM) ist eine Autoimmunerkrankung, bei der das eigene 
immunsystem gezielt die ?-Zellen der Langerhans Inseln zurstört. Als Folge der Zerstörung 
wird nicht ausreichend Insulin produziert, um den Glucosespiegel im Blut nach Mahlzeiten zu 
reduzieren und auf einem gesunden Niveau zu halten. Letzendlich führt die ?-Zell Zerstörung 
dazu, dass Betroffene ein Lebenlang von zugefügtem Insulin, in Form von Injektionen, 
abhängig sind. Die Krankheitsurasache hat einen genetischen Ursprung. Es ist etabliert, 
dass bestimmte HLA Allele mit dem T1DM stark assoziiert sind. In den letzten Jahrzehnten 
wurde ein stetiger Anstieg der Krankheitshäufigkeit beobachtet, der nicht durch die Genetik 
alleine erklärt werden kann [1, 2]. Es wird angenommen, dass zusätzlich zu den genetischen 
Faktoren auch Umweltfaktoren eine Rolle spielen und zu dem Anstieg beitragen. Zu den 
Umweltfaktoren zählen Virusinfektionen, die seit vielen Jahren mit T1DM assoziiert sind. 
Verschiedene Studien haben einen Zusammenhang zwischen Enteroviren, die zur Familie 
der Picornaviridae gehören, und T1DM gezeigt [4]. Dabei wurden vorallem Coxsackieviren 
der Gruppe B (CVB) besonders oft assoziiert. Eine Erklärung, wie eine Virusinfektion zum 
Ausbruch des T1DM führen kann, wurde noch nicht beschriben.  
In der vorliegenden Arbeit wurden humane Inseln mit zwei verschiedenen Serotypen, CVB3 
und CVB4, in vitro infiziert und molekulare mechanismen der Infektionen wurden untersucht. 
In der Arbeit konnte gezeigt werden, dass beide Serotypen zu einer ?-Zell spezifischen 
Infektion führen, die wiederum eine Induktion der ?-Zell Apoptose und die beeinträchtigung 
der ?-Zell Funktion zur Folge hatte. Des Weiteren konnte durch Genexpressionsanalysen 
gezeigt werden, dass die Infektionen zu gesteigerten Expressionen der Gene führte, die 
während der Aktivierung des angeborenen und adaptiven Immunsystems, eine Rolle spielen. 
So konnte die höchste Expression der CXCL10 und IFN? Gene beobachtet werden. Eine 
solche Induktion wird durch die Bindung von Molekülen, wie der dsRNA, an sogenannte 
Pattern Recognition Receptors (PRRs) ausgelöst. In der vorliegenden Arbeit konnte gezeigt 
werden, dass die CVB3 und CVB4 RNA Moleküle von der PKR, und den PRRs TLR3 und 
TLR7 gebunden wird. Die TLR3-RNA Interaktionen wurden zusätzlich durch RNA Interferenz 
Studien unterstützt. Inseln, die mittels siTLR3 transfiziert und mit CVB3 und CVB4 infiziert 
wurden, zeigten eine Reduktion der beobachteten Genexpressionen, vorallem der der 
CXCL10 und IFN ? Gene, was eindeutig für eine TLR3 vermittelte Aktivierung des 
angeborenen Immunsystems spricht.  
Des Weiteren, konnte in siTLR3 transfizierten und mit CVB3 und CVB4 infizierten Inseln, 
eine Reduktion der CVB3 und CVB4 induzierten Apoptose beobachtet werden. Weitere 
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Apoptose Untersuchungen zeigten dass neben TLR3 auch die JNK Kinase eine Rolle in der 
Virus induzierten Zell Apoptose spielte.  
Die Induktion der Expressionen von Inflammatorischen Genen und die Induktion der 
Apoptose können beide entscheidene Faktoren bei der Entstehung des T1DM sein. Cytokine 
und Chemokine aktivieren und locken zytotoxische T-Zellen zum Ort der Infektion, wo 
apoptotische Zelle von Antigen presentierenden Zellen phagozytiert werden und so virale 
und ?-Zell Antigene presentiert werden können.  
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2 Introduction 
 
2.1 Islets of Langerhans  
 
The pancreas is a gland organ located partially behind the stomach and in close proximity to 
the spine in the abdomen. It consists of the tail region located close to the spleen, the body 
region and the head region that is connected to the duodenum. The gland has two functional 
parts; the exocrine and the endocrine part. The exocrine part contains acinar cells which 
produce digestive enzymes important for food digestion in the duodenum. They are 
positioned around central ducts that drain into the pancreatic duct allowing the digestive 
enzymes to enter the small duodenum via the major duodenal papilla where they contribute 
to break down carbohydrates, proteins and lipids. The endocrine pancreas is made by the 
islets of Langerhans, first described by the German anatomist Paul Langerhans in 1869. 
They consist of clusters of different hormone producing cells, endothelial cells, nerves and 
fibroblasts. The size of the islets ranges from few to many thousand cells. Islets are scattered 
throughout the whole organ in about 1 million clusters and constitute around 1-2% of the 
mean pancreatic weight. Islets are highly vascularised mini-organs so that produced 
hormones are absorbed rapidly into the blood stream and thus distributed throughout the 
whole body. A collagen capsule around the islets separates the endocrine and the exocrine 
part [5].  
???????????????????????????????????????????????????????????????-cells, insulin producing ?-cells, 
????????????? ?????????? ?-cells, pancreatic polypeptide producing PP-cells and ghrelin 
???????????-cells [6]. All hormones regulate glucose homeostasis. 
Glucagon increases blood glucose levels during starvation. Low levels of blood glucose 
trigger its secretion and hepatic glucose output increases to supply organs with glucose. The 
source of glucose is maintained by glucogenogenesis and glycogenolysis, two mechanisms 
leading to synthesis of D-glucose from carbon substrates like pyruvate, lactate or glycerol 
and to the breakdown of glycogen in glucose respectively [7]. Glucagon is a 29-aminoacid 
peptide that is derived from the 180-aminoacid proglucagon by proteolytic cleavage. Other 
proglucagon cleavage products are glucagon-like peptide-1 and -2 (GLP-1, GLP-2). The 
???????????-cells per islet varies from 15 to 20% [6, 8].  
?-cells build the majority of cells per islet ranging from 50 to 80% [6, 8]. Insulin is secreted by 
the ?-cells in response to high blood glucose levels and acts on different tissues leading to 
glucose uptake from the blood, thus preventing hyperglycemia. It suppresses the glucose 
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output and increases the uptake by the liver and the skeletal muscles. In those organs it 
stimulates glucogenesis and inhibits gluconeogenesis and lipolysis in the fat tissue.  
Glucose molecules are take?????????-cells via the glucose transporter 2 (GLUT2) and are 
phosphorylated by glucokinase, the essential enzyme for gycolysis. During this metabolic 
process glucose is cleaved into 2 pyruvate molecules, which are decarboxylated and added 
to coenzyme A forming Acetyl-CoA, which enters the Krebs cycle. ATP is produced as result 
of the Krebs Cycle and during oxidative phosphorylation, in which electrons are transferred 
from electron donors to electron acceptors. The increase in the ATP/ADP ratio leads to the 
closure of potassium channels which in turn leads to membrane polarization. Consequently, 
calcium channels open and induce the release of insulin by exocytosis of insulin-containing 
granules [9].  
Insulin is generated by cleavage of a preproinsulin molecule composed of an A-chain, B-
chain and a C-chain. Proinsulin is formed by catalytic cleavage of the signal sequence in the 
Golgi apparatus and further cleaved in insulin in maturing granules. Its active form is a 51-
aminoacid protein containing two peptide chains, A-chain and B-chain that are combined by 
two disulfide bonds (Fig. 1) [10]. The C-chain (C-peptide) is released together with insulin at 
a 1:1 ratio.  
 
Figure 1: Posttranslational processing of preproinsulin to mature insulin [10]. 
 
?-cells produce somatostatin, a hormone which inhibits insulin and glucagon release. The 
hormone exists in two forms, a 14 and a 28 aminoacid-peptide. Islets contain only 5-???????-
cells [6, 8].  
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PP-cells produce pancreatic polypeptide (PP), a hormone that is involved in appetite 
regulation after food intake. Its release is mainly stimulated by food intake. PP is under vagal 
control and exerts its regulatory functions in different tissues, including the inhibition of 
digestive enzyme secretion from acinar cells and gallbladder motility. It is a 36 aminoacid-
peptide and belongs to and shares high homology to neuropeptides like neuropeptide Y [11]. 
There are few PP-cells in the islet; islets located in the head part of the pancreas contain 
larger numbers of PP-cells, while there are rarely any PP-cells in the tail part  [12]. 
The last discovered islet cell type are ?-cells which secrete ghrelin hormone acting on growth 
hormone secretion and regulation of metabolism. Little is known about this cell type, and 
further investigations are necessary [6]. 
The architecture of human islets shows a distribution of cell types without any obvious 
organization. ?????? ?????????????? ????????????????????????????-cells form the core of islets 
that is encircled by remaining cell types (Fig. 2) [8]. The most common disease associated 
with islets is Diabetes mellitus. 
 
     Mouse         Human 
        
Figure 2: Comparison of architecture between human and rodent islets. ?-cells are stained in 
????????-??????????????????-cells in blue [8]. 
 
 
2.2 Diabetes mellitus
 
Diabetes mellitus is a disease with high prevalence worldwide. Based on WHO (World Health 
Organization) 347 million people worldwide have diabetes. Studies on estimation of diabetes 
prevalence suggest that this number is expected to double to more than 500 million diabetes 
cases by the year 2030.  
This is mainly due to population growth, longer life expectation, urbanization and increasing 
incidence of obesity and physical inactivity. Especially in developing countries diabetes 
prevalence is expected to increase drastically by 2030 because of demographic change [13].  
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Diabetes mellitus is characterized by abnormal high blood glucose concentrations, 
hyperglycemia. Such elevated blood glucose levels over a long period of time lead to 
microvascular and macrovascular complications. This can result in impairment of neurons 
and blood circulation leading to neuropathy, retinopathy and blindness and nephropathy. The 
risk for stroke is highly increased in patients with diabetes, and poor wound healing and 
perfusion together with neuropathy can lead to the diabetic foot syndrome resulting in limb 
amputation.  
The main causes of hyperglycemia are insufficient blood insulin levels or in case of insulin 
resistance, failure in biological insulin functions. M?????????????????????? ???????????????????-
cells leads to insufficient secretion of insulin to maintain glucose levels in a normal range 
resulting in elevated blood glucose levels. 
The most common forms of Diabetes mellitus are Type 1 Diabetes mellitus (T1DM) and Type 
?? ????????? ????????? ???????? ????? ???????? ????? ????? ????? ???????????? ??? ?-cells and 
displays an autoimmune disorder, while T2DM is considered to result from insulin resistance 
together with the relative insul?????????????????????????????????-cell function and mass.  
 
 
2.2.1 Type 1 Diabetes  
 
T1DM is an autoimmune disease which ????????????????????????????????????????-cells by the 
own immune system, leading to reduced and finally no insulin production. It is estimated that 
approximately 5-10% of all diabetic patients suffer from T1DM [14]. The disease manifests 
itself usually in people younger than 30 years, and it is therefore also termed juvenile-onset 
diabetes. In the last decades the overall incidence is rising, especially in children under the 
age of 5 [1, 2]. During the last 100 years hygiene standards have drastically changed. The 
so-called “hygiene hypothesis” has been proposed as possible explanation for the T1DM 
increase and for allergy development. It suggests that lack of pathogen exposure in 
developed countries leads to malfunction of the immune system and increases allergies and 
autoimmune disorders [15]. This hypothesis correlates very well with the high T1DM 
incidence in children from 0 to 14 years in developed countries (Fig. 3) [16]. A similar 
hypothesis has been suggested for poliomyelitis [17].  
From 1989-2003 the annual increase in T1DM incidence in Europe was 3.9%, and it is 
predicted that T1DM cases in European children younger than 5 years will double between 
2005 and 2020 [18]. This increase is too big to be explained by genetic factors only. The 
concordance rate between monogenetic twins is only ~50% [19]. This implicates that 
environmental factors such as viral infections, early exposure to cow´s milk, wheat proteins 
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or vitamin D insufficiency also contribute to T1DM. The disease is thought to result from the 
interaction between genetic predisposition, immune system and environmental factors (Fig. 
4) [3]. 
 
Figure 3:  Worldwide incidence of Type 1 diabetes. The world map shows the T1DM 
incidence in children from 0-14 years. Numbers account for new cases per year/100,000 individuals. 
Adapted from [16]. 
 
T1DM is strongly associated with genetic susceptibility (poplygenic). The major susceptibility 
locus for T1DM is the MHC class II (major histocompatibility complex class II) or HLA II 
(human leukocyte antigen II) region on chromosome 6p21 or IDDM1 (insulin-dependent-
diabetes mellitus locus) [20]. 
 
 
 
Figure 4: Contributors in T1DM. The interplay between genetic factors, the immune system and 
environmental factors leads to breakdown of self tolerance and outcome of T1DM. Adapted from [21].      
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2.2.1.1 HLA class I and II 
The locus of HLA codes for MHC molecules, class I and class II. MHC class I is expressed 
by all nucleated cells. These complexes present intracellular antigens on their surface-like 
viral epitopes- and are bound by the T-cell receptors (TCR) of CD8+ cytotoxic T-lymphocytes 
(CD8+ T-cells). MHC class II molecules are expressed on antigen presenting cells (APC) like 
dendritic cells, macrophages and B-lymphocytes. They present extracellular antigens to 
CD4+ TCR´s. Genes encoding MHC class I molecules are MHC-A, MHC-B and MHC-C, and 
MHC class II are HLA-DP, HLA-DQ and HLA-DR. Every locus has a high number of variant 
alleles, making the HLA system highly polymorph (Fig. 5). 
 
 
 
Figure 5: Schematic representation of the HLA class I and class II system. Genes coding 
for the MHC class I and II molecules are located on chromosome 6.  
 
The HLA II genotype is a useful determinant to define inherited risk for T1DM. The genotype 
associated with the highest risk tor T1DM is HLA DRB1*03,*04; DQB1*0302 [22-24]. In 
children with these haplotypes and a T1DM relative the risk to develop T1DM is around 25% 
and with two or more affected family members even around 50% [25]. This predisposing HLA 
class II haplotypes are found in around 90% of T1DM cases [24]. 20% of the population have 
the haplotype DRB1*1501-DQA1*0102-DQB1*0602, but only 1% of T1DM patients, 
demonstrating a protective haplotype for T1DM [26]. Susceptibility loci were also found in the 
HLA I region [27-29]. HLA-A*02 increases the risk for T1DM in individuals with the high-risk 
class II DR3/4-DQ8 haplotype [30]. Among those, HLA-A *0201 is one of the most prevalent 
class I alleles, with an incidence rate of around 60% in T1DM patients [22]. Other non-HLA 
genes were also found to contribute to susceptibility. 
 
2.2.1.2 Non-HLA genetic factors 
The insulin gene region itself contributes to T1DM susceptibility. The mutation in the variable 
number of tandem repeats (VNTR´s) of the insulin gene promoter determines the 
susceptibility [31-33]. The number of the VNTR´s correlates with either protection or 
predisposition [33, 34]. It is hypothesized that VNTR´s regulate the insulin expression in the 
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thymus. Less VNTR´s would lead to less insulin gene transcription, which might reduce self 
tolerance and T1DM outcome [35]. 
PTPN22 encoding the lymphoid protein tyrosine phosphatase (LYP) is another T1DM 
susceptibility gene [36]. LYP is expressed in lymphocytes where it acts as a strong 
suppressor of Src family kinases which mediate TCR signaling. It is a strong inhibitor of T-
cell activation [36]. The mechanisms of how LYP leads to autoimmunity are still not fully 
understood [22].  
Genetic risk for development of T1D has also been found in the gene encoding Interleukin 2 
(IL-2) receptor alpha (IL-2Ralpha) [37]. The IL-2R appears in two forms as a moderate 
binding IL-2R not containing the IL-2Ralpha subunit expressed on T-cells, NK-cells (natural 
killer cells), and monocytes, and a high-affinity IL2-R containing the IL-2Ralpha subunit 
expressed on regulatory T-cells (Tregs). IL-2 binding to its receptor provides survival and 
growth of Tregs [38]. Tregs are specialized subsets of T-cells that suppress autoreactivity at the 
peripheral level. In T1DM, abnormalities in Treg function have been reported and implicated in 
the development of the disease [39]. 
Other T1DM susceptibility genes are T lymphocyte-associated protein 4 (CTLA-4), which is 
involved in the regulation of immune response, and Interferon-induced helicase 1 (IFIH1) that 
has been identified in genome wide association studies (GWAS) [22, 40]. IFIH1 encodes 
melanoma differentiation associated gene-5 (MDA5) that acts as an intracellular pattern 
recognition receptor (PRR) for viral double stranded RNA (dsRNA). Upon binding to dsRNA, 
MDA5 interacts with the adaptor protein mitochondrial antiviral signaling (MAVS) to induce 
type I interferons (IFNs) [41, 42]. GWAS demonstrated rare variants protecting from T1DM, 
whereas the majority of the population carries alleles predisposing to the disease [40]. IFIH1 
variants identified to be protective are encoding MDA5 proteins with reduced function due to 
truncation or failure in splicing [40, 43].  Other candidate genes that can have a function in 
host response against viruses are toll-like receptor 7 (TLR7) and TLR8 that recognize single-
stranded RNA (ssRNA) molecules from different viruses and initiate the upregulation of type I 
IFNs. A single-nucleotide polymorphism (SNP) in TLR7 and TLR8 has been associated with 
the risk for T1DM [44].  
 
2.2.1.3 Pattern recognition receptors (PRRs) 
Microorganism trying to invade hosts need to be detected and eliminated. During evolution, 
different detection receptors, so-called PRRs, developed to sense the invaders. In case of 
RNA viruses, dsRNA and ssRNA serve as pathogen associated molecular patterns (PAMPs) 
for specialized PRR´s to induce the first line of defence, the innate immune response. This 
includes upregulation and secretion of chemokines and cytokines like type 1 IFNs that in turn 
induce upregulation of many interferon stimulated genes (ISG´s) which have antiviral 
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properties to eliminate infection. The antiviral receptors or sensors are classified in two 
groups toll-like receptor (TLR) family members and retinoid-inducible gene I (RIG-I) like 
receptors (RLRs).  
TLRs are type I transmembrane proteins consisting of extracellular leucine-rich-repeats 
responsible for binding of PAMPs, a transmembrane region and a cytosolic domain 
homologous to the interleukin receptor 1 (IL-1R) named Toll/IL-1R (TIR) domain [45, 46]. So 
far 10 TLRs are identified in humans which are responsible for the detection of distinct 
PAMPS derived from viruses, bacteria, fungi, parasites and mycobacteria. They are located 
in cellular membranes or in intracellular vesicles like endosomes, the endoplasmatic 
reticulum, lysosomes or endolysosomes [45, 47]. Binding of distinct PAMPs to TLRs results 
in the recruitment of adapter proteins such as myeloid differentiation primary response gene 
(88) (MyD88) or TIR-domain-containing adapter-inducing interferon-? (TRIF) to the TIR 
domain and induction of a signal cascade inducing secretion of inflammatory cytokines, 
chemokines and type I IFN through translocation of the transcription factors NF-??? ????
interferon regulatory factor 3 (IRF3) and IRF7 [45, 46]. 
Viral dsRNA or the synthetic analogue polyinosine deoxycytidylic acid (Poly I:C) are 
recognized by TLR3, whereas ssRNA is bound by TLR7 and TLR8 [45, 48] . Upon binding of 
dsRNA or Poly I:C to TLR3, TRIF and other adaptor proteins associate with the intracellular 
region TIR leading to phosphorylation of TRIF. This results in TRIF dependent 
phosphorylation of TANK-???????? ??????? ?? ??????? ???? ???? ??????? ?? ??????? ???????? ???
phosphorylation and translocation of IRF3 and IRF7, which are critical transcription factors in 
type 1 IFN induction [49]?? ????? ??? ????????? ????? the ?????????? ??? ??? ?????? ???? ??? ?????
dependent activation of ????????????????????????????-activated protein kinase 1 (TAK1) and 
the IKK comple?? ???????? ???????????????? ???? ??????????????? ??? ????? ????????? ?????
translocates to the nucleus where it induces type 1 IFN and inflammatory cytokine gene 
expression (Fig. 6) [50, 51]. Simultaneously, TAK1 activates the MAP kinase pathway 
resulting in activation of the transcription factor activating protein-1 (AP-1) composed of c-
Jun and activating transcription factor 2 (ATF-2). MAP kinases involved in this pathway are c-
Jun N-terminal kinase (JNK), p38 and extracellular signalregulated kinase (ERK) [52].  
Another feature of TRIF in TLR3 signalling is its induction of apoptosis as important antiviral 
action restricting the spreading of viruses [53, 54]. Binding of ssRNA to TLR7 recruits the 
essential adapter protein MyD88, which together with other adaptor proteins leads to TLR3 
signalling ??????????????????????????????????????????????????????????????????????????????????
IRF translocation [45, 47]. 
RLRs are intracellular dsRNA sensors which include MDA5, RIG-I and Laboratory of 
Genetics and Physiology 2 (LGP2) and contain a DExD/H-box RNA helicase domain. After 
binding to dsRNA, RIG-I and MDA5 interact with the mitochondrial adaptor protein MAVS 
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[55-57]?? ????? ????????? ???? ??????????? ??? ????? ???? ????, resulting in phosphorylation and 
translocation of IRF3 and IRF7 to the nucleus. ??????????????? ??? ????????? ????? ???? ???a 
MAVS dependent fashion (Fig. 6) [57, 58].  
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Figure 6: Induction of type I interferons upon binding of PRR to dsRNA and ssRNA. dsRNA or 
ssRNA, which can be present in the endosomes after uncoating of the viral capsid, bind to TLR3 or 
TLR7 leading to recruitment of adaptor proteins TRIF and MyD88. This activates IKKs and TBK1, 
resulting in phosphorylation and dimerization of IRF3 and degradation of IkB, leading to translocation 
of the transcription factors into the nucleus wh???? ????? ??????? ????????????????????????? ??????????
hand intracellular PRR RIG-I and MDA5 can bind to intracellular dsRNA and activate IKKs and TBK1 
in a MAVS dependent fashion leading also to translocation of IRF3 and NFkB. 
 
Protein kinase regulated by RNA (PKR) is an IFN-inducible, dsRNA binding antiviral protein. 
Its antiviral property is mediated trough translational stop after infection. dsRNA binding 
leads to dimerisation and phosphorylation of PKR. Activated PKR is phosphorylating 
eukaryotic translational initiation factor 2-?????? ???????? ???????? ??? ???????? ??????????? ???
translation [59]. PKR has been shown to be involved in insulin resistance through 
phosphorylation of the insulin receptor and activation JNK [60].  
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2.2.1.4 Autoantibodies and immune mediated destruction of ?-cells 
The etiology of T1DM is very complex. It is still under investigation how genetic susceptibility 
????????????????????????????????????? ??? ?????????-cells and finally to the onset of the disease. 
T1DM is characterized as an autoimmune mediated disease with ??????????????????????????-
cells by islet infiltrating immune cells, a process also called insulitis. Environmental factors as 
pathogens can be triggering events responsible for autoimmunity. The first indication of self 
reactivity and autoimmunity in T1DM is the appearance of autoantibodies. Insulitis can 
persist for years before clinical symptoms occur (Fig. 7). 
Autoantibodies can be present in the sera of individuals many years before diabetes onset. 
Until now four groups of autoantibodies binding to islet antigens are identified recognizing 
preproinsulin (PPI) and insulin, glutamic acid decarboxylase 65 or 67 (GAD65 or GAD67),  
insulinoma-associated antigen 2 (IA-2) and zink transporter 8 (ZnT8). Other islet-specific 
antibodies exist which are called islet cell antibodies (ICA) [23]. Those four different groups 
of autoantibodies are used as biomarkers to predict the risk for T1DM progression in children 
and young adults with and without family history [61, 62]. Thereby mostly the number of 
different autoantibody groups determines the risk. The presence of one autoantibody raises, 
but two or more autoantibodies markedly increase the risk for T1DM [23]. 
 
 
 
 Figure 7: Pathogenesis of T1DM. In genetic susceptible individuals, triggering events like 
environmental factors such as pathogen infections can lead to the appearance of autoantibodies. In 
the pre-diabetic state autoreactive CD8+ destroy the ?-cells T1DM manifests after destruction of ~70-
80% the ?-cells. 
 
Autoantibodies can appear in the early stage long before the onset of the disease, indicating 
involvement of plasma B-cells in the initial phase of the disease. T1DM susceptibility or 
resistance HLA II genotypes are mapped to peptide binding pockets of the MHC class II 
receptors present on APC [63]. B-cells are APC that become plasma B-cells producing and 
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secreting antibodies upon activation. Indeed, a study by Pescovitz et al. showed that B-
lymphocytes contribute to the pathogenesis of T1DM, since application of an anti-CD20 
monoclonal antibody rituximab ?????????? ?-cell function. CD20 is present on B-cells until 
plasma B-cell differentiation and the application of anti-CD20 monoclonal antibody rituximab 
can selectively deplete B-lymphocytes [64].  
Another hallmark of prediabetic stage and early onset of T1DM are autoreactive T-cells. 
CD8+ T-cells are thought to be ????????? ? ?????????-cell killers [65]. APCs such as B-cells 
can actively contribute to autoimmunity by presenting autoantigens to diabetogenic CD4+ and 
CD8+ T-cells [22]. The main autoreactive T-cell epitopes are also the major antibody targets, 
namely proinsulin and PPI, GAD65, IA-2 and ZnT8 [66]. Autoreactive CD8+ T-cells can 
?????????-cells upon binding to MHC class I molecules which are shown to be upregulated on 
?-cells in CD8+ T-cell infiltrated islets from T1DM patients [67].  
Recent immunohistochemical investigations of a collection of samples confirmed pre-existing 
observations and gave more insight into chronological events. Modern immunohistochemical 
techniques were applied on old samples from 29 patients with  recent onset T1DM collected 
from 1960 to 1985 [68]. ????????????????????????????????????????????????????????????-cell mass 
in different categories from islets with normal ?-cell mass to islets where only very few or no 
?-cells were present. CD8+ T-cells were the most prominent immune cells in insulitis and the 
cell number correlated with the ??????? ??? ?-cell demise. Macrophages followed the same 
??????????????????????????????-cell death. CD20+ B-cells were present in low number but were 
??????????????????-cell demise. CD4+ T-cells were present with no increase in number at any 
stage and Tregs were not present in inflamed islets. ?-cell deficient islets showed no infiltration 
of immune cells or any signs of insulitis [69]. 
Programmed cell death or apoptosis is probably ??????????????????-cell death in T1DM [70]. 
?-cell loss during insulitis is most likely caused by direct contact with CD8+ T-cells or 
macrophages. Upon ligation of the TCR with MHC class I molecules, CD8+ cytotoxic T-cells 
induce apoptosis through release of granules containing perforin and granzymes. Perforin is 
introducing holes in the target cell membrane allowing granzymes to enter the cytosol where 
they can activate caspases and nucleases, the main apoptotic effector proteins. Another 
possibility is the ligation of Fas expressed on target cells with Fas ligand (FasL) present on 
T-cells. Fas/FasL interaction leads to activation of intracellular proapoptotic proteins and 
consequently to cell death [70, 71]. Macrophages and other immune cells can induce 
secretion of proinflammatory cytokines like IL-?????????????????????????????????????????????????
cytokine induced cell death [72, 73] (Fig. 8).  
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Figure 8: ????????? ??????????? ??? ?-cell death. A: CD8+ T-????? ????????? ??????????? ?-cell 
????????? ?????????? ??? ???? ?? ??? ?-cells. Apoptosis can be induced via perforin or the Fas/FasL 
system. B: CD4+ or CD8+ T-?????????????????-cell antigens presented by APC´s. This results in ? -cell 
killing possibly through (i) the Fas/FasL system, (ii) secretion of soluble death mediators like IL-6, 
??????IL-???????????????????????????????????????????????? ????????????????????????????????stimulation of 
secretion of soluble cell death mediators ????-cells [74]. 
 
The triggers which induce the initial autoimmune process leading to appearance of 
autoantibodies are still largely unknown. The precipitating event must include ????????????-
??????????????????????-cell death ??????????????-cell antigen presentation by APC.  
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2.3 Viruses in the etiology of T1DM 
 
Accumulating evidence suggests viral infections as inducers for T1DM. Infections can lead to 
activation of the innate and adaptive immune system and local inflammation. IFIH1 encoding 
a sensor protein for dsRNA molecules which are generated during certain RNA virus 
replication, has been identified as a susceptible gene for T1DM [40]. Epidemiological data 
imply that T1DM onset follows a seasonal pattern which strongly correlates with viral 
infections [75].  During the last decades many different viruses have been associated with 
the induction of T1DM.  
 
 
2.3.1 Viruses associated with T1DM 
 
Scientific observations connect different virus infections with T1DM. Among those, mumps 
virus was one of the first viruses associated with T1DM due to a case of diabetes onset after 
mumps infection in 1898. Infections were also connected with the appearance of 
autoantibodies [75] and recently mumps infection was implicated in a fulminant T1DM case 
[76]. However, vaccination programs against mumps had no impact on the rise of T1DM [77].  
Rotaviruses were investigated due to sequence homologies between rotavirus proteins and 
autoreactive T-cell epitopes IA-2 and GAD, suggesting possible cross-reactivity between 
rotavirus and islet antigens [78]. Studies in Australian children at risk to develop T1DM 
showed increased frequency of islet autoantibodies soon after rotavirus infection [79]. 
However, this was challenged by a study in children at risk from Finland where no 
association between autoantibodies and rotavirus infection was observed [80]. Finland is the 
country with the highest T1DM incidence rate.  
Approximately 20% of patients suffering from the congenital rubella syndrome develop T1DM 
in their life. However, it is thought that rubella infection does not contribute to autoimmunity 
but leads ???????????????????????????????-cell mass. Vaccination programs against rubella 
almost eliminated the virus, suggesting that it is not involved in recent T1DM increase [77].  
Cytomegalovirus (CMV), a member of the herpes virus family, has also been associated with 
T1DM. The first connection was observed in a child that developed T1DM after suffering from 
congenital CMV infection. Studies of patients with T1DM and their healthy siblings showed a 
strong correlation between autoantibodies and anti-CMV antibodies [81]. However, further 
studies failed to correlate CMV with autoantibodies or T1DM [75].  
So far, the best investigated viral environmental factors with the most strongly documented 
connection to T1DM are human enteroviruses (EV) [4]. 
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2.3.1.1 Human enteroviruses 
Epidemiological and serological studies have linked human enteroviruses, and among those 
especially CVB (group B coxsackieviruses), to the etiology of T1DM [15].  
The EV genus belongs to the large family of Picornaviridae. Among this genus human EV 
are classified in different species namely human EV-A, human EV-B, human EV-C and 
human EV-D. The six different serotypes of CVB1-6 belong to the human EV-B species [82].  
Human EV consists of non-enveloped virus particles having an icosahedral shape and a size 
of 25-30 nm. The viral capsid is built up by four different viral structural proteins, viral protein 
1 to 4 (VP1 to VP4). VP1, VP2 and VP3 form the surface of the capsid while VP4 is located 
in the inner surface (Fig. 9A). Particles contain a positive-sense single strand (ss) RNA 
(+ssRNA) genome of about 7500 bp which is linear, not segmented and can be directly 
translated after infection. The genome codes for structural as well as non-structural proteins 
and is flanked by 5´- and 3´- noncoding regions (Fig. 9B).  
Human EVs enter cells through distinct receptors resulting in endocytosis of the particle, 
uncoating of viral proteins and release of +ssRNA into the cytoplasm. The translation of the 
+ssRNA occurs in a 5´-cap independent fashion. Instead, EVs possess an internal ribosomal 
entry site (IRES) at the 5´end, which serves to initiate translation of the RNA to a large 
polyprotein. This is processed by autocatalytic cleavage resulting in different structural and 
non-structural proteins. The virally encoded RNA-dependent-RNA polymerase performs RNA 
replication, which takes place in the replication complex at the outer surface of virus-induced 
membrane vesicles. During this step dsRNA is formed as a replication intermediate. 
Generated minus sense single strand RNA (-ssRNA) serves as template for the synthesis of 
new +ssRNA molecules. Newly synthesized particles are probably released due to cell lysis 
(Fig. 9C) [83]. 
A  
 
B 
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Figure 9: Enterovirus structure and replication. A: The viral capsid has an icosahedral shape and 
consists of four different viral structure proteins VP1 to VP4. B The viral genome is ssRNA which is 
flanked by 5´- and 3´- noncoding regions. It codes for structural and nonstructural proteins. C The 
virus enters the cell by receptor mediated endocytosis. Viral RNA is released into the cytoplasm where 
it can be directly translated into the polyprotein which is autocatalytically cleaved into different 
proteins. For viral RNA replication -ssRNA needs to be generated that serves as template for further 
+ssRNA replication. RNA encapsidation and assembly of viral proteins leads to formation of new viral 
particles that are released.  
 
The transmission between individuals occurs through the fecal-oral route. Most infections are 
asymptomatic or lead to mild respiratory syndromes. In some cases virus can spread to other 
organs and lead to severe disease. CVB infection is the most common infectious cause for 
myocarditis and delayed cardiomyopathie. In addition, CVB infection can cause meningitis, 
encephalitis pancreatitis and T1DM [84]. 
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2.3.2 Evidence for human enteroviruses as inducers of T1DM  
 
2.3.2.1 Cross-sectional and prospective studies 
The first evidence for a connection between EV and the etiology of T1DM arose from studies 
by Gamble et al. in 1969, showing higher concentrations of neutralization antibodies against 
CVB in the serum of recent onset patients compared to controls [85]. Ten years later CVB 
was strongly linked to diabetes based on the finding by Yoon et al. who isolated the CVB4 
from the pancreas of a 10 year old boy who died due to ketoacedosis in 1979 [86]. Another 
study tested the serum of recent onset patients for the presence of antibodies against 
different viruses and found the most significant association with CVB [87]. Human EV RNA 
was detected in 64% of children at onset of diabetes compared to 4% control children using 
the reverse transcription-polymerase chain reaction (RT-PCR) technique. The sequences of 
human EVs detected in positive patients showed strong homology to CVB3 and CVB4 [88]. 
Other cross-sectional studies found human EV RNA in the blood of T1DM patients, again 
linking EVs to T1DM [89]. 
These studies suggest that human EV and especially CVB are associated with autoimmunity 
and T1DM. But it is still not clear whether infections cause autoimmunity or T1DM or whether 
EV infections are more frequent in T1DM patients, possibly due to weaker immune response. 
To answer this question, prospective studies were carried out. The advantage of such 
studies is that patients can be followed up for a long period of time until disease occurs. The 
timing between the appearance of viral infections and the development of autoantibodies can 
be analysed. Prospective studies in the Finnish population showed that human EVs were 
more frequent in children who developed diabetes later in life [90-94]. However, other 
prospective studies from Germany or the USA showed no association of EV infection in 
autoantibody positive children [95, 96]. These findings can be due to differences in 
methodology or population. Scientists hope to gain more knowledge from large international 
studies such as The Environmental Determinants of Diabetes in the Young (TEDDY) which is 
currently in progress [89]. Cross-sectional and prospective studies can be additionally 
complicated by the fact that infections can be “hit and run” effects and therefore difficult to 
determine. For more details about prospective studies see reference [97].  
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2.3.2.2 Pancreas and in vitro studies  
In addition to cross-sectional and prospective studies, direct evidence for the association of 
human EV infection and diabetes comes from observations of pancreatic tissues from T1DM 
patients.  
Positive EV VP1 immunostaining was observed in the gut mucosa, which is closely located 
to the pancreas, in patients with T1DM [98], showing a virus reservoir in close proximity to 
the pancreas. However, this could not be confirmed in a recent study [99]. Richardson et al. 
showed the presence of VP1 immunostaining in ?-cells in more than 60% of patients with 
recent-onset T1DM and in only 6% of control patients. In addition, VP1 positive cells were 
also positive for PKR, a kinase involved in antiviral defence, indicating that virus induces 
signal transduction in infecte???-cells [100]. This was also confirmed by Dotta et al. showing 
specific VP-1 colocalization in ?-cells in pancreatic tissues from T1DM patients, suggesting a 
?-cell specific infection in vivo. The isolated and sequenced virus was CVB4 [101]. EVs were 
also detected in ?-cells in cases of fulminant T1DM [102].  
All CVBs use one major receptor coxsackievirus and adenovirus receptor (CAR) to enter the 
cell, but decay accelerating factor (DAF), also called CD55, was also reported [103, 104]. 
Immunostaining of post mortem pancreatic tissues from a donor positive for islet 
autoantibodies showed CAR expression solely colocalizing with Islet cells, while the exocrine 
tissue showed no CAR expression. Islets in this study were VP1 positive [105]. The restricted 
expression of the coxsackievirus receptor CAR can contribute to virus tropism [102, 106]. A 
recent meta-analysis of 33 prevalence studies in which virus infection was detected  by 
various molecular methods like RT-PCR, in situ hybridization, or immunostaining showed a 
significant association between EV infection and islet autoimmunity or T1DM [107]. 
In summary these findings show the presence of human enteroviruses including CVB in 
islets from post-mortem pancreatic tissue of T1DM, patients implicating a direct role of islet 
CVB infection in T1DM. This indicates that virus particles can reach the pancreas and that 
infection occurs specifically in islets ???? ?-cells which express the CVB receptor CAR. 
Although human EVs are linked to T1DM, and serotypes belonging to human EV-B species 
were found to be associated with T1DM and can be responsible for T1DM outcome in at 
least some cases, no specific causative virus serotype or strain has been identified yet.  
To investigate mechanisms underlying human EV infection of human islets, in vitro studies 
were performed on isolated human islets infected with different serotypes and strains of 
human EVs. Most of the analyzed human EVs, especially CVB, efficiently infect and replicate 
in isolated human islets, reaching high titres in a period of about 24h [108]. Different 
serotypes of CVB induce destruction of islet cells indicated by loss of islet integrity and 
rounded cells detaching from the whole islets, a condition also called cytopathic effect (CPE) 
[109]. In addition ????-cell destruction, adequate ?-cell response to glucose challenge was 
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impaired after infection with different human EVs [110]. The property of virus replication and 
subsequent islet cell destruction is not only serotype specific, it also varies in different virus 
stains [108]. 
To investigate changes in gene expression patterns after CVB infection, microarray studies 
were carried out. Human islets infected with CVB3, CVB4 and CVB5 showed increased 
expression levels of genes specifically linked to inflammation and antiviral defence. 
Inflammatory cytokines and chemokines like IL-1b, IL-6, IL-8, CXCL10 (IP-10), CX3CL1 
(fractalkine), CXCL1 (MIP-???????????????-???????????????-??????????(ENA78), CXCL11 
(I-TAC), CCL8 (MCP-2), CCL5 (RANTES), CCL3 (MIP-???? ???? ????? ????-???? ?????
significantly increased upon infection as well as IFN-??? ?? ??????? ?????????? protein; an 
increased secretion of some of those cytokines and chemokines was also confirmed [111-
113].  
Genes involved in dsRNA recognition like TLR3, RIG-I and MDA5 as well as ISGs, which act 
as antiviral proteins like PKR and 2´-5´-oligoadenylate synthetase 1 (OAS1) were shown to 
be upregulated upon infection [113]. An additional study performed by Ylipaasto et al. 
showed upregulation of MHC class I molecules and several other genes involved in the 
antigen presentation and processing. Genes involve?? ??? ?-cell function like glycolysis and 
insulin secretion were downregulated suggesting a role in impaired insulin secretion [114].  
In summary, those studies show that infection of human islets initiates an antiviral response 
including MHC class I, IFN and inflammatory cytokine and chemokine expression and 
secretion which in vivo can contribute to attraction of immune cells and autoimmune 
????????????????-cells initiating T1DM.  
 
 
2.3.3 Possible mechanisms of virus triggered T1DM   
 
Although human EVs and especially CVB are associated with autoimmunity or T1DM, the 
mechanism how infections contribute to accelerate or trigger T1DM is not yet well 
established.  
Direct i?????????????-cells can result in ce??????????????????????????????????-cell mass resulting 
in diabetes in a non autoimmune fashion. This form of diabetes induction can probably be 
responsible for rare cases of fulminant T1D [75].  
Another possible mechanism that has been proposed is induction of autoimmunity due to 
molecular mimicry which has been implicated in autoimmune stromal keratitis following HSV-
1 (herpes simplex virus-1) [115]. This term describes a condition where TCR of T- and BCR 
of B-cells recognize an epitope from pathogens which shares similarity to self epitopes 
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resulting in cross-reactivity. In this case immune cells directed against a pathogen can cross-
react with self antigens leading to autoimmunity. It was shown that the CVB4 non-structural 
protein 2C shares similarities with GAD65 [116]. It was suggested that those similarities 
result in cross-reactivity leading to autoimmunity and T1DM [117, 118]. However, studies 
performed in mice failed to establish a relationship between molecular mimicry and 
autoimmunity [119]. In addition, studies on autoreactive T-cell clones specific for GAD65 
failed to proliferate upon viral epitope stimulation [120].  
Autoimmune disease can result from “bystander activation”. This concept has also been 
applied as mechanism in virus induced T1DM. Damage of ?-cells and release of sequestered 
islet antigens can induce autoantigen presentation by activated APC. Here the APC presents 
?-cell antigens to pre-existing autoreactive T-cells resulting in bystander activation and 
proliferation. This can lead further to autoimmune ????????????????-cells by autoreactive T-
cells [115]. Accordingly, it has been shown in mice that phagocytosis of ????? ??????????-
cells by macrophages lead to an increase in islet antigen presentation which was associated 
with T1DM [121]. Release of soluble inflammatory factors can induce bystander damage of 
non infected cells in a T-cell independent fashion [122].  
The initial damage of ?-cells resulting in uptake and presentation of autoantigens by APC 
seems to be crucial in initiation of autoimmunity. Damage ????-cells can occur through limited 
?-cell infection or through inflammatory factors secreted ??? ? ????? ?????? ??? ?-cells 
themselves.  
During an infection of cells the first line of defence is the induction of the innate immune 
system. This defence system consists of different receptors called PRR´s which bind to 
molecules that are normally not present in the extracellular space or in the cell called 
PAMPs. The engagement of PAMPs with PPRs results in the induction of an innate immune 
response [123]. In the case of human EV infection, specialized PRRs recognize dsRNA. This 
results in upregulation of chemokines and cytokines, and among those type I IFNs. 
Upon EV infection in vitro, interferon-?-inducible protein (IP-10) or CXCL10 is secreted from 
human islets [113, 124]. CXCL10 attracts CXCR3 expressing cells like activated T-cells, 
monocytes and natural killer cells and thus initiates immune attraction during insulitis [125]. 
In T1DM CXCL10 serum levels are elevated in newly diagnosed and in patients with high risk 
to develop the disease [126-128]. Immunohistochemical staining of pancreatic sections from 
?? ????????? ????? ??? ?????? ????? ??????? ????????? ??? ???? ???? ?-cell specific CXCL10 
expression. In addition, islets were infiltrated by CXCR3+ T-cells and CXCL10 serum levels, 
were elevated suggesting a key role for CXCL10 in insulitis [102]. A study performed in mice 
showed that LCMV (lymphocytic choriomeningitis virus) infection of RIP-GP mice  leads to 
early expression of CXCL10 in the pancreas and induction of T1DM, which was prevented by 
application of CXCL10 neutralizing antibodies, demonstrating a role of CXCL10 in virus 
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induced T1DM [129]. RIP-GP mice are transgenic mice expressing the lymphocytic 
choriomeningitis virus glycoprotein (LCMV-GP) under the control of the rat insulin promoter 
(RIP) resulting in expression of LCMV-???????-cells). 
? ??????????????????????????????????????????? ????????????????????????????????????? [101]. 
Type 1 IFNs are potent inducers of MHC class I molecules. In 1987, Foulis et al. showed 
hyperexpression of ???? ?????? ?? ?????????? ???? ???? on islets of a recently diagnosed 
diabetic child [130]. This has been confirmed by other studies showing hyperexpression of 
MHC class I in inflamed islet cells of T1DM patients. No such observations were made in 
healthy individuals [131]. ????? ???? ??????????? ??? ???? ?????? ?? ?????????? ??? ?-cells the 
destruction by CD8+ T-cells would be very efficient. A model of virus induced T1DM is still not 
established and needs further investigation.  
The aim of this study was to investigate possible consequences of in vitro infection of islets 
with CVB3 and CVB4.  
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3 Materials and methods 
 
3.1 Isolated human islets and cell lines  
 
Isolated human islets were obtained through the European Consortium for Islet 
Transplantation (ECIT) – Islet for Basic Research program and through the Integrated Islet 
Distribution Program (IIDP), administered by the ABCC, and supported by NCRR, NIDDK, 
JDRF and the Chicago Diabetes Project. Human pancreatic sections were provided by the 
National Disease Research Interchange (NDRI). 
Mouse pancreatic sections were kindly provided by Brigitte Glück, Universitätsklinikum Jena. 
Germany. 
Human insulinoma CM cell line was kindly provided by Dr Paolo Pozzilli, Barts and the 
London School of Medicine, Queen Mary, University of London, UK.  
The fetal rhesus monkey kidney cell line FRhK-4 was kindly provided by Prof. Dr. Andreas 
Dotzauer, Institut für Virologie, University of Bremen, Germany. 
 
3.2 Viruses 
 
Hepatitis A virus PI (HAV PI), Cytomegalovirus, (CMV), coxsackievirus B2 (CVB2), CVB3 
(Nancy) and CVB4 (JVB) were kindly provided by Prof. Dr. Andreas Dotzauer, Institut für 
Virologie, University of Bremen, Germany. 
 
3.3 Plasmids 
 
pcDNA3-Flag Jnk1a1 (apf) (dnJNK) plasmid was purchased from addgene. The plasmid 
codes for the dominant negative JNK1 isotype with a FLAG-tagg. The phosphorylation motif 
Thr(183)-Pro-Tyr(185) was replaced with Ala-Pro-Phe, which resulted in an inactive form of 
JNK1. 
pEGFP-N2 plasmid encodes a red-shifted variant of wild-type green fluorescent protein 
(GFP) which has been optimized for brighter fluorescence and higher expression in 
mammalian cells. 
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3.4 Inhibitors 
 
The JNK inhibitor SP600125 (Sigma Aldrich, Steinheim, DE) is a reversible ATP-
competitive inhibitor.  
2-Aminopurin (2-AP) (Sigma Aldrich, Missouri, USA) is a highly mutagenic base analog. It 
inhibits the PKR kinase activity due to interaction with the ATP-binding site.  
PKRi (Calbiochem, San Diego, CA) is an imidazolo-oxindole compound that acts as a potent 
ATP-binding site directed inhibitor of PKR. 
Protease and phosphatase inhibitor (100x HaltTM Protease and Phosphatase Inhibitor 
Cocktail, Thermo Scientific, Bonn, Germany) was diluted to 1x in protein-lysis buffer. 
 
3.5 Human islet and cell line culture 
 
Obtained islets were normally approximately 95 % viable and 85 % pure, as assessed after 
islet isolation. After arriving isolated human islets were centrifuged and washed in CMRL-
1066 (Gibco, life technologies, UK) medium. Isolated human islets were cultured on 
extracellular matrix coated dishes (ECM) from bovine corneal endothelial cells (Novamed, 
Jerusalem, Israel) in CMRL-1066 containing 5.5 mM glucose supplemented with 10% FBS 
(PAA Laboratories GmbH Pasching, Austria), 2 mM L-glutamine (PAA Laboratories GmbH 
Pasching, Austria), 100 U/ml penicillin (PAA Laboratories GmbH Pasching, Austria) and 0,1 
mg/ml streptomycin (PAA Laboratories GmbH Pasching, Austria) (complete media) at 37°C 
and 5 % CO2. To allow islets to attach to the surface, islets were cultured for two to three 
days before experiments were started.  
 
Cell lines 
CM cells were cultured on 10 cm tissue culture dishes and maintained in RPMI-1640 (PAA 
Laboratories GmbH, Pasching, Austria) supplemented with 10 % FBS, 2 mM L-glutamine, 25 
mM Hepes (Sigma Aldrich, Steinheim, DE), 1 mM sodium pyruvate (Sigma Aldrich, 
Steinheim, DE), 100 U/ml penicillin and 0,1 mg/ml streptomycin (complete media) at 37°C 
and 5 % CO2. Every three to five days cells were split at a ratio of 1:3. Firstly, cells were 
washed with PBS (140 mM NaCl, 2.7 mM KCl, 6.5 mM Na2HPO4 and 1.5 mM KH2PO4, pH 
of 7.4 was adjusted with HCl) followed by incubation with trypsin/EDTA (PAA Laboratories 
GmbH Pasching, Austria) for 3 to 5 min at RT (room temperature). Detached cells were 
resuspended in complete RPMI media and seeded on new tissue culture dishes. Media was 
changed every two days. For western blot experiments detached cells were counted using 
the Neubauer chamber and around 2.5 x 105 cells were seeded per 35mm dishes.  
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FRhK-4 cells were cultured on 80 cm2 tissue culture flasks in DMEM (Dulbecco’s Modified 
Eagle Medium) (Sigma Aldrich, Steinheim, DE) supplemented with 1% FBS, 100 U/ml 
penicillin and 0,1 mg/ml streptomycin at 37°C 5 % CO2 (maintenance media). Media was 
changed twice weekly. Every seven to ten days cells were split at a ratio of 1:8. Therefore 
cells were firstly washed with trypsin/EDTA following incubation with trypsin/EDTA for 5 to 10 
min at 37°C and 5 % CO2. Detached cells were resuspended in DMEM containing 10 % FBS 
(growth media) and placed in new tissue culture flasks. Next day, media was changed to 
maintenance media which contained 1 % FBS. For titration assays FRhK-4 cells were 
seeded in 96-well plates and for virus stock preparations on 180 cm2 cell culture flasks at a 
ratio of 1:6. 
 
3.5.1 Islet treatment and neutralization study 
 
Isolated human islets were treated with 1, 5, 10, 50, 100, or 500 U of ???????????? ???? 
(Antigenix America, NY, USA). 24 h after treatment cells were lysed and RNA was extracted.  
For the CXCL10 neutralization study isolated human islets were pre-treated for 1 h with 
10 µg/ml CXCL10 antibody MDX1100 (Medarex) or with the same concentration of human 
IgG (Medarex) before infection. After infection islets were treated the same way with same 
concentrations. 
Treatment of islets with 25 µg Poly I:C (Sigma Aldrich, Sigma Aldrich, Steinheim, DE) for 
24 h was used to induce expression of pro-inflammatory genes. 
 
 
3.6 Virus preparations 
 
3.6.1 Production of virus stocks 
To produce sufficient amount of virus to perform infection experiments, CVB3 and CVB4 
virus stocks needed to be expanded. Virus stocks were generated using FRhK-cells because 
this cell line showed to be permissive for different picornaviruses [132]. Therefore, FRhK-4 
cells were seeded on 180 cm2 tissue culture flasks and cultured at 37°C and 5 % CO2 until 
cells reached around 90 % confluency. For each condition three flasks were prepared. Cells 
were overlaid with 15 ml of DMEM maintenance media containing or not containing diluted 
virus for 2h at 37°C and 5 % CO2. Then tissue culture flasks were filled up to 30 ml with 
maintenance medium and cultured for three days at 37°C and 5% CO2. Three days post 
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infection (p.i.) a clear CPE (cytopathic effect) was visible in cells from infected flasks in 
contrast to non-infected, showing detachment of cells and lesions in the cell monolayer. 
When almost all cells showed a CPE, flasks were freeze and thawed three times and media 
containing cell debris was centrifuged for 10 min at 2000 rpm. The cleared supernatant was 
aliquoted and stored at -80°C. Supernatants from non-infected lysed cells represent the 
mock stocks which were used as control.   
 
3.6.2 Virus purification 
 
To omit the mock condition and contamination of virus stocks with cell proteins, virus stocks 
were purified using a sucrose gradient. FRhK-4 cells were grown in six 180 cm2 flasks, three 
were infected with CVB3 and three with CVB4 as described. Following three freeze and thaw 
cycles, media containing cell lysate was centrifuged two times at 5000 rpm for 10 min and 
after that transferred in ultracentrifugation tubes (Beckman Polyallomer Centrifugation Tubes, 
CA, USA). Then tubes were ultracentrifuged (Beckman Ultracentrifuge LE-70) at 15000 rpm 
for 10 min and 8°C in a SW 28 rotor. 10 ml of the sucrose containing solution (40% sucrose 
(Sigma Aldrich, Steinheim, DE), 10 mM Tris pH 7.5 100 mM NaCl and 1 mM EDTA) was 
added in ultracentrifugation tubes and cleared supernatant was carefully overlaid, which 
resulted in a gradient. Tubes were ultracentrifuged overnight at 25000 rpm and 8°C in a SW 
28 rotor. Next day both phases were discarded and purified non visible virus pellet was 
resuspended in 250µl PBS. To get high yield of virus the 250 µl PBS were transferred from 
one tube to another to concentrate virus particles.10 µl virus stock aliquots were stored at -
80°C.   
 
3.6.3 Virus titration 
 
The TCID50 (tissue culture infectious dose 50 %) was determined using serial dilutions of 
virus stocks or media supernatants containing lysates from infected islets. Firstly, Frhk-4 
cells were grown in 96-well plates in 10 % FBS containing DMEM (growth media). When 
cells reached confluence titration study was performed. Virus stocks were serially diluted 
from 10-1 to 10-11 in duplicate. Per virus serotype two 96-well plates were infected. For that, 
900 µl 1 % FBS containing DMEM was added in eleven tubes. In the first tube virus stock or 
supernatant from infected islets were diluted 1:10 and 100 µl of this dilution was transferred 
to the next tube and so on. The first 11 columns were infected with 100 µl of 10-1 to 10-11 
virus dilutions. The 12th column was left uninfected or treated with mock and was used as 
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control. Cells were incubated for 2h at 37°C and 5 % CO2 to allow absorption of virus 
particles to cells. Then, cells were washed three times with PBS and fresh 1 % FBS 
containing DMEM was added to each well; subsequently cells were incubated for 7 days at 
37°C and 5 % CO2. To determine the TCID50 each well was investigated using a light 
microscope; wells with a clear CPE showed lesions in the cell monolayer and were declared 
as positive. The TCID50/ml was calculated using the Spearman-Kärber formula [133]. 
Average of TCID50 from two plates was calculated. 
 
3.6.4 CM cell and human islet infections  
 
CM cells were infected with indicated viruses at MOI (multiplicity of infection) of 5. To infect 
CM cells with CVB3 or CVB4, virus serotypes were diluted in FBS free RPMI complete media 
and cells were inoculated with 750 µl for 2h at 37°C and 5% CO2. As controls CM cells were 
incubated with 750 µl of diluted mock or media alone. Cells were then washed twice with 
PBS and overlaid with 2 ml of fresh complete RPMI media containing 10 % FBS. After 
certain time infections were stopped. Therefore supernatants were discarded and cells were 
washed thrice with PBS.  
Infection of isolated human islets with CMV, HAV, CVB2, CVB3 or CVB4 were performed 
either on 35 mm ECM dishes or 35 mm suspension dishes dependent on which experiment 
was performed with a MOI of 5, 10 or 20. To infect isolated human islets with indicated 
viruses, those were diluted in FBS free CMRL complete media and islets were inoculated 
with 750 µl for 2h at 37°C and 5% CO2. Human islets incubated with 750 µl of diluted mock or 
media alone were used as controls. Cells were then washed twice with PBS and overlaid 
with 2 ml of fresh complete CMRL media containing 10 % FBS. This time point represents 
the 0 h of infection.  
 
3.6.5 Inhibition of JNK and PKR in CM cells and human islets 
 
To investigate JNK and PKR dependent effects in CVB infected CM cells and isolated human 
islets JNK was inhibited using the inhibitor SP600125 and PKR using 2-AP or PKRi. Prior to 
infection cells and human islets were pre-incubated with 25 mM of SP600125 for 1h at 37°C 
and 5 % CO2. Then media containing SP600125 was removed and cells and islets were 
inoculated with virus containing media supplemented with 25 mM SP600125. Infection was 
performed as described. After infection fresh media was added to the cells and islets, again 
supplemented with 25 mM SP600125.  
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Inhibition of PKR was performed using either 2-AP or PKRi. After infection islets were treated 
with 10 mM 2-AP. Inhibitor was kept on the islets throughout the whole experiment. Control 
islets were treated with the same volume like 2-AP only with the diluent (PBS:glacial acetic 
acid 200:1). 
CM cells or human islets were pre-treated with different concentrations of PKRi ranging from 
1 µM to 2.5 µM for 12 h at 37°C and 5 % CO2. Transfections, infections and further culturing 
were carried out in the presence of the inhibitor. 
This procedure made sure that the inhibitor was present in the cell supernatants throughout 
the whole experiment. 
 
 
3.7 Protein analysis 
 
3.7.1 Protein extraction 
 
Proteins from CM cells and human islets were isolated and analysed by western blot. 
Experiments were performed with 200 islets per ECM dish or 2.5 x 105 CM cells per 35 mm 
tissue culture dish, respectively. After indicated time p.i. (post infection) supernatants were 
either kept for further analysis or discarded, cells were washed twice with PBS and 55 µl of 
RIPA buffer (50 mM Tris HCl pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 
0.1% SDS) containing 1x protease and phosphatase inhibitor (100x) (Thermo Scientific, 
Bonn, Germany) was applied per dish to lyse the cells. Then dishes were wrapped with 
parafilm and frozen at -80°C. CM cells were thawed on ice and cells were scraped off.  
Dishes with isolated human islets were freeze and thawed thrice. During the last freeze and 
thaw cycle dishes were thawed on ice and islets were scraped off. Lysis buffer containing 
proteins and islet debris was transferred to tubes. To obtain higher protein yields tubes were 
vortexed for 2 to 3 min following centrifugation at 12000 rpm for 15 min at 4°C. Protein 
containing supernatants were collected and transferred to new tubes. Cell debris pellets were 
discarded. To prevent degradation protein samples were always kept on ice.  
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3.7.2 BCA Assay for quantification of proteins  
 
Concentration of proteins was quantified using the BCA (bicinchoninic acid assay) assay 
(Pierce, Thermo Scientific, Rockford, IL USA) according to manufacturers’ instructions. 25 µl 
of 1:5 diluted protein samples (dilution was performed in RIPA buffer supplemented with 
protease and phosphatase inhibitor) and 25 µl of standards were added in wells of a 96-well 
plate. Sufficient amount of BCA reagent was prepared by dilution of 1 part of reagent A in 50 
parts of reagent B. 200 µl of reagent was added to protein or standard samples per well. 
Plate was covered with aluminium foil and incubated at 37°C for 30 min in the dark. In 
proportion to protein concentration the colour is changing from green to purple. After 
incubation measurement of the absorption spectra at 570 nm was assessed using a 
photometer (Multiskan Ascent, Thermo Scientific). Protein amounts were calculated by 
comparing absorption spectra from sample and standards with known protein concentrations. 
RIPA buffer with proteinase and phosphatase inhibitor alone was representing the blank. 
 
3.7.3 Co-Immunoprecipitation (Co-IP) 
 
For each condition three ECM dishes with around 250 islets were cultured. Islets were 
infected as described for 24 h. Then Islets were washed twice with PBS followed by addition 
of 1 ml 1 % formaldehyde (37 %, Merck, Darmstadt, Germany) (diluted in PBS) to fix the 
protein-RNA interactions. Islets were incubated for 30 min on a shaker. The formaldehyde 
solution was discarded and 2 mM glycine (Riedel de Haen, Germany) was added to the 
dishes which were incubated for 15 min on a shaker. Islets were washed twice and around 
150 µl RIPA buffer was added to each dish. Dishes were freeze and thawed three times and 
proteins were extracted and concentration was determined as described above. To pre-clear 
proteins, around 250 µg of proteins in 500 µl of RIPA buffer were incubated with 2 µg of an 
antibody of the same species and isotype as the IP antibody for 30 min with gentle agitation 
at 4°C. In the mean time protein A agarose beads (protein A Agarose, Fast Flow, Millipore, 
California, USA) were washed with RIPA buffer. 70 µl of slurry beads were added to the 
proteins, followed by incubation with gentle rotation for 30 min at 4°C. The beads were 
pelleted and discarded. Aliquots of around 30 µl were kept at -80°C (input fraction) and pre-
cleared lysates were mixed with 2 µg K1 antibody (English and Scientific Consulting Bt) and 
incubated overnight at 4°C. The K1 antibody binds dsRNA, and it has been used 
successfully in a previous study [134]. 
70 µl protein A agarose beads were added to the lysates followed by incubation for 4 - 6 h 
with gentle rotation. Then the beads were spun down and supernatants (output fraction) were 
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kept for further analysis. Beads were three times washed with RIPA buffer. After the last 
washing beads (IP-fraction) were mixed with 50 µl 2x loading buffer (1:2 diluted with RIPA 
buffer) (NuPAGE® LDS Sample Buffer (4x), Invitrogen, Darmstadt, Germany) and 4 µl 
reducing agent (1??? ????????? ??? ?-mercaptoethanol (Merck, Darmstadt, Germany) in H2O). 
Before western blot analysis IP-fractions were incubated 45 min at 95°C, beads were spun 
down and around 30 µl of supernatants were applied in the western blot. 15 µl of input and 
output fractions were mixed with 7,5 µl loading buffer (4x), 2 µl reducing agent and 5,5 µl 
RIPA buffer. Tubes were incubated 10 min at 95°C before western blot analysis.  
 
3.7.4 Western blot  
 
For western blot studies 200 islets were cultured per ECM dish. After protein extraction and 
determination of concentrations 15-30 µg proteins were analyzed. Equal amount of proteins 
were mixed with 1X protein loading buffer (NuPAGE® LDS Sample Buffer (4x), Invitrogen, 
Darmstadt, Germany) 2 µl of reducing reagent (2 µl / 50 µl reaction volume) and ddH2O. 
Samples were heated up for 10 min at 95°C and then chilled on ice. Proteins were applied on 
precast gels (NuPAGE® 4 %-12 % Bis-Tris, Invitrogen Darmstadt, Germany) and separated 
according to their kDa size. Protein separation was performed in running buffer (NuPAGE® 
MES SDS Running Buffer, Invitrogen, Darmstadt, Germany) supplemented with 0.1 % 
antioxidant (NuPAGE® Antioxidant, Invitrogen, Darmstadt, Germany). Following separation 
proteins were blotted on polyvinylidene flouride-membrane (PVDF) (Roti, Karlsruhe, 
Germany). Therefore, membranes were incubated for 1 min in methanol and for 30 sec in 
H2O. Proteins were blotted in transfer buffer (500 mM Bis-Tris, 20.5 mM EDTA, 500 mM 
Bicine, 20 % v/v methanol 0,1 % antioxidant). Membranes were blocked with 2.5 % dry milk 
(Cell Signaling, Frankfurt Main, Germany) and 2.5 % bovine serum albumine (BSA) (Sigma-
Aldrich, Steinheim, DE) in TBS-T (50mM Tris, 150 mM NaCl pH 7.6 with HCl, 0.1 % Tween-
20 (Sigma- Aldrich). Following the blocking step membranes were incubated over night at 
4°C with primary antibodies diluted in TBS-T containing 5 % BSA.  
Following are the different primary antibodies used and the respective dilutions along with 
the product information. 
Cl. caspase 3  1:1000  Cell Signalling # 9664 
PARP   1:1000  Cell signalling # 9542 
VP1   1.1000  Dako clone 5-D8/1 
?-actin   1:1000  Cell signalling # 4967 
pPKR   1:1000  Abcam E120 
PKR   1:1000  Cell signalling # 3072 
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RIG-I   1:1000  Cell signalling # 4200 
MDA5   1:1000  Cell signalling #5321 
??????  1:1000  Cell signalling # 9721  
pJNK   1:1000  Cell signalling # 9251 
JNK   1:1000  Cell signalling # 9252 
p c-Jun  1:1000  Cell signalling # 9261 
Tubulin  1:1000  Cell signalling # 2146 
CXCL10  1:5000  RnD systems BAF266 
 
Membranes were washed three times for five minutes in TBS-T. Secondary antibodies HRP 
(horse radish peroxidase) conjugated goat anti mouse IgG (Jackson Immuno 
Research, USA) was diluted 1:3000 and HRP-conjugated goat ant rabbit IgG (Jackson 
Immuno Research, USA) 1:10000 in TBS-T containing 2.5 % dry milk and membranes were 
incubated for 1h at RT. Then membranes were washed four times in TBS-T on a shaker, 
each time for 10 min. Peroxidase was activated by applying HRP substrate solution 
(Immobilon Western, Millipore, Schwalbach, Germany). Protein bands were visualized using 
UVP BioSpectrum AC Imaging System (UVP, Upland, Canada). 
 
 
3.7.5 Glucose Stimulated Insulin Secretion (GSIS) 
 
Infected human islets were tested for their ability to secrete insulin upon acute glucose 
challenge. 24, 48 and 72h p.i., islets were washed and pre-incubated for 30 min in KRB 
(Krebs-Ringer bicarbonate buffer) (115 mM NaCl, 5 mM KCl, 2.5 mM CaCl2, 1.2 mM 
KH2PO4, 1,2 mM MgSo4, 1M Hepes, 5mM NaHCO3, 0,5 % BSA) containing 2.8 mM glucose 
at 37°C. KRB was replaced with 1 ml of fresh KRB containing 2.8 mM glucose and islets 
were incubated for 1h at 37°C. Then supernatant was collected (basal insulin secretion) and 
replaced with 1 ml of KRB containing 16.7 mM glucose and incubated again for 1h at 37°C. 
Supernatant was collected (stimulated insulin secretion). To avoid contamination with cells, 
tubes containing basal and stimulated insulin were centrifuged at 2000 rpm for 5 min and 
supernatants were transferred to new tubes and kept at -20°C. The insulin secretion 
stimulation index was calculated by dividing the amount of stimulated insulin by the amount 
of insulin produced at basal conditions. 
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3.7.6 Human insulin and CXCL10 ELISA 
 
Human Insulin ELISA 
Insulin secreted under basal and stimulated conditions was analysed using the human insulin 
enzyme-linked immunosorbent assay (ELISA) (ALPCO Diagnostics, Salem, NH) according to 
manufacturers’ instructions. Concentration was determined photometrically at 450 nm 
(Molecular Devices, Emax precision microplate reader). 
 
Human CXCL10 ELISA 
Islet culture supernatants were collected and frozen at -20°C until measurement. Human 
CXCL10 (ELISA) (DB OptEIATM Set human IP-10) was obtained from BD Biosciences (BD 
Biosciences, San Diego, CA, USA) and performed according to manufacturers’ instructions. 
96-well ELISA-plates (BD Biosciences, Heidelbach, Germany) were pre-coated ????????????
per well of capture anti-human IP-10 antibody diluted 1:250 in coating buffer (0.1 M sodium 
carbonate, pH 9.5; 7.13 g NaHCO3, 1.59 g Na2CO3; pH to 9.5 with 10 N NaOH) (BD 
Biosciences). Concentration was determined photometrically at 450 nm (Molecular Devices, 
Emax precision microplate reader).  
 
 
3.8 RNA analysis 
 
3.8.1 RNA isolation  
 
For RNA analysis 100 islets were cultured on 35 mm ECM dishes. RNA extraction was 
performed using peqGOLD TriFast (peqlab, Erlangen, Germany). Islets were lysed with 1 ml 
of peqGOLD reagent and either kept at -80°C or further processed. Reagent containing 
lysate was transferred to tubes and mixed with 200 µl chloroform. Then Tubes were shaken 
for 15 sec and incubated for 2 – 3 min at RT. Then Tubes were centrifuged at 12000 rpm for 
15 min at 4°C. The upper aqueous phase was collected and mixed with 10 µg glycogen 
(Fermentas). 500 µl of isopropanol were added in each tube, followed by centrifugation at 
12000 rpm for 30 min at 4°C. Isopropanol was discarded and RNA pellets were washed with 
1 ml of Ethanol. For washing, pellet was centrifuged again at 12000 rpm for 30 min at 4°C. 
RNA pellet was dried and resuspendet in 10 µl DEPC-H2O.  
RNA concentration was determined using the spectrophotometer at 260 nm (NanoDrop 
ND1000). 
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3.8.2 RT-reaction 
 
Around 500 ng RNA was reverse transcribed using the RevertAidTM Reverse Transcriptase 
and reaction buffer (Fermentas). Before this, RNA was treated with 1 U DNase I (Fermentas) 
for 1,5 h at 37°C in a reaction volume of 10 µl. Reaction was stopped by adding 1 µl EDTA 
(Fermentas) followed by the incubation for 15 min at 65°C. RNA was mixed with random 
hexamer primers (Fermentas Life Sciences) and incubated for 5 min at 65°C. The tubes 
were chilled on ice and 5x reaction buffer (Fermentas Life Sciences), 10 mM dNTPs (each) 
(Thermo Scientific) and 100 U of Moloney Murine Leukemia virus (M-MuLV) reverse 
transcriptase (Fermentas) were added. Reactions were incubated for 10 min at 25°C 
followed by 60 min at 42°C and 10 min at 70°C in the PCR cycler (eppendorf Mastercycler 
gradient).  
For each sample a negative control was included, where the reverse transcriptase was 
exchanged with DEPC-H2O (-RT samples). 
 
3.8.3 Polymerase chain reaction (PCR) 
 
Before qPCR analysis, cDNA and –RT samples were checked in a regular PCR. A 10 µl 
reaction contained 1x buffer (DreamTaq™ 10x Buffer, Thermo Scientific) 1 U polymerase 
(DreamTaq™ Polymerase, Thermo Scientific) 200 µM dNTPs (each), 500 pM tubulin primers 
(each), 25ng cDNA and ddH2O. PCR was performed in a PCR cycler with a primer annealing 
temperature at 60°C.  
PCR products were run in a 1 % agarose gel (LE Agarose, Biozym, Oldendorf, Germany) 
and visualized with DNA stain G (Serva, Heidelberg, Germany).  
 
3.8.4 Real-Time PCR (qPCR) 
 
qPCR was performed using Sybr Green (Power Sybr Green, Applied Biosystems) and 
TaqMan primer probes. For sybr Green, each reaction was performed in a volume of 10 µl 
and contained 10 ng cDNA, 5 µl Sybr Green, 0.25 µM primers (each) and ddH2O. All primers 
annealed at 60°C and qPCR was run for 40 cycles. 
Following are the sequences of the primers used in this study:  
TLR3 fw 5´ AGCCTTCAACGACTGATGCT 3´ rev 5´ TTTCCAGAGCCGTGCTAAGT 3´ 
MDA5 fw 5´ ACCAAATACAGGAGCCATGC 3´ rev 5´ RGCGATTTCCTTCTTTTGCAG 3´ 
RIG-I fw 5´ FAGAGCACTTGTGGACGCTTT 3´ rev 5´ RTGCAATGTCAATGCCTTCAT 3´ 
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PKR fw 5´ FACGCTTTGGGGCTAATTCTT 3´ rev 5´ RTTCTCTGGGCTTTTCTTCCA 3´ 
18s fw 5´ FAAACGGCTACCACATCCAAG 3´ rev 5´ RCCTCCAATGGATCCTCGTTA 3´ 
Cyclophillin fw 5´ F TTCATCTGCACTGCCAAGAC 3´  
rev 5´ TCGAGTTGTCCACAGTCAGC 3´ 
 
For TaqMan probes, reactions were also carried out in 10 µl using 1x PCR master mix 
(TaqMan Fast Universal PCR Master mix (2x), Applied Biosystems), 1x TaqMan primer 
probes (TaqMan Assay (20x), Applied Biosystems) 10 ng cDNA and ddH2O.  
Following TaqMan Assays were used in this study: 
CXCL10 Hs00171042_m1 
????????????????s1 
IL-6 Hs99999032_m1 
IL-???Hs00174103_m1 
?????????????????? 
Cyclophillin Hs99999904_m1 
qPCR was performed using the StepOnePlus (Applied Biosystems) qPCR machine. Results 
were analysed with the StepOnePlus software. 
 
3.8.5 RNA-Immunoprecipitation (RIP) 
 
For each condition three ECM dishes with around 250 islets were cultured. Islets were 
infected as described for 24 h and 48 h. Human islets were washed once with PBS at room 
temperature and fixed with 1% formaldehyde in PBS at RT for 10 min. Cells were quickly 
rinsed twice in ice-cold PBS and 100µl of lysis buffer A was added (100mM KCl, 5mM 
MgCl2, 10mM Hepes pH 7, 0.5% NP40, 1mM DTT, 100U/ml RnaseOUT (Invitrogen), 400 µM 
vanadyl ribonucleoside complexes VRC (New England Biolab), Protease/phosphatase 
inhibitor cocktail). The samples were freeze and thawed followed by pipetting and vortexing 
to completely lyse the cells. 2 mg of total protein was used for RNA-IP. Protein-A Sepharose 
beads were pre-swelled in buffer B (50mM Tris-HCl pH7.4, 150mM NaCl, 1mM MgCl2, 
0.05% NP-40) supplemented with 5 % BSA to a final ration of 1:5 for 2h at 4°C before use.   
2 µg TLR3 antibodies (IMG-315A, Imgenex, USA) or 2 µg TLR7 antibodies (IMG-581A, 
Imgenex, USA) were added to the slurry beads and incubated overnight tumbling end over 
end at 4°C. The following day the antibody-coated beads were washed with 1ml of ice-cold 
buffer B for 5 times. After the final wash the beads were resuspended in 850 µl of ice-cold 
buffer B supplemented with 200 U RNase inhibitor, 400 µM VRC, 1,2 mM DTT and 20 mM 
EDTA. 100µl were removed as imput fraction. RNA-protein complexes were incubated with 
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beads-antibody for 5h at 4°C tumbling end over end. After incubation the supernatant was 
saved as output fraction and the beads washed 5 times with 1ml of ice-cold buffer B 
supplemented with 1% SDS to reduce background. The beads were resuspended in 100µl of 
buffer B supplemented with 30ug of Proteinase K and the mixture incubated for 60 min at 
55°C with occasional vortexing. RNA was isolated using PeqGold reagent following 
manufacturer instructions. RNA was reverse transcribed and analysed by qPCR using CVB 
primes. Values were expressed as arbitrary units. 
 
 
3.9 Immunocyto- and histochemistry 
 
 
TUNEL Assay and immunocytochemistry 
For TUNEL assay usually 30 islets were plated per ECM dish. Cells were fixed for 30 min at 
room temperature (RT) with 4 % paraformaldehyde following cell permeabilisation with 0,5 % 
Triton X-100 for 4 min at RT and blocking with 3 % BSA for 1 h. Cell death was detected 
using the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) 
technique according to the manufacturer’s instructions (In situ cell death detection kit, Roche, 
Mannheim, Germany). Islets were incubated overnight with primary antibodies guinea pig 
anti-insulin (Dako) diluted 1:100 and mouse anti-VP1 (Dako clone 5-D8/1) diluted 1:500. 
Islets were washed thrice with PBS and incubated with secondary antibodies Cy3-conjugated 
donkey anti guinea pig IgG (Jackson ImmunoResearch Laboratories, West Grove, PA) and 
VP1 was visualized using the biotin HRP-conjugated streptavidin system (Histostain®, 
Invitrogen, USA) according to manufacturer’s instructions, following AEC chromogen 
incubation. Islets were mounted using mounting media containing DAPI (Vector Laboratories, 
Burlingame, CA). 
 
Immunohistochemistry 
Islets were washed with PBS and fixed with Bouin´s fixate (Sigma Aldrich) for 15 min at RT 
and added to melted 2 % agarose. Islets were spun down and dehydrated in ethanol (70 %, 
80 %, 95 %, 100 %, each for 2h and toluene for 4 h). Agarose pellets were embedded in 
paraffin and microtome sections were cut (4µm). Tissue sections were deparaffinized, 
rehydrated (toluene, 100 %, 95%, 70 % ethanol and H2O) and antigen retrieval was 
performed in low pH antigen unmasking solution (Vector Laboratories, Burlingame, CA) 
using a microwave. Slides were microwaved three times for 5 min. After permeabilisation in 
0,4% Triton X-100 in PBS and blocking in 3% BSA sections were incubated with primary 
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antibodies over night, biotinylated anti-human CXCL10 (RnD, Minneapolis, USA) diluted 
1:200, mouse anti-VP1 diluted 1:500, donkey anti-glucagon (Dako) 1:100, guinea pig anti-
insulin 1:100. After incubation with primary antibodies, islets were washed thrice with PBS 
and incubated for 1 h at RT with 1:100 diluted secondary antibodies, Cy3-conjugated donkey 
anti guinea pig IgG, AMCA-conjugated donkey anti guinea pig IgG, Cy3-conjugated donkey 
anti mouse IgG, FITC-conjugated donkey anti rabbit IgG and FITC-conjugated donkey anti 
guinea pig IgG (all Vector Laboratories, Burlingame, CA). CXCL10 was visualized using the 
biotin HRP-conjugated streptavidin system (Histostain®, Invitrogen, USA) according to 
manufacturer’s instructions, following AEC chromogen incubation. 
For TUNEL staining, slides were not treated with antigen retrieval solution and tissue was not 
permeabilized. Instead sections were treated with protease K (Roche, Mannheim, Germany) 
diluted 1:1000 in 10 mM Tris-HCl pH was adjusted to 7.4.  
Cryosections were covered with PBS and blocked for 30 min with 3% BSA at RT. Due to 
optimizations, tissue sections were not fixed. Sections were incubated over night with mouse 
anti-TLR3 (Imgenex, IMG315-A, San Diego, USA), rabbit anti-TLR7 (Imgenex, IMG-581A, 
San Diego, USA), guinea pig anti-insulin and donkey anti-glucagon antibodies. All antibodies 
were diluted 1:100. After incubation with primary antibodies, islets were washed thrice with 
PBS and incubated for 1 h at RT with secondary antibodies, Cy3-conjugated donkey anti-
mouse IgG, FITC-conjugated donkey anti-guinea pig IgG, Cy3-conjugated donkey anti rabbit 
IgG and followed by secondary antibody incubation and TLR7 was visualised using biotin 
HRP-conjugated streptavidin system (Histostain®, Invitrogen, USA) according to 
manufacturer’s instructions, following AEC chromogen incubation. 
Sections were mounted in mounting media containing DAPI or glycerol gelatin (Sigma, 
Steinheim, Germany). 
 
 
3.10 Human islet transfection   
 
Around 200 islets per dish were dispersed with accutase (PAA Laboratories GmbHPasching, 
Austria) for 5 min at 37°C to improve the access of the transfection mixes to islet cells. 
Dispersion was aborted by addition of fresh complete media. Islets were cultured for two 
days and experiments were carried out. TLR3 knockdown in human islets was performed 
using the siTLR3 (ON-TARGETplus SMARTpool, Dharmacon). The siRNA is a mix of ON-
TARGETplus siRNAs directed against the following sequences: 
GAACUAAAGAUCAUCGAUU, CAGCAUCUGUCUUUAAUAA, 
AGACCAAUCUCUCUCCAAUUU, UCACGCAAUUGGAAGAUUA. Before transfection, islets 
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were incubated for 1 h in an optimized Ca2+-KRH transfection medium (KCl 4.74 mM, 
KH2PO4 1.19 mM, MgCl26H2O 1.19 mM, NaCl 119 mM, CaCl2 2.54 mM, NaHCO3 25 mM, 
HEPES 10 mM) at 37°C. Transfection was carried out with 100 nM siTLR3 or siScr or with 
DNA plasmids dnJNK and GFP. For gene silencing, 100 pM siRNA was mixed with 5 µl of 
transfection reagent, for overexpression studies DNA was mixed at a ratio 2,5:1 and 800 ng 
Poly I:C were mixed with 5µl lipofectamine (Lipofectamine2000, Invitrogen). Mixes were 
incubated at RT for 45 min and added to the islets. Transfection was carried out in half of the 
volume. After 6 h 2x media containing 20 % FBS was added to the dishes.  
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4 Results 
 
4.1 Establishment of CVB infection in isolated human islets    
 
In the beginning of this study, infection of isolated human islets was established and confirmed 
with the published data. For this purpose, isolated human islets were infected as indicated and 
different experiments were carried out to investigate the properties of the infection. I focused on 
virus effects on human islets including proof of infection, destruction of islet cells, replication of 
viral particles and effects on function and cell specific actions. The infection was studied in a 
time frame of 72 h. 
 
 
4.1.1 CVB3 and CVB4 infect human islet cells and induce cell death 
 
Isolated human islets were infected in vitro with the 3 different CVB serotypes- 2, 3 or 4, HAV 
(Hepatitis A virus) another representative of the Picornaviridae or CMV (Cytomegalovirus) 
belonging to the Herpesviridae. 72 h after infection the destruction of islet cells was investigated 
using the TUNEL technique. TUNEL and insulin double positive cells were quantified and results 
?????????????????????????????????????????????-cells.  
Infection of human islets with CVB2, 3 or 4 resulted in 8-fold, 6-fold and 7-fold increase in 
apoptosis, respectively, as compared to mock treatment, whereas CMV and HAV had no effect 
on apoptosis (Fig. 10A).  
CMV and HAV were excluded from further experiments. Due to the frequent association of 
CVB3 and CVB4 serotypes in virus induced diabetes, further experiments were performed with 
those serotypes; CVB2 was excluded. 
TUNEL staining detects DNA fragmentation which occurs during apoptosis. Due to the fact that 
TUNEL was shown to label inappropriate DNA strand breaks during necrosis, western blot 
analysis was performed to confirm apoptosis [135]. Protein analysis showed cleavage of pro-
apoptotic proteins PARP and caspase 3 during CVB3 and CVB4 infections of human islets 48 h 
p.i., in contrast to non-infected control islets. VP1 bands confirmed CVB3 and CVB4 infections, 
?????-actin bands were used as protein loading controls (Fig. 10B).  
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To determine whether infected cells were mainly apoptotic, triple immunostaining of VP1, insulin 
and TUNEL was performed. CVB3 and CVB4 infected islets showed TUNEL specific black 
staining of nuclei accompanied with red stained VP1 positive cells indicating apoptosis in 
infected islet. In contrast, media and mock treated islets showed no signs of infection or cell 
death (Fig. 10C).  
All further studies were performed using purified virus stocks; hence mock treatment was 
discontinued. As control, media treated islets were included in all further experiments. Infection 
of islets with purified CVB3 or CVB4 had the same effect on apoptosis as non-purified virus 
stocks and led to 4- and 3-fold induction of apoptosis, respectively as compared to control 
(*p< 0.05) (Fig. 10D).   
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Figure 10: CVB3 and CVB4 induce cell death in isolated human islets. A: Isolated human 
islets were cultured for two days followed by infection with HAV, CMV, CVB2, CVB3 or CVB4 (MOI of 10). 
Media and mock treatment were included as controls. 72 h p.i. islets were fixed and double stained with 
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TUNEL and insulin. TUNEL positive black stained nuclei in insulin positive cells were quantified and 
expressed as percentage of total insulin positive cells (error bars represent ± SD from triplicate). B: 
Western blot analysis of proteins from control and CVB3 or CVB4 infected islets (MOI of 5) isolated 48 h 
after infection showed cleavage of PARP and caspase 3. ???????????????????????????????????-actin was 
used as control for equal protein input. C: Isolated human islets infected with CVB3 or CVB4 (MOI of 5), 
or treated with media or mock were fixed 48 h p.i. and triple immunostaining was performed. Upper panel 
shows fluorescent insulin staining in red and lower panel black stained TUNEL positive nuclei surrounded 
by red stained VP1 positive cells in bright field (magnification: x 400). D: In order to ensure that purified 
virus stocks had the same effects on apoptosis as not purified stocks, human islets were infected (MOI of 
5) and TUNEL assay performed. TUNEL positive black stained nuclei in insulin positive cells were 
quantified and expressed as percentage of total insulin positive cells (error bars represent ± SEM from five 
independent experiments from 5 different donors; *p< 0,05).   
 
 
4.1.2 CVB3 and CVB4 reach high titers in isolated human islets  
 
To investigate if infection of isolated human islets leads to progeny of viruses, titration assays of 
infected islets were carried out. Supernatants and lysates from CVB3 or CVB4 infected islets 
obtained at 0 h, 24 h, 48 h and 72 h were titrated using FRhK-4-cells. CVB3 and CVB4 
replicated regularly in human islets and the maximum of titre was reached 24 h p.i. (Fig. 11).  
The time point 0 h indicated bound viral particles which were not washed off. Titres stayed 
constant over the observed time. To investigate if virus particles were released during infection, 
supernatants were titrated, showing the same pattern of virus replication (data not shown).   
 
Figure 11: CVB3 and CVB4 replicate in isolated human islets. Human islets infected with CVB3 
or CVB4 (MOI of 5) were lysed at 0 h, 24 h, 48 h and 72 h p.i. and cell debris were pelleted. Serial 
dilutions of cleared supernatants were titrated on FRhK-4-cells. Results show the TCID50/ml in logarithmic 
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manner of one representative result out of three from three different donors (error bars indicate ± SD from 
technical replicate). 
 
 
4.1.3 ??????????????? ??????-cell function  
 
The results achieved showed that infection of human islets in vitro ?????????????????????-cells and 
progeny of virus. The next question was whether CVB3 and CVB4 infections have an impact on 
?-cell function. To investigate the CVB3 and CVB4 ????????????-cell function, glucose stimulated 
insulin secretion (GSIS) was performed. Isolated human islets were infected with CVB3 or CVB4 
in vitro for 24 h and 48 h, respectively, and at indicated time points, islets were challenged for 1 
h with a low glucose concentration of 2.8 mM, which corresponds to the basal insulin secretion. 
Then the islets were challenged for an additional hour with a high glucose concentration of 16.7 
mM, corresponding to the stimulated insulin secretion. Secreted insulin amounts were measured 
and stimulatory indices calculated based on the ratio of stimulated to basal insulin levels.  
24 h p.i. GSIS was unaffected by infections. CVB3 as well as CVB4 significantly reduced 
stimulatory indices from 5.7 ± 1.17 in the control to 3.2 ± 0.76 and 2.7 ± 0.21 respectively 48 h 
p.i. (*p< 0.05) (Fig. 12).  
 
Figure 12: CVB3 and CVB4 infections impair glucose stimulated insulin secretion in 
human islets. Isolated human islets were infected with CVB3 or CVB4 (MOI of 5) and GSIS was 
performed 24 h and 48 h p.i. Islets were incubated with 2.8 mM followed by 16.7 mM glucose 
concentrations for 1 h, respectively. Secreted insulin was measured using insulin ELISA. Stimulatory 
indices were calculated by dividing stimulated insulin amount by basal insulin amount (error bars indicate 
± SED from three independent experiments from three different donors, *p< 0.05 compared to control at 
48 h).   
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4.1.4 CVB3 infect mainly ?-cells ???????????????????- and a certain portion 
of ?-cells  
 
To investigate if CVB3 or CVB4 infect all islet cells or show any tropism towards a specific islet 
cell type, immunostaining was performed. Microtome sections from paraffin embedded islets 
infected with CVB3 or CVB4 for 24 h, 48 h and 72 h were prepared. Triple immunostaining was 
performed for insulin glucagon and VP1. Sections were microscopically analyzed and 
colocalization of VP1 with either insulin or glucagon was quantified. Results are expressed as 
????????????????????????????- ????-cells, respectively.  
CVB3 VP1 staining was observed in 60.6% ± 9.6% and ?????????????????????????-cells 24 h 
p.i. The later time points displayed similar high values, which decreased gradually. CVB3 
infected only 3.3% ± 0.8% and 2.5% ± 0.3% of ?-cells at 48 h and 72 h p.i., in contrast to CVB4, 
which showed significantly higher VP1 positive ?-cell values of 12.1% ± 4.0% and 8.1% ± 2.8% 
at 48 h and 72 h p.i. (*p< 0,05) (Fig. 13A).  
Results showed that both virus serotypes ??????????-, but ??????? ?-cells. Immunofluorescence 
staining showed no VP1 positive cells in control islets but strong colocalization of CVB3 VP1 
with insulin positive cells and of CVB4 VP1 with insulin and glucagon positive cells (Fig. 13B).  
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Figure 13??????????????????????? ???????-cells and CVB4 additionally a certain portion of 
?-cells. A: Isolated human islets were infected with CVB3 or CVB4 (MOI of 5) for 24 h, 48 h and 72 h. 
Islets were fixed, pelleted and paraffin embedded. Pellets were microtome sectioned and stained for 
insulin, glucagon and VP1. Colocalization of VP1 with either insulin or glucagon was quantified; results are 
?????????????????????????????????????????- ????-cells (error bars indicate ± SEM from three independent 
experiments from three different donors, *p< 0.05). B: Immunofluorescence analysis of paraffin 
embedded sections from islets infected with CVB3 or CVB4 (MOI or 5) demonstrate individual staining for 
insulin in blue, glucagon in green and VP1 in red 48 h p.i. Merge images show the colocalization of insulin 
and VP1 indicated by purple colour in islets infected with CVB3; and insulin, glucagon and VP1 indicated 
by purple and yellow staining in islets infected with CVB4 (magnification x 400). 
 
 
4.1.5 CVB3 and CVB4 induce ?-cell death 
 
As CVB3 and CVB4 mainly ??????????-cells, it was investigated whether cell death was restricted 
????-cells or if it occurred in all islet cell types. Paraffin embedded sections from islets infected 
with CVB3 or CVB4 were analyzed for cell specific apoptosis by TUNEL assay. Sections were 
stained for insulin or glucagon and colocalization with TUNEL positive nuclei was quantified and 
?????????? ??? ??????????? ??? ?????? ??????? ??? ?- ??? ?-cells. Both virus serotypes increased 
????????????????????????????-cells at 48 h and 72 h from 1.1% ± 0.1% and 1.6% ± 0.6% in control 
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islets to 8.4% ± 1.6% (#p< 0.01) and 6.7% ± 0.4% (#p< 0.01) in CVB3 and to 4.4% ± 0.8 (#p< 
0.01) and 6.4% ± 1.3% (*p< 0.05) in CVB4 infected islets, at indicated time points (Fig. 14A).  
Contrary to ?-??????? ???????????????????????????????? ????-cell apoptosis at any time point after 
CVB4 infection, which was in contrast to the elevated ?-cell infection by CVB4. Results imply 
that ?????????????????????-cells, ????????????????????????-cell specific apoptosis.  
? ???????????????????????????????????????????????????????-cell apoptosis indicated by red 
????????????????????????????????????????????????-cells merging with DAPI 48 h p.i. In contrast to 
that, glucagon positive cells showed no increase in TUNEL positive staining. Control islets 
showed basal moderate apoptosis rates 48 h p.i. (Fig. 14B). 
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Figure 14: CVB3 and CVB4 infections of islets induc??????????????????????????????-cells. A: 
Isolated human islets infected with CVB3 or CVB4 (MOI of 5) for 24 h, 48 h and 72 h were subsequently 
fixed, pelleted and paraffin embedded. Islet sections were double stained for TUNEL and insulin or 
TUNEL and glucagon. Insulin or glucagon positive cells containing a TUNEL positive nuclei were 
quantified; results are expressed as percentage of TUNEL ??????????- ????-cells (error bars indicate ± SEM 
from three independent experiments from three different donors; *p< 0.05, #p< 0.01 compared to controls 
at the same time points). B: Paraffin embedded islet sections from control, CVB3 or CVB4 (MOI of 5) 
infected islets were triple stained for insulin in the upper panel or glucagon in the lower panel in green, 
TUNEL in red and DAPI in blue 48 h p.i. TUNEL positive nuclei were indicated by purple staining due to 
colocalization with DAPI (magnification x 400). 
 
 
In this part of the study, CVB3 and CVB4 in vitro infections of isolated human islets were 
established and revealed that both virus serotypes replicated efficiently in isolated human islets, 
and led to infection and induction of ?????????? ??????? ??? ?-?????? ?????????? ??? ? ??????? ?-cell 
function to respond to elevated glucose concentrations. CVB4 infected a certain porti???????-
cells in contrast to CVB3; however, ????????????????-cell apoptosis was not observed. The MOI 
of 5 did not result in rapid cell death, and therefor infection could be analyzed in a time frame of 
72 h. This MOI was used in all experiments, unless stated otherwise. In all further studies a 
media treated control was included.  
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4.2 Induction of inflammation-related genes as result of CVB3 and 
CVB4 islet infections  
 
CVB infected human islets upregulate several genes involved in inflammation like cytokines and 
chemokines [111-113]. Pro-inflammatory proteins can contribute in vivo to activation and 
attraction of immune cells resulting in the destruction of pancreatic tissue. In this study the 
transcription of different inflammatory genes was investigated using Real-time PCR (qPCR) 
technique. 
 
 
4.2.1 In vitro CVB3 and CVB4 infections of human islets induce 
transcription of inflammatory cytokine and chemokine genes 
 
In order to confirm that infection of human islets in vitro induces expression of different genes 
involved in virus defence and inflammation, isolated human islets were infected with CVB3 or 
CVB4 and gene expression analyses were performed.  
In accordance with previous reports, mRNA transcription of the pro-inflammatory cytokines and 
chemokines CXCL10, IL-6, ???? and ???? was increased after CVB3 or CVB4 infections, in 
which the highest gene expressions were observed 72h p.i. Values represent the relative gene 
expression as compared to control islets at the same time points. CXCL10 mRNA showed 
2194.3- and 1117.7-, IL-6 28.0- and 5.8-, ?????157.7- and 140.3- and ?????4.7- and 2.1-fold 
increase in expression in CVB3 or CVB4 infected islets respectively, compared to control islets. 
In addition Poly I:C, the viral dsRNA analog, which is known to induce CXCL10 gene 
transcription was added as positive control. Treatment or transfection of human islets with Poly 
I:C resulted also in the increase of expression of tested genes, however, highest gene 
expressions were observed 24 h p.i. possibly due to Poly I:C degradation at later time points 
(Fig. 15A).  
Among the probes tested, CXCL10 showed the highest gene expression levels after both CVB3 
and CVB4 infections. ??????the classical inducer of CXCL10, was not detected at any time point, 
?????????????? ????? ????????????CXCL10 induction. Cell culture supernatants from CVB3 and 
CVB4 infected islets showed significantly elevated CXCL10 levels of 1.6 ng/ml ± 0.7 ng/ml and 
2.8 ng/ml ± 0.8 ng/ml 48h and 72h after CVB3 and 2.0 ng/ml ± 0.8 ng/ml and 2.5 ng/ml ± 
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1.4 ng/ml 48 h and 72 h after CVB4 infections, compared to control at same time points (*p< 
0.05; #p< 0.01). Treatment with Poly I:C resulted in high secretion of CXCL10 up to 4.9 ng/ml  ± 
0.05 ng/ml and 6.3 ng/ml ± 1.2 ng/ml at 48 h and 72 h (#p< 0.01) (Fig. 15B).  
The ???? gene expression ?????????????????????????????????????????????????????????????????????
be detected in cell culture supernatants using ELISA (data not shown). 
???????????????????????????????????????????????????????-cells, the cell type secreting CXCL10 
w?????????????????? ???????????????????????????????????????????????????????????????-cells 48 
??????????????????????????????????????????????-cells as source of CXCL10. In contrast, control 
islets showed no positive staining for CXCL10 (Fig. 15C).  
It has been shown, that ???? treatment of isolated human islets leads to gene upregulation of 
CXCL10 [136] In order to confirm that human islets can be stimulated in vitro ??????????? ???????
were treated with two different concentrations and gene expression of CXCL10 was investigated 
by qPCR 24 h after treatment. Results showed a 5-fold and a 43-fold increase in CXCL10 mRNA 
?????? ????????????????????????????????? ??????????????? ????????????????????? ???????????????????
that isolat???????????????????????????????????????????????????? 
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Figure 15: CVB3 and CVB4 induce cytokine and chemokine gene transcription and 
secretion of CXCL10 in isolated human islets. A: Human pancreatic islets were infected with 
CVB3 or CVB4, or treated (25 µg/ml) or transfected (5 µg) with Poly I:C. RNA was extracted 24 h, 48 h 
and 72 h p.i cDNA was generated and mRNA expression levels were analysed using qPCR technique. 
Reference gene was cyclophilin; shown are the mRNA amounts as multiplying factors of the mRNA 
amount obtained without virus or Poly I:C (controls) in a logarithmic scale (values show one representative 
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result out of three from three different donors). B: CXCL10 secretion was analysed in the supernatants 
from infected and Poly I:C (25 ng/ml) treated  human islets by ELISA, 48 h and 72 h after infections and 
treatment (error bars indicate  ± SEM from three independent experiments from three different donors, 
*p<0.05; # p<0.01 ). C: Paraffin embedded sections from CVB3 and CVB4 infected islets were 
immunostained for insulin in red, glucagon in green and CXCL10 in brown 48 h after infection. Merge 
shows colocalization of CXCL10 with insulin or glucagon positive cells (magnification x 400). D Isolated 
?????????????????????????????????????????????????????, and 24 h after treatment RNA was isolated and 
reversely transcribed. CXCL10 mRNA transcription was analysed; cyclophilin was used as reference gene 
(result shows one experiment). 
 
 
4.2.2 Neutralization of CXCL10 does not protect from virus induced ?-cell 
apoptosis 
 
Infection of isolated human islets resulted in a strong CXCL10 gene expression and protein 
secretion. Treatment of isolated human islets in vitro with the recombinant CXCL10 protein 
res????????????????????-cell apoptosis [137]. To investigate a possible involvement of CXCL10 on 
?-cell survival and function, isolated human islets were infected with CVB3 or CVB4 and were 
additionally treated with a CXCL10 neutralizing antibody. IgG was included as control. CVB3 and 
CVB4 infections of isolated human islets resulted in a 2.3-fold and 1.7-fold induction of 
apoptosis. Application of the CXCL10 neutralizing antibody had no effect on virus induced 
apoptosis (Fig. 16).  
CXCL10 neutralization also showed no effects on GSIS, which was performed with the same 
samples (data not shown).   
 
Figure 16????????????????????????????????????????????-cell survival and function. Isolated 
human islets were infected with CVB3 or CVB4. CXCL10 neutralizing antibody (MDX1100) (10 µg/ml) or 
human IgG (10 µg/ml) were added to the islets at the beginning of the infection. 48 h p.i. GSIS analysis 
was performed. Then the ????????????????????????????????????????????????????????????????????????????-
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cells were quantified and results expressed as percentage of TUNEL positive cells (error bars indicate ± 
SD from triplicate, result shows one representative experiment of three from three different donors).  
 
4.2.3 PRRs are upregulated upon infection of isolated human islets 
 
PRRs recognizing viral ss/dsRNA are involved in the induction of several cytokines and 
chemokines and especially type 1 IFN genes. To investigate if the gene expression of certain 
PRRs was increased in CVB3 or CVB4 infected islets, qPCR analysis was performed. TLR3, 
RIG-I, MDA5 and PKR mRNA showed a time-dependent increase with highest expression levels 
detected at 72 h after CVB3 or CVB4 infections. Values represent the relative gene expression 
compared to control islets at the same time points. TLR3 mRNA transcription was 6.2- and 4.7-, 
RIG-I 23.5- and 15.4-, MDA5 17.5- and 13.0- and PKR 7.3- and 6.1-fold increased upon CVB3 
or CVB4 infections, respectively, compared to control at 72 h. In this experiment, too, poly I:C 
treatment and transfection was included and resulted in  increased expressions of PRR genes 
analyzed (Fig. 17A). 
??? ???????????? ???????? ????? ?????????? ??? ????????? ??????? ???????? ??? ?????????? ??? ???? ?????
???????????? ????????? ?????? ??????? ????? ???????? ????? ??????????? ??????????????? ??? ??????
Treatment for 24 h resulted in a concentration-dependent increase of mRNA levels of 
??????????????????????????????????????? ???????????????????????????????????? 
The reference genes used in this study were cyclophillin and 18s. To exclude the effect of CVB3 
or CVB4 infections on the stability of the reference genes, a qPCR of cDNAs from CVB3 or 
CVB4 infected and non-infected control islets was performed 48 h p.i. Results revealed that both 
housekeeping genes were equally expressed (Fig. 17C). 
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Figure 17: Distinct PRR genes are upregulated in isolated human islets after CVB3 and 
CVB4 infections, and Poly I:C treatment and transfection. Human pancreatic islets were 
infected with CVB3 or CVB4, or treated (25 µg/ml) or transfected (5 µg) with Poly I:C, and RNA was 
extracted 24 h, 48 h and 72 h after infection and treatment. RNA was reversely transcribed and PRR 
mRNAs were analysed using qPCR technique. The reference gene was 18s; shown are the mRNA 
amounts as multiplying factors of the mRNA amount obtained without virus or Poly I:C (controls) in a 
logarithmic scale (values show one representative result out of three, from three different donors). B: 
??????????????? ???????????? ????????????? ??????????????????? ??????????????? ?????????????????????????????
reverse transcription. PRR mRNAs were analysed by qPCR (result shows one experiment). C: Human 
pancreatic islets were infected with CVB3 or CVB4 and RNA was extracted 48 h after infection. RNA was 
reversely transcribed and the expression of cyclophilin mRNA was analysed using qPCR technique. 18s 
was used as reference gene (error bars indicate ± SD from technical replicate, result shows one 
experiment). 
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4.3 Involvement of PRRs in CVB sensing 
 
The increase of cytokine, chemokine and especially type I IFN gene expressions are the first 
defence mechanisms of the innate immune system in virus infected cells, which belong. The first 
step leading to the initiation of the signal cascade leading to the induction of gene transcription is 
the binding of viral nucleic acids to PRRs. So far, a specific PRR sensing CVB RNA in isolated 
human islets has not been found. In order to investigate which receptor binds to CVB3 or CVB4 
nucleic acids, protein- and RNA- immunoprecipitation studies were performed.  
 
 
4.3.1 CVB3 RNA is sensed by TLR3 and PKR and CVB4 RNA by TLR3, PKR, 
as well as by TLR7 
 
Protein- and RNA-immunoprecipitation studies were performed in collaboration by Dr. Federico 
Paroni.   
To immunoprecipitate proteins bound to CVB dsRNA, protein lysates from CVB3 or CVB4 
infected islets and control islets were incubated with the K1 antibody, which is directed against 
dsRNA. Input protein lysates (in), supernatants after immunoprecipitation (out) and 
immunoprecipitated (IP) fractions were analysed by western blotting. RIG-I and MDA5 showed 
no bands in the immunoprecipitated fractions of CVB3, CVB4 infected and control islet lysates in 
contrast to out- and input fractions, suggesting no binding of dsRNA to RIG-I and MDA5 24 h p.i. 
the analysis of the same fractions for presence of PKR showed a strong band in the 
immunoprecipitated fractions of CVB3 and CVB4 infected islets, while no bands were observed 
in the control, indicating that CVB3 and CVB4 RNA was bound by PKR during infection of islets 
(Fig. 18A).  
PKR is phosphorylated and activated following dsRNA binding, which leads to the 
phosphorylation of its downstream target eIF2a and consequently to the inhibition of translation, 
as an antiviral effect. Western blot analyses of lysates obtained from CVB3 or CVB4 infected 
islets showed phosphorylation of PKR as well as its downstream target eIF2a in contrast to 
lysates from control islets, confirming the immunoprecipitation results (Fig. 18B).  
Using the same strategy, positive bands for TLR3 and TLR7 could not be obtained. To 
investigate if TLR3 or TLR7 were involved in CVB3 or CVB4 RNA binding an opposite strategy, 
RNA-immunoprecipitation (RNA-IP), was performed. Lysates from CVB3- or CVB4-infected and 
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control islets were incubated with antibodies directed against TLR3 and TLR7, respectively. RNA 
was precipitated from the immunoprecipitated fractions. Only, RNA which was bound to TLR3 or 
TLR7 was reversely transcribed to cDNA and analysed by qPCR. CVB3 RNA was bound by 
TLR3 while CVB4 RNA was bound by both receptors, TLR3 and TLR7, 24 h and 48 h p.i. 
suggesting an involvement of TLR3 and TLR7 in the CVB3 and CVB4 RNA sensing in the early 
phase of infection. Binding of CVB RNA by TLR3 and TLR7 increased over time. RNA 
precipitated from control islets showed no binding to TLR3 or TLR7 (Fig. 18C). Values represent 
arbitrary units. 
A        B 
 
 
                  
C 
 
 
 
Figure 18: PKR, TLR3 and TLR7 are involved in CVB3 and CVB4 RNA binding. A: 24 h after 
CVB3 or CVB4 infections of isolated human islets, proteins were cross-linked and islets were lysed. Equal 
protein concentrations were incubated with the K1 antibody directed against dsRNA, followed by 
immunoprecipitation (IP). IP, output (out) and input (in) fractions were analysed for the presence of RIG-I, 
MDA5 and PKR. B: 48 h p.i. lysates from CVB3 and CVB4 infected human islets were analysed by 
western blot for presence of the phosphorylated form of PKR and its downstream target phospho-???????
The antibodies ??????????????????????????????????????????????????????????-actin was used as control for 
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equal protein load. C: RNA-IP was performed from human islets infected with CVB3 or CVB4 24 h and 48 
h p.i. RNA-protein complexes were cross-linked and islets were lysed. Equal amount of proteins were 
incubated with either TLR3 of TLR7 antibodies following IP. RNA was precipitated from IP fractions, 
reversely transcribed and analysed for the presence of CVB cDNA, using CVB primers (result shows one 
representative experiment out of three, from three different donors).  
 
 
4.3.2 TLR3 and TLR7 are differentially expressed within human islets 
 
The cellular expression and localization of TLR3 and TLR7 was investigated. The 
immunohistochemical analysis of cryo- and paraffin embedded pancreatic sections from healthy 
donors was performed. Immunostaining revealed that TLR3 was expressed in islet cells 
???????????????????????????????????????????????????????????????-cell specific staining, suggesting 
?????????????? ????????????????????-???????????????????- cells (Fig. 19).  
To exclude unspecific binding of secondary antibodies, immunostaining without primary antibody 
was performed showing no TLR3 or TLR7 staining. 
 
 
 
 
Insulin TLR3 DAPI merge 
Insulin Glucagon TLR7 DAPI 
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Figure 19?? ????? ??? ??????? ?????????? ??? ?-?????? ?????? ????? ??? ?????????? ??? ?-cells. 
Fluorescence and bright field immunostaining was performed on cryo- and paraffin sections from healthy 
donors. The upper panel shows fluorescent insulin staining in green, TLR3 staining in red and DAPI 
nuclear staining in blue. The merge image demonstrated colocalization of TLR3 with insulin positive cells 
indicated in yellow colour. Lower panels show fluorescent insulin and glucagon staining in green and in 
red and DAPI in blue. TLR7 bright field red immunostaining was colocalized with glucagon positive cells 
indicated by merge images. Sections incubated with only secondary antibodies against mouse and rabbit 
(magnification 400x).  
 
 
4.3.3 TLR3 depletion decrease cytokine and chemokine gene expression in 
CVB3 and CVB4 infected human islets  
 
Since TLR3 is expressed ????-cells and was shown to bind to CVB RNA, the function of TLR3 
was investigated using small interfering RNA (siRNA) technique. Because commercially 
available TLR3 antibody did not show reliable results by western blotting, TLR3 down regulation 
was confirmed based on mRNA levels. To achieve high transfection efficiency, isolated human 
islets were dispersed by accutase treatment 48 h before transfection. siTLR3 transfection of 
human islets resulted in significant decrease of TLR3 mRNA levels to 42% ± 13% (*p< 0.05) as 
compared to small interfering scrambled (siScr) RNA transfected control islets, 96 h after 
transfection (Fig. 20A).  
To proof the functionality of TLR3 protein downregulation, an indirect approach was performed. 
Poly I:C, a known TLR3 ligand, induced strong CXCL10 secretion (Fig. 15B). Isolated human 
islets were siScr or siTLR3 transfected for 48 h followed by treatment with Poly I:C for additional 
24h. Poly I:C induced a massive CXCL10 gene expression in siScr transfected islets, which was 
clearly decreased in siTLR3 transfected human islets, from 1042.8-fold to 433.3-fold as 
compared to non-treated control islets (Fig. 20A).  
sec. anti-mouse sec. anti-rabbit 
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The increase of CXCL10 gene expression was confirmed on protein levels using CXCL10 
ELISA, demonstrating a 2-fold reduction in CXCL10 secretion ad compared to siScr (Fig. 20A). 
Next, the effect of TLR3 on virus-induced cytokine and chemokine gene expression was 
investigated. CVB3 and CVB4 infections (MOI of 20) of human islets led to increased CXCL10, 
????, IL-6 and ???? mRNA levels in siScr transfected islets 24 h p.i., whereas TLR3 depletion 
resulted in 4.5-fold and 6-fold decreased CXCL10, 6.5-fold and 3.7-fold decreased ????, 1.5-fold 
and 1.3-fold decreased IL-6 and 3-fold and 1.3-fold decreased TNF? mRNA transcription, 
respectively (Fig. 20B).  
CXCL10 gene expression was confirmed on protein levels using CXCL10 ELISA, which showed 
a clear reduction of CXCL10 secretion from CVB3 and CVB4 infected islets transfected with 
siTLR3, as compared to siScr. CVB3 and CVB4 infections of human islets transfected with siScr 
led to 0.98 ng/ml ± 0.20 ng/ml and to 0.51 ng/ml ± 0.08 ng/ml secretion of CXCL10, respectively, 
as compared to 0.08 ng/ml ± 0.07 ng/ml from control islets. In contrast, TLR3 knock down 
resulted in 2-fold and 1.6-fold decrease in CXCL10 secretion from CVB3 and CVB4 infected 
islets. Non-infected TLR3 depleted human islets led to a low basal CXCL10 secretion of 
0.15 ng/ml ± 0.14 ng/ml (Fig. 20C).  
This suggests TLR3 as a sensor inducing inflammatory gene upregulation in isolated human 
islets following CVB3 and CVB4 infections.  
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Figure 20: TLR3 is involved in CVB3 and CVB4 dependent upregulation of cytokine and 
chemokine gene expression. A: Human islets were treated with accutase for 5 min at 37°C and 
cultured for 48h. Then the islets were transfected with either siScr or siTLR3. 96 h after transfection RNA  
was isolated, reversely transcribed and TLR3 gene expression was analysed (error bars indicate ± SED 
from three independent experiments from different donors, *p< 0.05 compared to siScr). Islets were 
treated and transfected as described above and 48 h after siTLR3 and siScr transfections human islets 
were treated with Poly I:C (25 µg/ml) for additional 24 h. CXCL10 gene expression was analysed by 
qPCR. Supernatants from the same samples were analysed by CXCL10 ELISA (results show one single 
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experiment). B: 48 h after the siScr and siTLR3 transfections, isolated human islets were infected with 
CVB3 or CVB4 (MOI of 20). 24 h p.i. RNA was extracted and CXCL10, ????, ???? and IL-6 gene 
expressions were analysed by qPCR (error bars represent ± technical replicate, results show one 
experiment). C: Supernatants from control and CVB3 and CVB4 infected human islets transfected with 
siScr and siTLR3 were analysed by CXCL10 ELISA (error bars represent ± SED from two independent 
experiments). 
 
The results show the involvement of TLR3 and TLR7 in CVB infection of human islets and a 
distinct protein expression ????- ?????-cells. TLR3 silencing confirmed TLR3 as sensor, since 
depletion led to decrease in expression of the cytokine and chemokine genes analysed. 
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4.4 ?????????????-cell apoptosis is partially TLR3 and JNK 
dependent  
 
Apoptosis is the main form of cell death in T1DM [70]. CVB serotypes, such as CVB3 and CVB4 
are implicated as agents triggering T1DM in genetically susceptible individuals. In vitro infections 
of isolated human islets with CVB3 and CVB4 ????????-cell apoptosis, compared to non-infected 
islets. This virus induced destruction can be a precipitating event in T1DM. TLR3 and JNK were 
investigated as possible mediators of virus-?????????-cell apoptosis. 
 
 
4.4.1 TLR3 depletion protects from CVB induced apoptosis 
 
To investigate if TLR3 is involved in CVB3-and CVB4-induced apoptosis in isolated human 
islets, TLR3 was depleted and western blotting and TUNEL analyses were performed.  Human 
islets were transfected with siScr and siTLR3 for 48 h followed by infection with CVB3 or CVB4. 
24h p.i. the cells were lysed and the proteins were analysed by western blotting. siScr 
transfected CVB3- and CVB4-infected human islets showed cleaved caspase 3 bands. The 
Intensity of the bands was clearly decreased upon siTLR3 transfection, suggesting an 
involvement of TLR3 in CVB induced apoptosis. In contrast, there was no cleavage of caspase 3 
in control conditions. VP1 expression confirmed CVB3 and CVB4 infections of islets, 
interestingly those bands were increased in siTLR3 transfected CVB3 and CVB4 infected islets, 
as ?????????????? ????????????????????????????????????????????????????????????????????????????????-
actin was used as protein loading control (Fig. 21A).  
To confirm that TLR3 had an effect on CVB3 and CVB4-induced apoptosis, a TUNEL assay was 
performed. Here, isolated human islets were siScr and siTLR3 transfected for 48 h followed by 
CVB3 or CVB4 infections. 24 h p.i. cells were fixed and double immunostaining for TUNEL and 
insulin was performed. Black stained nuclei in insulin positive cells were quantified and results 
????????????????????????????????????????????????-cells. Results showed that CVB3 and CVB4 
?????????? ?????????? ??? ?-cells transfected with siScr islets from 2.7% ± 0.2% in not infected 
control islets to 8.7% ± 0.8% and 6.4% ± 0.7%, respectively. However, depletion of TLR3 
resulted in 1.4-fold and 2-fold decrease of CVB3 and CVB4 induced apoptosis, respectively, 
confirming western blot analysis (Fig. 21B). 
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Figure 21: TLR3 depletion protects from CVB3 and CVB4 induced apoptosis. A: Human 
islets were treated with accutase for 5 min at 37°C and cultured for 48 h. Then the islets were transfected  
with either siScr or siTLR3, and 48 h after transfection the islets were infected with CVB3 or CVB4. 24 h 
p.i. islets were lysed and western blot analysis performed. Cleavage of caspase 3 was investigated as 
???????????????????????????? ????????? ?????????????????????????-actin was used as protein loading control 
(western blot shows one representative result out of four from four different donors) B: Islets were treated 
as described above and transfected with siScr and siTLR3 for 48 h. Then isolated human islets were 
infected with CVB3 or CVB4, and 24 h p.i. islets were fixed and costained with insulin and TUNEL to 
???????? ??????????? ?????? ????????? ?-cells were quantified; values are expressed as percentage of 
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????????????????-?????????? ???????-cells (error bars indicated ± SED from two independent experiments 
from two different donors).  
 
 
4.4.2 pJNK as mediator of CVB induced apoptosis  
 
???? ?-cell line CM was used as a model cell line for the investigation of virus mediated cell 
apoptosis. Lysates from control treated and CVB3-infected CM cells were investigated by 
western blotting. Results showed a time-dependent increase in cleavage of caspase 3 upon 
CVB3 infection correlating with phosphorylation of JNK, already 3 h, 4 h and 5 h p.i. VP1 bands 
appeared at same the time points as the cleavage of caspase 3 and phosphorylation of JNK 
???????????????-actin was used as protein loading control (Fig. 22A). 
To confirm JNK phosphorylation in infected human islets, western blot of lysates from CVB3 
infected human islets was performed. JNK phosphorylation was observed after infection and 6 h 
and 24 h p.i. After 24 h, pJNK correlated with the cleavage of caspase 3 and the appearance of 
CXCL10 and VP1 bands (Fig. 22B).  
To investigate a possible link between pJNK and CVB3 induced apoptosis, a JNKi (JNK 
inhibitor) was applied. Isolated human islets were pre-treated with JNKi following infection with 
CVB3 or CVB4. 48 h p.i. the islets were lysed and the proteins were analysed by western 
bloting. CVB3 and CVB4 infections resulted in an increase of phosphorylation of JNK and its 
downstream target c-Jun, as compared to non infected control islets. Pre-treatment with JNKi 
resulted in an abrogation of phosphorylation of JNK as well as of c-Jun, indicating successful 
JNK inhibition. Caspase 3 was cleaved in islet lysates from CVB3 and CVB4 infected islets in 
contrast to media treated control islets. Pre-treatment with JNKi revealed a decrease in the 
cleavage of caspase 3. In addition, pre-treatment also resulted in a decrease in VP1 bands in 
contrast to non pre-treated islets. The decrease in VP1 is possibly due to unspecific effects on 
virus replication caused by the JNKi. Thus, the decrease of cleavage of caspase 3 in JNKi pre-
treated and CVB3- and CVB4-infected islets cannot be solely explained by the JNK inhibition, 
but rather by unspecific effects of the inhibitor on virus replication (Fig. 22C).  
To exclude side effects, a vector containing a dominant negative form of JNK (dnJNK) was 
overexpressed in isolated human islets. As controls, islets were either treated with Lipofectamine 
(LF) or transfected with GFP-plasmid to exclude effects derived from the transfection procedure 
or protein overexpression. 48 h after transfection, islets were media treated or CVB3 infected. 
48h p.i Islets were lysed and proteins were investigated by western blotting. To confirm dnJNK 
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overexpression and decreased JNK function, c-Jun phosphorylation and total JNK levels were 
investigated. Upon dnJNK overexpression and CVB3 infection, no phosphorylation of c-Jun was 
evident in contrast to GFP overexpressing CVB3 infected islets. In addition, total JNK bands 
were increased upon dnJNK transfection as compared to the control, suggesting successful 
dnJNK overexpression and impaired JNK function. GFP overexpression and CVB3 infections 
were confirmed by visualisation of GFP and VP1 bands, respectively. Results showed increase 
in cleavage of PARP and caspase 3 in GFP control transfected and CVB3 infected islets, which 
was decreased in CVB3 infected islets overexpressing dnJNK, suggesting a role for pJNK in 
virus i????????-cell apoptosis (Fig. 22D).  
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Figure 22??????? ??? ????????? ???????? ?????????-cell apoptosis. A: CM cells were used as a 
model cell line for investigation of CVB3 induced apoptosis. Prior to infection, cells were lysed and used 
as control b.i. (before infection). Cells were infected with CVB3 and lysed in a time dependent manner 
starting after infection (p.i.) to 5h p.i., at each time point a non-infected media treated control was included. 
Phosphorylation of JNK and cleavage of caspase 3 were analysed during the first hours of infection. VP1 
?????? ?????????????????????????????-actin was used as protein loading control (western blot shows one 
representative result out of three). B: Isolated human islets were lysed and used as control b.i., islets 
were infected with CVB3 and lysed 1 h, 2 h, 6 h, and 24 h p.i. Lysates were analysed by western blotting 
fo????????????????????????????????????????????????????????????????????????????????????????-actin was 
used as protein loading control (western blot shows one representative result out of two from two different 
donors). C: Isolated human islets were pre-treated with the JNK inhibitor SP600125 (25µM) 1h prior to 
infection, during infection and p.i. Islets, pre-treated with JNKi, were CVB3 or CVB4 infected. 48 h p.i. the 
islets were lysed and the effects of the JNK inhibition were analysed by western blotting. pJNK and its 
downstream target p-c-?????????????????????????????????????????????????????????????-actin was used as 
protein loading control. D: Isolated human islets were dispersed for 5 min at 37°C using accutase and 
cultured for 48 h. Attached islets were transfected with either dnJNK- or GFP-plasmid or were treated with 
the transfection reagent LF (Lipofectamine). GFP and dnJNK transfected islets were infected with CVB3. 
In addition, LF treated and dnJNK transfected islets represent non infected controls. Islets were lysed 48 h 
p.i. and lysates were analysed by western blotting for total JNK, GFP and VP1 expressions as well as for 
phosphorylation of c-Jun and cleavage of PARP and caspase 3. Tubulin and GAPDH were used as 
protein loading controls (result shows one performed experiment). 
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4.4.3 PKR does not contribute to virus induced cell death 
 
To investigate a possible role for PKR in the virus induced apoptosis, PKR was inhibited using 
two different inhibitors, 2-AP and PKRi.  
Isolated human islets were infected with CVB3 and 4 and after infections, islets were treated 
with 2-AP. Inhibition of phosphorylation was analysed by western blotting. CVB3 infection 
resulted in phosphorylation of PKR, which was abrogated in islets treated with 2-AP, however 
VP1 bands were clearly reduced in islets treated whit 2-AP, suggesting that the inhibitor caused 
unspecific effects and altered the virus replication (Fig. 23A). 
Since 2-AP showed no PKR specificity, another inhibitor, PKRi, was applied. CM cells were 
treated with different concentrations of PKRi 12 h before Poly I:C transfection. 6 h after 
transfection cells were lysed and proteins were analysed by western blotting.  
PKR phosphorylation was decreased with increasing PKRi concentrations. Interestingly, 
cleavage of caspase 3 was completely preserved, suggesting that PKR might be involved in 
Poly I:C induced apoptosis (Fig. 23 B).  
To investigate the PKR effect, isolated human islets were pre-treated with 2.5 µM PKRi for 12h 
before infection. 48 h p.i. TUNEL analysis showed that the PKRi inhibitor had no effect on virus 
induced apoptosis in isolated human islets (Fig. 23 C).  
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Figure 23: Inhibition of PKR had no effect on virus induced apoptosis. A: Isolated human 
were infected with CVB3 and CVB4 and after infection islets were exposed to 10 mM 2-AP. 24 h and 48 h 
????????????????????????????????????????????????????????????????????????-actin was used as protein loading 
control (western blot shows one representative result out of two). B: CM cells were pre-incubated with 
1 µM, 1,5 µM, 2 µM and 2,5 µM of PKRi for 12h. Following that, islets were transfected with 800 ng 
Poly I:C. The inhibitor was added to the transfection mixes as well as after the transfection. 6 h after 
trans????????? ??????????? ???????????????????????????????????????????????????-actin was used as protein 
loading control (western blot shows one representative result out of two). C: Isolated human islets were 
pre-treated with PKRi for 12 h, following that, islets were infected with CVB3 and CVB4. Inhibitor was 
present in the cell culture supernatants at every step. 48 h p.i. islets were fixed and TUNEL analysis 
performed (graph shows one representative result out of two). 
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4.5 CVB3 infects the exocrine tissue in mice 
 
To analyse in vivo effects of CVB3 on islets, pancreatic sections from infected A.CA/SnJ-mice 
were immunohistochemically investigated. Mice infected with CVB3 were sacrificed four days p.i. 
and pancreas was isolated and paraffin embedded. Pancreatic paraffin sections were 
immunostained for VP1 and CXCL10. 
Results showed a massive infection of the exocrine tissue indicated by VP1 staining with no 
signs of VP1 expression in islets. Interestingly, CXCL10 immunostaining showed a clear 
???????????????-cells, while the exocrine tissue showed no CXCL10 staining (Fig. 24).  
Control mice showed no VP1 or CXCL10 positive staining.  
Since islets were not infected in mice, no further studies of in vivo infection were performed.  
  
Figure 24: ????????????????????????????????????????????????????????????????????????????-
cells in mice. A.CA/SnJ-mice were inoculated intraperitoneally with 2x104 PFU of CVB3 (Nancy) or with 
PBS. Four days p.i., infected and control mice were sacrificed and pancreata isolated, fixed, paraffin 
embedded and microtome sectioned. Bright field staining for VP1 in red and fluorescent staining for insulin 
in blue, glucagon in green and CXCL10 in red were performed. Merge shows the colocalization of 
CXCL10 with either insulin positive or glucagon positive cells. 
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5 Discussion 
????? ??? ??? ????? ????? ???????? ??? ?????? ?-cells are selectively destroyed by the immune 
???????????????????????????-cell destruction insulin levels decline, this ends finally in complete 
insulin deficiency. T1DM is highly associated with genetic susceptibility, however over the last 
decades the overall incidence is rising especially in children under the age of 5, suggesting that 
environmental factors contribute to the manifestation of the disease [1, 2]. T1DM is thought to 
result from the interaction between genetic predisposition, immune system and environmental 
factors [3]. Such environmental factors may be viral infections, which have been associated with 
T1DM for many years. So far, the best investigated viral environmental factors with the best 
documented connection to T1DM are human EVs [4]. Epidemiological studies and analysis of 
pancreatic tissue samples show the clear involvement of EV infections in T1DM patients. 
However, the molecular mechanisms of islet infection and how viruses can lead to the disease 
are still not discovered.  
The present study showed that infection of isolated human islets with CVB3 or CVB4 resulted in 
?????????? ??? ?-cell apoptosis and expression of genes involved in inflammation which were 
abrogated upon TLR3 depletion, suggesting that the TLR3 pathway is involved in islet infections 
with CVB3 and CVB4.  
This study showed that infection of isolated human islets with CVB3 and CVB4 resulted in viral 
replication, confirming published results [108]. Immunohistochemical analysis of pancreatic 
tissues from T1DM patients shows a specific VP1 colocalization with insulin positive cells, 
??????????? ?? ?-cell specific infection in vivo [101]. In my study, i????????????? ????- ???? ?-cell 
specific infections with CVB3 and CVB4 showed that both virus serotypes infected high amounts 
mainly of ?-cells 24 h p.i. CVB3 infected only a small amount ??? ?-cells while CVB4 infected 
significantly higher numbers of this cell type, displaying different tropisms of CVB3 and CVB4. 
Tropism of viruses to certain cells results from different expressions of receptors and other host 
cellular proteins which are needed by the virus to propagate. CVBs use CAR (coxsackie and 
adenovirus receptor) and DAF (decay accelerating factor) to enter human cells [103, 138, 139]. 
CAR has been shown to be expressed in human islets, and the application of antibodies 
neutralizing CAR leads to strong reduction of VP1 positive cells or prevents infection with CVB3 
and CVB4. In contrast DAF was not found to be expressed in human islets [140, 141]. So far it is 
not known which other factors can contribute to the different tropism of CVB3 and CVB???????- 
?????-cells.  
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Cell death, either necrosis or apoptosis, is induced as the result of various virus infections. CMV, 
which has been linked to T1DM [81], failed to induce apoptosis in human islets, suggesting that 
infection of islets did not result in cell death, at least not 72 h p.i. HAV, as CVB is a 
representative of the picornavirus family, also failed to induce apoptosis. The in vitro induced 
CPE in isolated human islets infected with CVB is shown to be due to cytolysis [142], however, 
apoptosis has also been observed [109]. At MOIs above 100 it has been shown that CVB5 
induces necrosis, while low MOIs lead predominantly to apoptosis [143]. In my study, the MOI of 
5 resulted in an increase of cell apoptosis. This was demonstrated by TUNEL staining and 
cleavage of proapoptotic proteins PARP and caspase 3 in CVB3 and CVB4 infected islets. The 
????? ???? ????? ???????? ?????????? ???? ??????????? ??? ?-cells, which correlated ????? ?-cell 
infection, as mainly this cell type showed to be infected by CVB3 and CVB4. In correlation with 
?-?????????????????????-cell function was impaired during CVB3 and CVB4 infections indicated by 
GSIS 48 h p.i., confirming published data [110, 144]????????????????????????????????????-cells. In 
?????????? ????????? ???????????????? ?????? ????? ??? ? ??????? ?-cell function. Many +ssRNA 
viruses, such as picornaviruses replicate on intracellular membranes. Parts of the membranous 
structures are shown to be derived from autophagosomes [145]. Such membrane 
rearrangements can possibly affect formation of insulin granules, resulting in impaired insulin 
secretion. ????? ?????????? ??? ?-cells did not resulted in apoptosis. This implies that CVB4 
infections have different outcomes ????- ?????-cells. So far, ???????????????????????????????-cell 
infections were investigated. Whether infection also resulted in necrosis in addition to apoptosis, 
it was not further investigated. 
The engagement of PAMPs with PRRs induces the expression of chemokines and cytokines like 
Type I IFNs as antiviral defence mechanism [123]. The present study showed that mRNA 
transcription of PRRs involved in recognition of viral infections, in particular TLR3, RIG-I, MDA5 
and PKR, were induced after CVB3 and CVB4 infections of isolated human islets 48 h and 72 h 
p.i. The highest expression was observed 72 h p.i. This time-dependent increase may result 
from viral progeny. Due to the increasing number of viral particles, which accumulate during 
infection, virus spreads to neighbouring cells resulting in PRR gene expression.  
Picornaviruses are thought to be sensed by MDA5 [146, 147]. However, this does not apply for 
all members of the picornavirus family. Various studies show the involvement of different PRRs 
in CVB recognition and antiviral response. MDA5 has been reported to play a role in CVB3 
infection. Mice deficient in MDA5 are highly susceptibility to CVB3 infection. Virus replication was 
shown to be faster and to result in an increase of the mortality [148]. It has also been shown that 
TLR3 knockout mice are highly susceptible to CVB3 infection, resulting in increased mortality 
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and viral replication, which suggests that TLR3 limits CVB3 infection [149]. However, CVB3 
infection of human cardiac cells is shown to be sensed by TLR7 and 8 [150]. Interestingly TLR4, 
which binds bacterial LPS, has been implicated in CVB3 infection, as TLR4 deficient mice 
infected with CVB3 display reduced levels of myocarditis and viral replication. This suggests that 
TLR4 exacerbates CVB3 infection [151]. CVB4 infection of TLR4 and CD14 overexpressing 
HEK293 cells triggers the production of pro-inflammatory cytokines [152].  
In the present study it was investigated which PRR binds to CVB3 and CVB4 RNA during 
infection of human islets. IP analysis showed that 24 h p.i. RIG-I and MDA5 showed no binding 
but PKR was bound to CVB3 and CVB4 RNA. PKR is not a classical PRR, it is an antiviral 
protein with dsRNA binding potential. Its antiviral property is mediated through stop of translation 
after infection. dsRNA binding leads to dimerisation and phosphorylation of PKR. Activated PKR 
is phosphorylating ?????? leading to general inhibition of the translation [59]. High PKR 
expressions have also been found in VP1 positive human islets in sections from T1DM and 
T2DM patients, showing a clear involvement in the EV infection of the islets [100]. In my study, 
???????? ??????????????? ??????? ?????? ??????? ??? ????????????????? during CVB3 and CVB4 
infections of isolated human islets, as indicated by western blot analysis.  
The use of the same strategy to investigate the possible binding of CVB3 and CVB4 RNA to 
TLR3 and TLR7 showed unreliable results. TLR7 is binding ssRNA molecules. As CVBs are 
ssRNA viruses, the usage of the K1 antibody, which binds to dsRNA, could have led to 
misleading results. In order to avoid this, an RNA-IP has been performed with TLR3 and TLR7 
antibodies. The results showed that CVB3 RNA was bound by TLR3 while CVB4 RNA was 
bound by both endosomal receptors TLR3 and TLR7, 24 h and 48 h p.i., suggesting an 
involvement of TLR3 and TLR7 in CVB3 and CVB4 RNA sensing in isolated human islets in the 
early phase of the infection. 48 h p.i. binding of CVB RNA to TLR3 and TLR7 was increased, 
????? ?????????????????????-cell infection. A possible explanation for the binding of the CVB3 and 
CVB4 RNAs to different TLRs may be the different tropism of CVB3 and CVB4. As mentioned 
????????????????????????????????????????????????????-cells, while CVB4 infected also a certain 
????????????-cells. Immmunohistochemical analysis showed that TLR3 was mainly expressed in 
?-cells, while TLR7 showed a str?????????????????????????-cells. This is a possible explanation 
why CVB3 RNA was bound to TLR3 and CVB4 RNA to TLR3 and also TLR7 (Fig. 25). 
 The findings observed could be additionally supported by other methods like RNA label transfer 
and RNA mobility shift assays.  
CVBs enter cells through receptor mediated endocytosis and interaction with TLR3 and TLR7 
might occur during this step. Possibly, vesicles containing virions fuse with endosomes where 
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virions uncoat to release their RNA which might bind to TLR3 and TLR7. However, TLR3 is 
usually a dsRNA binding receptor. As described above, CVBs are ssRNA viruses which form a 
dsRNA intermediate in the cytoplasm during replication. It raises the question, how endosomal 
TLR3 can be engaged by CVB dsRNA. It is conceivable that TLR3 interacts with the IRES 
structure of the virus genome, which contains large dsRNA regions. Another possibility is that 
TLR3 binds CVB dsRNA during the replication. EVs replicate on intracellular membranes derived 
in part from autophagosomes [145]. Phagosomes may fuse with TLR3 containing endosomes, 
and thus allowing TLR3 to engage with CVB dsRNA [153].  
TLR3 and TLR7 might bind to the RNAs in the early phase of the infection as shown 24 h p.i., 
followed by binding to possibly MDA5 later in the infection. This is supported by the study of 
Wang et al. who suggested a cooperation of TLR3 and MDA5 in CVB3 RNA sensing, since 
CVB3 infection of TLR3 and MDA5 double knockout mice show a pronounced effect on mortality 
[41]. It has also been reported that CVB3 infection of MDA5 knockout mice does not result in an 
?????????????????????????????????????????????????????????????????????????????????????????
[148]. An involvement of MDA5 is further supported by the finding that IFIH1 gene encoding 
MDA5 is susceptible to T1DM [40]. As mentioned above, the present study showed no binding of 
MDA5 and RIG-I to CVB3 and CVB4 RNA 24 h p.i. This suggests that MDA5 and RIG-I are not 
involved in CVB sensing in isolated human islets. Another possible explanation is that 
expression of both receptors was too low in infected cells 24 h p.i. and that thus IP analysis 
showed no binding of those receptors to CVB3 and CVB4 RNA. This is supported by the qPCR 
results which showed that 24 h p.i. expression of PRRs in CVB3 and CVB4 infected cells was 
comparable to those in the control. 
As mentioned above, the engagement of PAMPs with PRRs induces the expression of 
chemokines and cytokines like Type I IFNs as antiviral defence mechanism. Previous microarray 
studies show that upon CVB4 and CVB5 infection, various genes involved in inflammation and 
antiviral defence were induced [111, 114]. Schulte at al. confirmed the secretion of several 
cytokines and chemokines [113]. In the present study the mRNA transcription of cytokines and 
chemokines ????????????????-6, IL-?? and ???? was induced, as those of PRRs, after CVB3 
and CVB4 infections of the islets and showed the same gene expression pattern as that of 
PRRs. Using a higher MOI of 20 resulted in earlier cytokine and chemokine gene expressions. 
The TLR3 knockdown using RNA interference showed that cytokine and chemokine levels 
especially of CXCL10 and ???? were drastically reduced after CVB3 and CVB4 infections, 
supporting the involvement of TLR3 in CVB3 and CVB4 infections of human islets. 
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The highest induction and secretion was found for CXCL10, consistent with reported data [111, 
113, 154]. The source of CXCL10 were ?????-cells itself, as demonstrated by immunostaining. It 
has been shown that CXCL10 induced activation of the TLR4 pathway has deleterious effects on 
?-cell survival [137]. In my study the application of a CXCL10 neutralizing antibody had no effect 
??? ?????? ???????? ?-cell destruction, suggesting that apoptosis was induced by other 
mechanisms. CXCL10 attracts CXCR3 expressing cells such as activated T-cells, monocytes 
and natural killer cells [125]. It has been shown that CXCL10 serum levels are elevated in T1DM 
and in patients with a high risk to develop the disease [126-128]. In addition, CXCL10 expression 
has been detected in pancreatic sections from three patients who died due to fulminant T1DM. 
All three patients showed VP1 expression in islets which were infiltrated by CXCR3+ T-cells, 
suggesting an important role for CXCL10 in virus-induced insulitis [102]. This is supported by a 
study performed in LCMV infected RIP-GP mice where the application of CXCL10 neutralizing 
antibodies prevented the induction of T1DM [129].  
Together with CXCL10, the ???? gene was highly transcribed in CVB3 and CVB4 infected islets. 
However, consistent with previous reports, ?????protein secretion was not detectable neither by 
???????????????plaque reduction assay (data not shown) [113]. ?????????????????????belong to 
the family of type I IFNs, have very strong antiviral activities. ???????????????????????????????????
and paracrine way. It binds to the ubiquitously expressed ??????? ????????? ?IFNAR) on 
neighbouring cells, which results in the expression of various ISGs (e.g. PKR, OAS1, ISG-15) 
through the JAK/STAT pathway [155]. The finding t???? ????? ???????? ???? ???? ???????ble in 
supernatants from islets infected with CVB3 or CVB4, might be explained by rapid uptake by 
neighbouring cells. This explanation is supported by the finding that the percentage of CVB3 and 
CVB4 ??????????-cells decreas?????????? ????????????????????????can act in a paracrine manner 
and induce expression of proteins with antiviral activities and hence protect from CVB3 and 
CVB4 ?-cell infection. In addition?? ??????????????????????????? ?????????????? ??? ???????????????
expression of PRRs and CXCL10, showing ????????????????? ????????????????????????????????????
islets, confirming a study demonstrating induction of the antiviral state in human islets upon ?????
stimulation [136]. Another possible explanation for the non detection of ?????????????might be a 
CVB induced disruption of protein translation or secretion. Many viruses, including 
picornaviruses, evade host cell defences. Viral proteins interfere with pathways inducing IFN? 
gene expression or signalling or overcome the action of antiviral proteins [155]. It has been 
reported that CVB3 infection of HEK293 cells results in an only modest IRF3 induced ???? 
expression. The viral protease 3C cleaves the adaptor proteins MAVS and TRIF, which mediate 
RIG-I, MDA5 and TLR3 signalling [156].  
Discussion 
74 
The locally produced proinflammatory cytokines and chemokines may have adverse effects on 
?-cells, leading to cell death [72, 73]. IL-6 is a cytokine with various biological functions in 
inflammation, immune regulation, hematopoiesis and oncogenesis. Its expression is induced 
upon viral infections and it has been shown to be also ?????????????-cells. Elevated IL-6 levels 
are implicated in autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis 
(RA), possibly due to its ability to inhibit TGF-?-induced Treg differentiation [157]. It has been 
shown that IL-6 induces insulin resistance in adipose tissue and in the liver, and it may synergize 
with other proinflammatory cytokines to induc???-cell apoptosis [158].  
IL-??? ???? ????? ? ????????? ??? the co-stimulation of T-cell function, B-cell proliferation and 
generation of Th17 response [159]. Various studies show that IL-??? affects ?-cell survival. 
Exposure of isolated human islets to IL-??? ?????? ??? ? ??????? ?-cell survival and function and 
induction [70]. It has been shown that elevated glucose concentrations trigger the production of 
IL-??, resulting in IL-??????????????????????????????????????????[160].  
???? alone or in combination with IL-?????????????????????????????????????-cell apoptosis [73]. 
 
TLR3 has been shown to have pro-apoptotic functions [161]. In the present study, the infection 
of TLR3 depleted ?????????????????????????????????????????????????????????-cell apoptosis, 
???????????????????????????????????? ?????????-cell death. This was demonstrated by cleavage of 
caspase 3 and the TUNEL assay. This result is supported by the finding that islets isolated from 
????????????????????????????????????????????????????????????????????????????-cell apoptosis, 
suggesting a pro-????????????????????????????-cells [162]. In addition, CVB 3C protein has been 
shown to interfere with the Type I IFN pathway, as already mentioned above, and to reduce the 
TLR3-TRIF-dependent apoptosis [156]. Furthermore TLR3 induces apoptosis in prostate cancer 
cells [163] and human breast cancer cells [164]. The Poly I:C induced apoptosis in melanoma 
cells was reported to be caspase 8-dependent [161]. A recent study by Sun et al. showed that 
both extrinsic and intrinsic apoptotic pathways are involved in TLR3 dependent apoptosis. This is 
due to the TLR3 dependent activation of a p53-???????????????????????????????????????????????????
(TAp63??? which activates both apoptotic pathways [165].  
In the present study, the decrease of caspase 3 correlated with an increase in VP1 bands in 
TLR3 depleted islets infected with CVB3 and CVB4, suggesting that apoptosis was not induced 
by CVB3 and CVB4 but rather through cellular mechanism. Apoptosis is a potent antiviral 
mechanism, limiting viral spread [166]. Decrease of apoptosis in viral infected cells could lead to 
the increase in virus spread and thus to higher replication. In addition, TLR3 depletion can lead 
to lower gene expression and secretion of cytokines and chemokines like Type I IFNs, which 
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may result in a lower antiviral response and thus in higher viral replication. The finding observed 
is also supported by the fact that ????? ?????es the so called “antiviral state” by increasing the 
expression of various antiviral ISGs in neighbouring cells which are not infected. The infection of 
such a “warned” cell leads to apoptosis [166].  
It has been shown that the JNK pathway is activated upon various stress stimuli including, UV 
irradiation, hyperosmolarity, and heat shock, and upon exposure of pro-inflammatory cytokines 
????? ??? ????????? ??-??? [167]. JNK is a member if a group of serin/threonin protein kinases 
known as mitogen activated protein kinases (MAPK). The JNK pathway is involved in cell 
apoptosis. JNK dependent apoptosis is mediated by the transport of proapoptotic proteins like 
Bax to the mitochondria, resulting in cytochrome c release from mitochondria to the cytoplasm 
[168]. It has been reported that the JNK pathway is also involved in virus mediated apoptosis 
induced by some viruses such as poliovirus [169]. The MAP kinases JNK and p38 are also 
involved in the TLR, MDA5 and RIG-I mediated induction of Type I IFNs [52] and it has been 
reported that TLR3 mediated apoptosis was dependent on JNK and p38 in a human prostate 
cancer cell line. This was investigated by the application of the JNK and p38 inhibitors 
SB203580 and SP600125 which results in the decrease of apoptosis after Poly I:C treatment 
[163]. In addition, it has been shown that CVB3 infection of Hela cells results in cell apoptosis 
which is dependent on JNK [170]. 
The present study showed the involvement of JNK in CVB3 infected CM cells. JNK 
phosphorylation was also observed in CVB3 and CVB4 infected human islets. Here, the caspase 
3 cleavage correlated with the phosphorylation of JNK, demonstrated by western blotting, 
suggesting a possible role for pJNK in CVB3 mediated apoptosis in CM cells and human islets. 
In this study the application of the JNK inhibitor SP600125 also resulted in the decrease of 
apoptosis, as mentioned above, in CVB3 and CVB4 infected islets, as demonstrated by western 
blotting. However, SP600125 treatment also resulted in the decrease of VP1 bands, suggesting 
that the inhibitor causes alterations in CVB replication. Due to that, a dominant negative variant 
of JNK1 was overexpressed in isolated human islets. Overexpression resulted in increase of 
both isoforms of JNK, JNK1 and 2, suggesting a mutual regulation of JNK1 and 2 gene 
expressions. CVB3 infected isolated human islets overexpressing dnJNK1 showed less 
apoptosis compared to control. The results obtained imply a role for activated JNK in the CVB3 
induced apoptosis in isolated human islets. However, the rescuing effect was only partial 
demonstrated by reduced cleavage of caspase 3 and PARP, although JNK function was 
absolutely inhibited demonstrated by the loss of the phosphorylation of c-Jun. Due to the 
restricted access to isolated human islets, the results from the dnJNK overexpressing study were 
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performed once and need additional confirmation. The possible relationship between TLR3 and 
JNK pathways was not further investigated.  
Previous studies reveal that JNK activation can be mediated trough PKR [171]. In the present 
study it has been shown that PKR is engaged by CVB3 and CVB4 RNA, which resulted in the 
activation of PK??????????????????????????????????????????????????????????-immunoprecipitation 
analysis performed in this study showed no association between PKR and JNK, suggesting that 
PKR had no effect on JNK activation (data not shown).  
It has been clearly indicated that PKR is involved in virus induced apoptosis. This is mainly 
dependent on the FADD/caspase 8 pathway. In addition, it has been suggested that the 
??????????????????? ?????????? ???? ?????????????? ????????????????????????apoptosis [172]. In my 
study PKR inhibition with the known inhibitor 2-AP resulted in side effects including alterations in 
CVB3 and CVB4 replication demonstrated by the massive decrease of VP1 bands displayed by 
western blotting. 2-AP is a guanosine and adenosine analog. Possibly, integration of the analog 
during viral replication can lead to alterations in replication and less VP1 expression. The 
application of another PKR inhibitor, PKRi, resulted in decreased apoptosis in CM cells following 
Poly I:C transfection. However, PKRi had no effect on CVB3 and CVB4 induced apoptosis in 
isolated human islets, suggesting that PKR is not involved in the CVB mediated induction of 
apoptosis in human isolated islets. To eliminate side effects caused by inhibitors, other methods 
such as RNA interference should be applied.  
 
This study shows for the first time the involvement of TLR3 in virus induced expression of pro-
inflammatory genes and the involvement of TLR3 and JNK in ????????????????-cell apoptosis. 
Apoptotic ?-cells can be phagocytised by APCs leading to the presentation of viral but also of ?-
cell antigens. This results in activation of cytotoxic T-cells. In addition, high expression of 
cytokines and chemokines such as CXCL10 contribute to the attraction and the activation of 
immune cells. Both effects can be crucial for the initialization of autoimmunity in genetically 
susceptible individuals. 
 
In conclusion, this study showed that in vitro infection of isolated human islets with CVB3 and 
?????????????? ????-cell infection, apoptosis and impaired function. Both viruses induced TLR3 
dependent expression of several pro-inflammatory genes and CXCL10 secretion in which the 
????????????????????? ?????-cell itself. Virus indu?????-cell apoptosis was dependent on the 
TLR3 and JNK pathways. This study can contribute to the understanding of cellular mechanisms 
????????????-cell infection in order to develop new therapies to prevent CVB induced T1DM.  
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Figure 25: Proposed mechanism of CVB3 and CVB4 induced apoptosis and gene 
upregulation of cytokines and chemokines ????- ?????-cells. CVB3 and CVB4 infections ????-
cells result in binding of CVB3 and CVB4 RNA to TLR3 which leads to the activation of the TLR3 pathway 
and upregulation of cytokine, chemokine and PRR gene expressions. Binding of CVB3 and CVB4 RNA to 
PKR results in phosphorylation and activation of PKR, which in turn phosphorylates ?????? ???? ?????
induces translational stop. In addition JNK and TLR???????????????????????-cells. Whether JNK induced 
???????????????????????????????????????????????????????????????????????????-cells results in binding of 
CVB3 and CVB4 RNA to TLR3 as well as to TLR7. 
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XOMA 052, an Anti-IL-1b Monoclonal Antibody,
Improves Glucose Control and b-Cell Function in the
Diet-Induced Obesity Mouse Model
Alexander M. Owyang,* Kathrin Maedler,* Lisa Gross, Johnny Yin, Lin Esposito,
Luan Shu, Jaaee Jadhav, Erna Domsgen, Jennifer Bergemann, Steve Lee,
and Seema Kantak
Preclinical Research and Development (A.M.O., L.G., J.Y., L.E., S.L., S.K.), XOMA (US) LLC, Berkeley,
California 94710; and Centre for Biomolecular Interactions (K.M., L.S., J.J., E.D., J.B.), University of
Bremen, D-28359 Bremen, Germany
Recent evidence suggests that IL-1b-mediated glucotoxicity plays a critical role in type 2 diabetes
mellitus. Although previous work has shown that inhibiting IL-1b can lead to improvements in
glucose control and b-cell function, we hypothesized that more efficient targeting of IL-1b with a
novel monoclonal antibody, XOMA 052, would reveal an effect on additional parameters affecting
metabolic disease. In the diet-induced obesity model, XOMA 052 was administered to mice fed
either normal or high-fat diet (HFD) for up to 19 wk. XOMA 052 was administered as a prophylactic
treatment or as a therapy. Mice were analyzed for glucose tolerance, insulin tolerance, insulin
secretion, and lipid profile. In addition, the pancreata were analyzed for b-cell apoptosis, prolif-
eration, and b-cell mass. Mice on HFD exhibited elevated glucose and glycated hemoglobin levels,
impaired glucose tolerance and insulin secretion, and elevated lipid profile, which were prevented
by XOMA 052. XOMA 052 also reduced b-cell apoptosis and increased b-cell proliferation. XOMA
052 maintained the HFD-induced compensatory increase in b-cell mass, while also preventing the
loss in b-cell mass seen with extended HFD feeding. Analysis of fasting insulin and glucose levels
suggests that XOMA 052 prevented HFD-induced insulin resistance. These studies provide new
evidence that targeting IL-1b in vivo could improve insulin sensitivity and lead to b-cell sparing. This
is in addition to previously reported benefits on glycemic control. Taken together, the data pre-
sented suggest that XOMA 052 could be effective for treating many aspects of type 2 diabetes
mellitus. (Endocrinology 151: 2515–2527, 2010)
Type 2 diabetes mellitus (T2DM) is a worldwide epi-demic. Obesity and a sedentary lifestyle are major risk
factors for developing T2DM (1). T2DM occurs when the
b-cell fails to produce sufficient amounts of insulin to
maintain normoglycemia as a result of impaired b-cell
function and/or decreased b-cell mass (2), a condition gen-
erally accompanied by insulin resistance (3). Effective
treatments are necessary to prevent b-cell failure.
Obesity and insulin resistance have been associated
with chronic inflammation (4–6). Several inflammatory
molecules and pathways have been linked to insulin re-
sistance, including IL-1b, TNF-a, IL-6, and the nuclear
factor-kB pathway (7). Recent studies show that inflam-
matory markers (e.g. C-reactive protein and IL-1b) are
elevated in individuals with T2DM and in patients with a
significantly increased risk to develop the disease (8, 9).
IL-1b expression level and function are tightly regu-
lated by a complex system of IL-1 family members and
their receptors. IL-1b binds to the IL-1 receptor type I
(IL-1RI) expressed on all nucleated cells and highly ex-
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pressed on pancreatic islets (10), which triggers the re-
cruitment of the IL-1 receptor accessory protein to form
the active signaling complex. The natural inhibitor IL-1Ra
binds to IL-1RI but does not allow the recruitment of IL-1
receptor accessory protein (11, 12). IL-1b specifically im-
pairs survival of pancreatic b-cells and severely affects
b-cell insulin secretion (13). Moreover, blocking IL-1b by
specific IL-1b antibodies protects from the cytotoxic effect
induced by conditioned medium of activated mononu-
clear cells (14), indicating that IL-1b may play an impor-
tant role in the molecular mechanisms underlying auto-
immune b-cell destruction.
IL-1b has long been associated with autoimmune type
1 diabetes mellitus (15) and is also seen increasingly as a
key player in T2DM (16), although this has been under
debate (17). Studies on isolated islets have shown that
IL-1b is produced by the b-cell in response to chronic
glucose exposure (18–20). Elevated IL-1b expression was
observed in b-cells in pancreatic sections from autopsies
from patients with T2DM by immunostaining, as well as
by laser microdissection (18, 21), indicating that IL-b may
mediate b-cell destruction also in T2DM. Elevated pan-
creatic b-cell expression of IL-1b under hyperglycemic
conditions has also been observed in two animal mod-
els, Psammomys obesus and the Goto-Kakizaki (GK)
rat (18, 22).
Blocking IL-1b as a therapeutic strategy for T2DM has
been examined in several studies. In vitro, recombinant
IL-1Ra protected b-cells from glucose-induced apoptosis
and impaired function. Daily injection of recombinant IL-
1Ra in mice fed a high-fat/high-sucrose diet (HFD) im-
proved glycemia, glucose stimulated insulin secretion, and
b-cell survival (23) and reversed the islet inflammatory
phenotype in the GK rat (24). Importantly, results from a
recent clinical study in patients with T2DM showed that
recombinant IL-1Ra improved glycemic control and b-cell
function (25).
Because IL-1Ra has a short half-life, and must block the
ubiquitous IL-1RI to neutralize IL-1 activity, we were in-
terested in testing the efficacy of an agent that specifically
targets the ligand IL-1b, which is usually secreted only in
the local environment during inflammation. In the present
study, we show that inhibiting IL-1b with the monoclonal
antibody XOMA 052 improves glycemic control, b-cell
function and survival, dyslipidemia, and insulin sensitivity
in the diet-induced obesity (DIO) model of T2DM.
Materials and Methods
D10.G4.1 (D10) assay
Resting D10 cells (TIB-224; American Type Culture Collec-
tion, Manassas, VA) (26) were seeded in triplicate at 2 3 104
cells/well and were activated with 2.5 mg/ml of concanavalin A
(Con A) in combination with recombinant IL-1b (R&D Systems,
Minneapolis, MN). Proliferation was measured after 72 h by
Alamar Blue redox viability dye. To determine the potency of
XOMA 052, cells were treated with IL-1b and various amounts
of XOMA 052. IC50 values were determined using the curve-
fitting software program Prism (GraphPad Software, La Jolla,
CA). EC50 values for recombinant and native forms of IL-1b
were derived from dose-response curves generated by titrations
of recombinant cytokine or lipopolysaccharide-stimulated pe-
ripheral blood mononuclear cell supernatants.
In vivo assay for IL-1b activity
Female C57BL/6 mice were pretreated with PBS or XOMA
052, ip. Twenty-four hours later, they were injected sc with 20
ng of human IL-1b (hIL-1b) or mouse IL-1b (mIL-1b). Two
hours after IL-1b injection, blood was collected via retroorbital
bleed. Induction of IL-6 was measured by mIL-6 ELISA (BD
PharMingen, San Diego, CA).
Animals
C57BL/6J male mice were obtained from The Jackson Lab-
oratory (Bar Harbor, ME) at 5 wk of age. Beginning at 6 wk of
age, mice were fed either a normal diet (ND) (Harlan Teklad
Rodent Diet 8604, containing 12.2, 57.6, and 30.2% calories
from fat, carbohydrate, and protein, respectively; Harlan Lab-
oratories, Inc., Indianapolis, IN) or a HFD (containing 58, 26,
and 16% calories from fat, carbohydrate, and protein, respec-
tively; “Surwit” Research Diets, New Brunswick, NJ) (27) for
12–19 wk. Animals fed a HFD developed DIO.
Prophylactic studies
C57BL/6J male mice were treated twice weekly with ip in-
jections of XOMA 052 or isotype control (antikeyhole limpet
hemocyanin IgG2) or daily ip injections of recombinant IL-1Ra
(10 mg/kg, Kineret; Amgen, Thousand Oaks, CA) or vehicle
control, starting at 6 wk of age. Body weight and food consump-
tion were monitored weekly.
Therapeutic studies
The HFD was initiated in 6-wk-old C57BL/6 male mice with-
out drug injections. After 10 wk, XOMA 052 and vehicle were
given twice weekly for an additional 9 wk.
Treatment groups
The following treatment groups were examined: 1) ND IgG
(mice on ND and isotype control), 2) ND XOMA 052 (mice on
ND and XOMA 052), 3) HFD IgG (mice on HFD and isotype
control), 4) HFD XOMA 052 (mice on HFD and XOMA 052)
(for both prophylactic and therapeutic studies), 5) ND C (mice
on ND and vehicle control), 6) ND IL-1Ra (mice on ND and
IL-1Ra), 7) HFD C (mice on HFD and vehicle control), and 8)
HFD IL-1Ra (mice on HFD and vehicle IL-1Ra) (for prophylac-
tic studies).
Independent experiments were performed at three different
institutions: at XOMA (US) LLC, at The Jackson Laboratory–
West (Sacramento, CA), and at the University of Bremen.
All animals were housed in a temperature-controlled room
with a 12-h light, 12-h dark cycle and were allowed free access
to food and water according to the protocol and approved by the
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XOMA Institutional Animal Care and Use Committee and The
Jackson Laboratory–West Institutional Animal Care and Use
Committee, in compliance with the Guide for the Care and Use
of Laboratory Animals and the Bremen Senate in agreement with
the National Institutes of Health Animal Care Guidelines and
Section 8 of the German animal protection law.
Intraperitoneal glucose tolerance test (ipGTT) and
ip insulin tolerance test (ipITT)
After 4, 8, and 12 wk of diet and treatment (prophylactic
studies), or 10 and 19 wk of diet (therapeutic studies), all animals
underwent in vivo assays. For ipGTTs, mice were fasted 12 h
overnight and injected ip with glucose (40%; Phoenix Pharma-
ceuticals, Inc., St. Josephs, MO) at a dose of 1 g/kg body weight.
Blood samples were obtained at time points 0, 15, 30, 60, 90, and
120 min (prophylactic study) and at 0 and 30 min (therapeutic
studies) for glucose measurements using a Glucometer (Free-
style; TheraSense, Inc., Alameda, CA). For stimulated insulin
secretion, a dose of 2 g/kg body weight of glucose was injected,
and blood samples were obtained retroorbitally at time points 0
and 30 min. Serum insulin concentrations were determined using
a mouse insulin ultrasensitive ELISA (ALPCO, Salem, NH).
Stimulation index for insulin production was calculated by di-
viding the 30-min insulin values (stimulated) by the 0-min value
(basal).
For ipITTs, mice were injected ip with 0.75 U/kg body weight
recombinant human insulin (Novolin; Novo Nordisk, Bagsværd,
Denmark) after 5-h fasting, and glucose concentration was deter-
mined with the Freestyle Glucometer.
Histochemical analyses and b-cell mass
After 12 wk (prophylactic study) or 19 wk (therapeutic study)
of diet and treatment, pancreata were weighed and fixed over-
night in 4% paraformaldehyde at 4 C under continuous shaking,
followed by paraffin embedding, orienting pancreata such that
sections were cut along the head-tail axis.
Apoptosis, proliferation, and b-cell mass were analyzed as
described previously (23). Samples were evaluated in a random-
ized manner by two independent investigators (J.J. and K.M.)
who were blinded to the treatment conditions. Data are pre-
sented as means 6 SE and were analyzed by paired, Student’s t test
or by ANOVA with a Bonferroni correction for multiple group
comparisons. Histochemical analyses were performed on two of
three prophylactic studies and four of five therapeutic studies.
Homeostatic model of assessment-insulin
resistance (HOMA-IR)
HOMA-IR was calculated using the method employed by
Odegaard et al. (28): fasting insulin (ng/ml) 3 fasting glucose
(mmol/liter) 5 HOMA-IR.
IL-1b expression analysis
Total RNA from the epididymal fat pad, hypothalamus,
and pancreatic islets was extracted from mice in a prophylac-
tic study. Total RNA was isolated using the RNeasy Lipid Tis-
sue kit (QIAGEN, Inc., Valencia, CA). For quantitative analysis,
we used the LightCycler Quantitative PCR System (Roche Di-
agnostics, Indianapolis, IN) with a commercial kit (LightCycler
FastStart DNA Master plus SYBR Green I; Roche Diagnostics).
Mouse primers used were as follows: 59-gttggccaggctggtgtc-
cag-39 and 59-ctgtgatgagctgctcagggtgg-39 (tubulin), and 59-gac-
cttccaggatgaggaca-39 and 59-agctcatatgggtccgacag-39 (IL-1b).
Serum lipid analysis
Serum obtained by cardiac puncture at the time of killing was
analyzed for serum lipids by the University of California, Los
Angeles, Lipid and Lipoprotein Laboratory as described previ-
ously (29). All lipid assays were performed in triplicate. An ex-
ternal control sample with known analyte concentration was run
for each assay to assure accuracy. Free plasma glycerol concen-
trations were also determined and used to correct the triglyceride
values. Non-HDL cholesterol was calculated by subtracting
HDL levels from total cholesterol.
Glycated hemoglobin (HbA1c)
HbA1c was measured at the end of the study using A1CNow1
(Bayer Healthcare, Sunnyvale, CA).
Results
XOMA 052 neutralizes IL-1b activity in vitro and
in vivo
The human engineered anti-IL-1b IgG2 antibody,
XOMA 052, was developed for human therapeutic use
and has a very high affinity [dissociation constant (KD) 5
0.3 pM] to hIL-1b and a 10,000-fold lower affinity to
mIL-1b of 3.0 nM (Roell, M., H. Issafras, R. Bauer, K.
Michelson, N. Mendoza, S. Vanegas, L. Gross, P. Larsen,
D. Bedinger, D. Bohmann, G. Nonet, N. Liu, S. Lee, S.
Kantak, A. Horwitz, J. Hunter, A. Owyang, A. Mirax, J.
Corbin, and M. White, unpublished observations).
To determine the neutralization activity of XOMA 052
in vitro, we used the mouse D10 proliferation assay. Hu-
man, rhesus macaque, and mIL-1b are able to stimulate
D10 cells with a similar potency of 0.2–0.3 pM (Fig. 1A).
In neutralization experiments with D10 cells, XOMA 052
had an IC50 against hIL-1b in the low pM range (2.5 6 0.4
pM; Fig. 1B). Interestingly, XOMA 052 was also able to
neutralize mIL-1b activity, with an IC50 of 2.6 6 0.4 nM
(Fig. 1B). Neutralization of IL-1 activity was specific for
IL-1b, because XOMA 052 did not neutralize IL-1a (Sup-
plemental Fig. 1, published on The Endocrine Society’s
Journals Online web site at http://endo.endojournals.org).
We next tested the ability of XOMA 052 to neutralize
IL-1b in vivo. C57BL/6 mice were pretreated with various
doses of antibody. Twenty-four hours later, mice were
injected with 20 ng of either hIL-1b or mIL-1b. Mouse
IL-6 in the serum was measured after 2 h. As expected,
XOMA 052 at a low dose was able to neutralize the in vivo
activity of hIL-1b (Fig. 1C). The antibody achieved 73%
inhibition of IL-6 induction at 0.15 mg/kg and 66% in-
hibition at 15 mg/kg. XOMA 052 could also neutralize
mIL-1b, but only at the higher dose of 15 mg/kg, achieving
47% inhibition (Fig. 1D). Thus, although designed for
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human use, XOMA 052 exhibits sufficient potency for
studies in murine models.
XOMA 052 has no effect on weight gain or food
intake in mice
To assess the effect of specifically inhibiting IL-1b in
T2DM, studies with XOMA 052 were performed in the
DIO model. Mice were fed ND or HFD (“Surwit”) (30).
Two types of studies were performed, based on prophy-
lactic and therapeutic administration of XOMA 052. In
both cases, 5- to 6-wk-old C57BL/6J mice were fed either
ND or HFD, and either XOMA 052 or IgG2 isotype con-
trol antibody was administered twice weekly. In the pro-
phylactic studies, XOMA 052 treatment was adminis-
tered in parallel with the different diets at 5–6 wk of age
for 12–14 wk. In the therapeutic studies, mice were fed the
diets for 19 wk with treatment administered from wk
11–19 of the diet.
Mice fed HFD gained more weight than the ND group,
which reached significance at 3 wk. XOMA 052 had no
effect on food intake (data not shown) nor on weight gain.
After 12 wk of treatment, body weight of control mice was
32 6 0.7 g on HFD vs. 26 6 0.9 g on
ND, P , 0.01, and of XOMA 052-
treated mice, 32 6 1.2 g on HFD vs.
28 6 0.4 g on ND, P , 0.01 (prophy-
lactic study). In the therapeutic study (9
wk of antibody treatment), body weight
of control mice was 43 6 3.6 g on HFD
vs. 28 6 1.2 g on ND, P , 0.01, and of
XOMA 052-treated mice, 42 6 4.9 g on
HFD vs. 31 6 1.5 g on ND, P , 0.01.
XOMA 052 improves glucose
tolerance, insulin secretion, and
insulin sensitivity in mice
Prophylactic studies
After 4 wk on diet, untreated HFD
mice developed glucose intolerance as
measured by ipGTT. After 8 wk of diet,
HFD mice displayed elevated fasting
glucose levels relative to ND mice (90 6
3 mg/dl for untreated HFD control mice
vs. 77 6 4 mg/dl for ND control mice,
P , 0.05), which was prevented by
XOMA 052 treatment in the HFD
group (76 6 4 mg/dl, P , 0.05). The
study was performed in three indepen-
dent experiments with four to eight
mice in each group, respectively, and
showed similar results in each experi-
ment. Figure 2A, left panel, shows fast-
ing glucose after 12 wk on diet. Addi-
tionally, average long-term glycemic control was assessed
in the prophylactic studies by measuring the HbA1c levels
in serum. After 12 wk on HFD, untreated mice had ele-
vated HbA1c compared with ND mice, which was reduced
to control levels by XOMA 052 treatment (P , 0.01; Fig.
2B, left panel). In treated HFD mice, XOMA 052 was able
to significantly improve glucose tolerance after 4, 8, and
12 wk on HFD (ipGTT after 12 wk on diet; Fig. 2C, left
panel).Areaunder the curveanalysis revealed significantly
lower glucose levels in the XOMA 052-treated HFD mice
(P , 0.05; Fig. 2D, left panel). Treatment of mice with
daily injections of 10 mg/kg recombinant IL-1Ra im-
proved fasting glucose (Fig. 2A, right panel), HbA1c (Fig.
2B, right panel), and glucose tolerance (Fig. 2, C and D,
right panel), with results similar to XOMA 052 treatment.
Because inhibition of IL-1b led to an improvement in
glycemic control, mice were assessed for the effect of
XOMA 052 on insulin secretion. Fasted mice were chal-
lenged with 2 g/kg glucose, and insulin secretion was as-
sessed before (0 min) and 30 min after glucose injection. In
parallel with the hyperglycemia, high-fat feeding resulted
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in hyperinsulinemia (Fig. 3A) compared with ND mice.
Fasting insulin levels were 2.1-fold higher in untreated
HFD mice compared with ND (P , 0.05; Fig. 3A). In
addition, untreated HFD mice also failed to considerably
increase their insulin levels in response to a glucose chal-
lenge, whereas control ND mice exhibited a stimulatory
index of 2.2 and the ND-XOMA 052 mice of 2.7, respec-
tively (Fig. 3B). HFD mice under XOMA 052 treatment
exhibited significantly lower fasting insulin levels than un-
treated HFD mice (1.3-fold difference, P , 0.001; Fig.
3A), and glucose stimulated insulin se-
cretion was restored (1.4-fold increased
stimulatory index compared with un-
treated HFD control, P , 0.05; Fig. 3B).
Normalization of fasting insulin lev-
els in treated HFD mice suggests a pos-
sible effect of XOMA 052 on insulin
resistance. This observation was con-
firmed by the analysis of HOMA-IR
(Fig. 3C). HOMA-IR is shown as the
product of fasting insulin and fasting
glucose as employed previously (28). In
untreated mice, HOMA-IR was ele-
vated 4-fold by the HFD, which was
greatly reduced by XOMA 052 (2.4-
fold decrease compared with the un-
treated HFD control; Fig. 3C). To fur-
ther assess the effect of XOMA 052
treatment on insulin resistance, we per-
formed an ITT by measuring glucose
concentrations after ip injection of in-
sulin at 0.75 U/kg of body weight (ip-
ITT). No significant differences in glu-
cose levels were observed between
treated and untreated animals of the
ND group (Fig. 3D). Untreated HFD-
mice showed elevated glucose levels
throughout the test compared with ND
mice. In contrast, in the XOMA 052-
treated HFD mice, glucose levels were
significantly lower than the untreated
HFD mice before and at 90 min after the
insulin injection (P , 0.05; Fig. 3D).
Area under the curve analysis revealed
significantly lower glucose levels in the
XOMA 052-treated HFD mice at wk 8
and 12 (Fig. 3E; P , 0.05).
The impaired glucose and insulin tol-
erance in DIO mice correlated with an
increase in IL-1b expression. IL-1b
mRNA was significantly elevated by
HFD in the epididymal fat, hypothal-
amus, and pancreatic islets (Fig. 3F).
This was significantly reduced by XOMA 052 treatment.
Therapeutic studies
XOMA 052 also was tested for its ability to improve
glycemia and insulin secretion under conditions of exist-
ing impaired glucose tolerance. The study was performed
in five independent experiments with eight to 10 mice in
each group, respectively, and showed similar results in
each experiment. Untreated mice on HFD for 10 wk dis-
A
prophylactic dosing
150
Control
150
IgG *
50
100
Kineret
50
100
XOMA 052
g
lu
c
o
s
e
(m
g
/d
l)
 
g
lu
c
o
s
e
(m
g
/d
l)
 
*
**
**
B 6
IgG
IL-Ab
1
c
*
**
XOMA 052
6
Control
Kineret
1
c
*
**
00
4
5
%
 H
b
A
1
ND                       HFD
4
5
%
 H
b
A
1
ND                       HFD
C
300
450
/ d
l) 300
450
g
/d
l)
**
**
0
150
g
lu
c
o
s
e
 (
m
g
ND IgG
HFD IgG
ND XOMA 052
HFD XOMA 052
0
150
g
lu
c
o
s
e
 (
m
g
ND C-Kin
HFD C-Kin
ND Kin
HFD Kin
*
*
**
**
**
**
Week 4
Week 8
Week 12
30000
40000
**
**
**
o
s
e
)
D
min after injection  
0          15         30         60            90        120
min after injection  
0          15         30         60            90        120
30000
40000
Week 4
Week 8
Week 12
**
**
**
o
s
e
)
0
10000
20000
A
U
C
 (
g
lu
c
o
IgG                       XOMA 052 Control Kineret
0
10000
20000
A
U
C
 (
g
lu
c
o
FIG. 2. XOMA 052 improves glucose tolerance in mice: prophylactic study. Mice were fed a
ND or HFD and injected twice weekly with either IgG2 (control) or XOMA 052 at 1 mg/kg (left
panel) or daily with either 10 mg/kg recombinant IL-1Ra or vehicle (right panel) for 12 wk.
Data shown are from one representative experiment out of three (n 5 4 mice/group). A,
Fasting serum glucose after 12 wk of diet. B, GHbA1c after 12 wk of diet. C, ipGTT. Blood
glucose levels in mice after 12 wk of diet and XOMA 052 treatment after overnight fasting (0
min) and after ip injection of 1 g/kg body weight glucose. D, Area under the curve (AUC)
analysis of ipGTT results from the HFD groups after 4, 8, and 12 wk of diet. Data show
mean 6 SE. *, P , 0.05 HFD vs. ND, same treatment; **, P , 0.05 XOMA 052 vs. IgG2, same
diet. Kin, Kineret; C-Kin, vehicle control.
Endocrinology, June 2010, 151(6):2515–2527 endo.endojournals.org 2519
played increased fasting glucose (1.4-fold increase for
HFD vs. ND mice, P , 0.0001; Fig. 4A), as well as im-
paired glucose tolerance (1.3-fold increase in glucose lev-
els 30 min after glucose injection for HFD vs. ND mice,
P , 0.0001; Fig. 4A). The two diet groups were separated
into control and XOMA 052 groups, and the diet was
continued with XOMA 052 or isotype
control administration for 9 wk. Figure
4B shows fasting and stimulated glu-
cose levels (during ipGTT) at the end of
the study. Isotype control injected mice
on HFD showed higher fasting glucose
levels and higher stimulated glucose lev-
els compared with ND mice (Fig. 4B).
The elevated stimulated glucose was
lowered significantly by XOMA 052
treatment (Fig. 4B). In parallel, serum
insulin was measured before and after
glucose injection. After 10 wk of diet,
fasting insulin levels were 1.4-fold
higher in HFD than ND mice (P , 0.05;
Fig. 4C), and glucose stimulated insulin
secretion was abolished by the HFD
(P , 0.0001; Fig. 4D). When HFD mice
were treated with XOMA 052, glucose-
stimulated insulin secretion was sig-
nificantly restored (P , 0.05; Fig. 4F).
Although stimulatory index was de-
creased in the control HFD group com-
pared with the control ND group (Fig.
4F), stimulatory index was improved
by XOMA 052 treatment (1.7-fold in-
creased compared with the HFD con-
trol group, P , 0.05; Fig. 4F). As an
indicator of insulin resistance, HOMA-
IR was assessed before and after treat-
ment. At 10 wk of diet, HOMA-IR was
elevated more than 2-fold in HFD (Fig.
4G) and was further increased after 19
wk of HFD (2.9-fold increased in the
HFD vs. ND control mice, Fig. 4H).
Nine weeks of XOMA 052 treatment
inhibited the HFD-induced increase in
HOMA-IR (1.3-fold decrease in the
HFD-XOMA 052 vs. HFD control, P ,
0.01; Fig. 4H).
XOMA 052 improves b-cell
survival and restores b-cell mass
To investigate whether the XOMA
052 effects on improved glucose toler-
ance and insulin secretion were accom-
panied by improved b-cell survival, we
analyzed b-cell apoptosis, proliferation, and b-cell mass in
all four groups of mice in the prophylactic and all four
groups in the therapeutic studies after 12 and 19 wk of
diet, respectively. After 12 wk of diet, islet b-cell apoptosis
was increased by HFD feeding (2.3-fold increase in the
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HFD vs. ND control, P , 0.001; Fig. 5C). In contrast,
XOMA 052 completely restored b-cell survival: it de-
creased b-cell apoptosis and also increased proliferation.
XOMA 052 also decreased b-cell apoptosis under ND
conditions (3-fold reduction in XOMA 052-treated ND
mice vs. control ND mice, P , 0.05; Fig. 5C). Previously,
we reported increased b-cell mass in mice after 12 wk of
HFD despite the tendency for increased b-cell apoptosis at
that time point (23). Also, in the current studies, the HFD-
induced changes in apoptosis and proliferation were not
reflected in the b-cell mass results. HFD feeding induced a
compensatory increase in b-cell mass in both control and
XOMA 052 HFD-treated groups (P , 0.05; Fig. 5E).
In line with the results after 12 wk of diet, HFD feeding
induced apoptosis and reduced proliferation after 19 wk
of diet (Fig. 5, F and G, respectively). As in the prophy-
lactic studies, in the therapeutic studies, XOMA 052 sig-
nificantly inhibited apoptosis (P , 0.001; Fig. 5F) and
increased proliferation (P , 0.001; Fig. 5G) in HFD-fed
mice. In contrast to the findings after 12 wk of diet, no
compensatory increase in b-cell mass was observed in con-
trol mice after 19 wk on HFD compared with those on ND
(Fig. 5H). Importantly, the compensatory increase in
b-cell mass was maintained in XOMA 052-treated mice
after 19 wk (P , 0.001; Fig. 5H).
XOMA 052 protects from HFD-induced changes in
lipid levels
At the end of each study, we measured serum lipid lev-
els. HFD treatment has been shown to increase levels of
serum lipids, and elevation of lipids is known to affect
insulin action and secretion (31). Levels of triglycerides,
free fatty acids (FFA), total cholesterol, and high-density
lipoprotein (HDL) were analyzed after 12 and 19 wk of
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diet and treatment. Non-HDL cholesterol was calculated
by subtracting HDL levels from total cholesterol.
Triglyceride levels, FFA, total cholesterol, and non-
HDL cholesterol were increased by HFD feeding after 12
and 19 wk in the control IgG-treated mice [12 wk, P ,
0.05 (Fig. 6, A–D); 19 wk, P , 0.05 (Fig. 6, E–H)]. Treat-
ment of HFD mice with XOMA 052 significantly reduced
lipid levels relative to untreated HFD mice, and HDL lev-
els were unaffected by XOMA 052 (data not shown). In
the prophylactic study, there was a 35% reduction in trig-
lycerides, a 29% reduction in FFA, a 22% reduction in
total cholesterol, and a 73% reduction in non-HDL cho-
lesterol in XOMA 052-treated HFD compared with con-
trol HFD mice (P , 0.05; Fig. 6, A–D). The results of the
therapeutic studies were consistent with the prophylactic
results (Fig. 6, E–H). There was a 22% reduction in trig-
lycerides, a 14% reduction in FFA, a 16% reduction in
total cholesterol, and a 76% reduction in non-HDL cho-
lesterol in XOMA 052-treated HFD compared with con-
trol HFD mice (P , 0.05; Fig. 6, D–F).
FIG. 5. XOMA 052 improves b-cell survival and restores b-cell mass. A, Triple staining for terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) in red, insulin in green, and 49,6-diamidino-2-phenylindole (DAPI) in blue was performed on fixed, paraffin-embedded islet
sections (magnification, 3250). White arrows indicate TUNEL positive b-cells (triple stained). B, Triple staining for proliferation by Ki67-antibody in
red, insulin in green, and DAPI in blue was performed on fixed, paraffin-embedded mouse pancreas sections (magnification, 3250). White arrows
indicate Ki67 positive b-cells (triple stained). C and F, Results are expressed as percentage of TUNEL-positive b-cells 6 SE. The mean number of b-
cells scored was 8191 6 830 (C) or 7098 6 3011 (F) for each treatment condition in two (C) or four (F) independent experiments. D and G,
Results are expressed as percentage of Ki67-positive b-cells 6 SE. The mean number of b-cells scored was 5370 6 619 (D) or 3338 6 916 (G) for
each treatment condition in two (D) or four (G) independent experiments. E and H, b-Cell mass per pancreas was estimated as the product of the
relative cross-sectional area of b-cells (determined by quantification of the cross-sectional area occupied by b-cells divided by the cross-sectional
area of total tissue) and the weight of the pancreas. Ten sections per mouse spanning the width of the pancreas were included in the analysis.
Data show mean 6 SE from two (prophylactic; C–E) or four (therapeutic; F–H) independent experiments. *, P , 0.05 HFD vs. ND, same treatment;
**, P , 0.05 XOMA 052 vs. IgG2, same diet.
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The protective effect of XOMA 052 treatment was seen
for all three lipid measures (i.e. triglycerides, cholesterol,
and FFA), which all reached significance in two out of
three prophylactic studies; significance was reached for
triglycerides in two, for cholesterol in five, and for FFA in
three out of five therapeutic studies. The prophylactic
study experiments were performed three times and the
therapeutic study experiments five times in three animal
facilities. The use of multiple animal facilities may help
explain variations observed in serum lipid levels between
study experiments.
Discussion
Novel treatments for diabetes which target the preserva-
tion of the b-cell are urgently needed. In the present study,
we show that specific inhibition of IL-1b by an antibody
preserved b-cell mass and function sufficiently to main-
tain normoglycemia in a DIO model. The effect on gly-
cemic control observed for XOMA 052 was accompa-
nied by improved insulin secretion, improved lipid
profile, decreased b-cell apoptosis, and increased b-cell
proliferation.
An important advantage of XOMA 052 over the pre-
viously studied IL-1 pathway inhibitor IL-1Ra is that, due
to its longer circulatory half-life, XOMA 052 may be ad-
ministered much less frequently than the daily injections of
recombinant IL-1Ra required to achieve similar results.
The effects of XOMA 052 were observed despite the fact
that the affinity and in vivo potency of XOMA 052 for
mIL-1b is 1000- to 10,000-fold lower than for hIL-1b.
Thus, in comparison with IL-1Ra, which inhibits both
IL-1a and IL-1b, the longer half-life and specificity of
XOMA 052 for IL-1b may provide major advantages for
use as a therapy in human patients.
The initial doses of XOMA 052 in the DIO model were
based on previous work in the collagen-induced arthritis
model. Because the DIO model requires 12–14 wk of dos-
ing, and XOMA 052 is a human antibody, we wished to
avoid a potential mouse antihuman antibody response; 5
mg/kg was the top dose attempted, which is the lowest
effective dose in collagen-induced arthritis (our unpub-
lished observations). We have performed preliminary ex-
periments with 0.01, 0.1, 1, and 5 mg/kg; 0.1 and 1 mg/kg
XOMA 052 have so far been the optimal doses for im-
proving metabolic parameters.
Although the link between inflammation and insulin
resistance is substantial (4), in vivo evidence of a role for
IL-1b on the b-cell itself and in insulin resistance has not
yet been demonstrated in a model of T2DM. Previous
work used recombinant IL-1Ra, which blocks both IL-1a
and IL-1b. Other studies lack data on insulin resistance
FIG. 6. XOMA 052 prevents HFD-induced changes in lipid levels. Mice were fed a ND or HFD for 12 wk and injected from wk 0 to 12 with 1 mg/
kg XOMA 052 (prophylactic) or for 19 wk and injected from wk 11–19 with 1 mg/kg XOMA 052 (therapeutic). Fasting serum was obtained at the
end of the study and triglycerides (A and E), FFA (B and F), and total cholesterol (C and G) were measured. Non-HDL cholesterol (D and H) was
calculated by subtracting HDL from total cholesterol. A–D, Prophylactic study, performed in three separate experiments. Data show results from
one representative experiment. E–H, Therapeutic study, performed in five separate experiments. Data show results from one representative
experiment. Data show mean 6 SE. *, P , 0.05 HFD vs. ND, same treatment; **, P , 0.05 XOMA 052 vs. IgG2, same diet.
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and stimulated insulin secretion (32). The present work
provides evidence in vivo that IL-1b is a key mediator of
b-cell dysfunction, survival, and peripheral insulin
sensitivity.
The effect of IL-1b antibody on insulin sensitivity was
calculated by the HOMA-IR model. The calculated
HOMA-IR measure of insulin resistance was significantly
higher in the HFD-fed mice and was normalized by
XOMA 052 treatment. Although the HOMA-IR index is
not the most accurate method for assessing insulin resis-
tance compared with the hyperinsulinemic-euglycemic
clamp, the combined result of normalized HOMA-IR and
improved insulin sensitivity during an ipITT indicate a
protective effect of XOMA 052 on insulin sensitivity. In
line with our observation, administration of recombinant
IL-1Ra improved insulin sensitivity (as assessed by
HOMA-IR) in the GK rat (24).
The ability of XOMA 052 to improve glycemic control
and b-cell function was observed consistently across eight
independent experiments. A recent study with another anti-
IL-1b antibody, 1400.24.17, also showed a reduction in
HbA1c but did not show an effect on fasting plasma glucose
(32). There was no significant effect of the 1400.24.17 an-
tibody on serum lipid levels. Although we report some vari-
ation in effect on serum lipid levels among the mice, our
multiple studies with XOMA 052 show a consistent trend of
lipid lowering effects. Osborn et al. (32) report results of one
experiment with eight to 12 mice in each group, which could
be a possible explanation for the lack of observed effect on
plasma glucose and lipid levels.
In the current study, we included the additional ap-
proach of a therapeutic study. Treatment with XOMA
052 was initiated in mice that were already obese and that
demonstrated hyperglycemia and impaired glucose toler-
ance, as well as impaired insulin secretion. Importantly, in
the therapeutic study, serum glucose levels, which were
elevated during the HFD feeding, could be decreased by
XOMA 052 treatment for an additional 9 wk, even when
the HFD feeding was maintained. In addition, glucose
stimulated insulin secretion, which was abolished by the
HFD, was restored by XOMA 052 treatment. b-Cell sur-
vival was also significantly improved. This therapeutic
study design, rather than previously described prophylac-
tic studies (where the HFD was started concomitantly with
the drugs), better reflects the situation of an overweight
patient with progressing T2DM.
After 19 wk of diet, b-cell apoptosis was increased
from 0.15% with ND to 0.7% with HFD. These data are
comparable with b-cell apoptosis in humans published
by Butler et al. (33) using a large collection of autopsy
pancreata from nondiabetic control individuals and pa-
tients with T2DM. In general, numbers of apoptotic cells
are low due to the rapid clearance by macrophages within
5–10 min in vivo. Therefore, in situ apoptosis data are
difficult to extrapolate to the in vivo situation. In a pre-
vious study, we were unable to show significant changes in
apoptosis in vivo after 12 wk of diet (23). The fact that we
measured a significant increase in apoptosis in each pan-
creas, which was prevented by XOMA 052 treatment, led
us to the assumption that there is indeed an effect on b-cell
survival by long-term HFD diet, especially over 19 wk.
One important mechanism to adapt to conditions of
higher insulin demand (e.g. due to obesity-induced insulin
resistance) is the extraordinary capacity of the b-cell to
increase its mass to maintain normoglycemia (33). This
adaptive capacity was observed in the present study,
where HFD feeding increased b-cell mass after 12 wk,
although we had observed impaired b-cell turnover at this
time point, consistent with our previous studies (23, 34).
After 19 wk of diet, we observed that the compensatory
capacity of the b-cell could not be maintained in the un-
treated control group but was rescued in the XOMA 052-
treated mice, with those animals also showing increased
b-cell proliferation, decreased apoptosis, and increased
b-cell mass relative to control animals.
The lipid-lowering effects of XOMA 052 in both pro-
phylactic and therapeutic studies are interesting in light of
thepotential cardiovascular risks of currentdiabetesdrugs
(35). Recent reports have highlighted the role of inflamma-
tion, and IL-1b itself, in atherosclerosis and congestive heart
failure (36,37).Wearecurrentlyexploring thepotentialben-
efit of inhibiting IL-1b with XOMA 052 in animal models of
atherosclerosis. In addition, the ability of XOMA 052 to
improvethe lipidprofilealsosuggests that theantibodycould
reduce peripheral insulin resistance (38).
An effect of IL-1b on the insulin sensitivity of adipo-
cytes has been suggested by observations of its effects on
insulin signaling in such cells in vitro (39), as well as
through its established role as an inducer of IL-6 (40).
However, the effect of IL-1Ra on insulin sensitivity has
been debated because increased IL-1Ra serum levels have
been shown in some studies to correlate with obesity and
insulin resistance (41–45). Nevertheless, in a previous
study in DIO mice, daily recombinant IL-1Ra injections
for 12 wk did not impair insulin sensitivity as assessed by
ipITT. Moreover, basal insulin levels, which were in-
creased by the HFD due to insulin resistance, could be
maintained at normal levels in the IL-1Ra-treated group
(23). Recent results from the Whitehall Study show that
endogenous IL-1Ra levels are increased before the onset of
T2DM (46), which is consistent with findings in mice fed
with a HFD. With the progression of diabetes, endogenous
IL-1Ra has been shown to decrease in parallel with the
development of hyperglycemia and decreased b-cell mass
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in mice (34). Lower levels of endogenous IL-1Ra were also
measured in patients with T2DM (47).
Given the protective effect of XOMA 052 on both im-
proved b-cell function and lipid profile, there are ques-
tions regarding what tissue is primarily affected by IL-1b
blockade and what cells produce IL-1b under diabeto-
genic conditions. Intraislet IL-1b expression inT2DMwas
found in our earlier study (18). In line with this previous
observation, recent data from b-cells derived through laser
microdissection show increased IL-1b in T2DM (21),
which has also been confirmed by Igoillo-Esteve et al. (48).
However, the major role of IL-1b in the pathogenesis of
T2DM is so far not completely established. Infiltration of
macrophages in adipose tissue has been found in obesity in
mice and humans. This is linked to the development of
insulin resistance (49, 50) and involves the production of
inflammatory cytokines, among them IL-1b. Recently,
IL-1b production in response to obesity was also observed
in the hypothalamus and was connected to an inflamma-
tory response and insulin resistance (51). We therefore
investigated the possibility that blocking IL-1b may in-
hibit the increase in IL-1b in the tissues where diabetes-
induced IL-1b production has been shown. In all the tested
tissues, the hypothalamus, the epididymal fat pads, as well
as in isolated pancreatic islets, we found IL-1b mRNA
present in the HFD-fed mice. In contrast, XOMA 052
significantly inhibited IL-1b gene expression in all three
tissues. These data confirm the well-known phenomenon
of IL-1b to induce its own expression (52, 53), which has
recently been shown in b-cells (10). Importantly, IL-1b
stimulates pro-IL-1b mRNA in human islet cultures,
which is completely blocked by XOMA 052 or IL-1Ra
(10). Thus, IL-1b treatment of human islets results in
IL-1b autostimulation, which is inhibited by IL-1b block-
ade. Similarly, we show here that the increase in IL-1b
mRNA induced by the HFD did not occur in mice where
IL-1b was blocked by XOMA 052. These data indicate
that a cycle of increased IL-1b expression in IL-1b-ex-
pressing tissue can be blocked by XOMA 052, and thus
provide a possible mechanism of XOMA 052-induced
protection from the establishment of severe impairment of
insulin action and insulin secretion. Although we have not
investigated the cellular source of IL-1b production in the
isolated islets, we believe that the production of IL-1b in
the insulin target tissue plays an important role in the
interorgan network with the b-cell.
The work presented here provides the first proof in
animals that IL-1b inhibition is effective in T2DM even
after disease onset, suggesting that antibody therapy may
be successful at treating many aspects of T2DM. The
present DIO model of HFD-treated mouse, although a
standard for metabolic research, has a distinct pathogen-
esis from diabetes pathophysiology in humans. Therefore,
results from clinical trials using XOMA 052 will help in
understanding whether regulating IL-1b is an effective
therapy for T2DM. In favor of our data, early results from
a phase I clinical trial of XOMA 052 show an overall
reduction in HbA1c and an increase in stimulated insulin
secretion for at least 3 months in T2DM patients with
established disease and who have received a single dose of
XOMA 052 (54).
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The ability of the ?-cells to control blood glucose levels depends on their 
function and mass. In both, type 1 and 
type 2 diabetes mellitus the main processes 
leading to ?-cell failure are apoptosis and 
loss of function.
Many studies demonstrate how cytok-
ines and chemokines have an active role in 
triggering the immune-response against 
the ?-cell population. In a recent study 
we have identified that the chemokine 
CXCL10 may play an active role in trig-
gering ?-cell destruction.
We have identified the Toll like recep-
tor 4 as the receptor for CXCL10 and as 
new pathway for the induction of ?-cell 
apoptosis. Our findings may open new 
therapeutic approaches to fight onset and 
progression of the disease. 
As evidenced by numerous studies 
from human pancreata and mouse mod-
els, ?-cell apoptosis is the main process 
leading to ?-cell mass depletion.1,2
Apoptosis in type 1 diabetes (T1DM) 
is triggered by an auto-immune reaction; 
the interaction between antigen present-
ing cells and T-cells leads to prolonged 
presence in high intra-islet concentra-
tions of inflammatory mediators: cytok-
ines, chemokines, reactive oxygen species 
(ROS) and other death effectors, which all 
lead to specific destruction of the ?-cells 
and disease development.3-5
Similarly, T2DM is characterized by 
the presence of immune cell infiltration,6 
toxic amyloid oligomer deposition,7,8 ele-
vated levels of cytokines in the serum as 
well as inside the pancreatic islets,9 and 
apoptotic ?-cells, leading to the decrease 
of ?-cell mass and disease progression.
Hyperglycemia and hyperlipidemia, 
so called “lipoglucotoxicity” then initi-
ates a vicious cycle in ?-cell destruction.10 
Through the accumulation of oxidative 
protein folding, elevated ER stress mark-
ers are present in diabetes,11 however, it 
remains to be clarified whether ER stress 
is causative for ?-cell failure.12,13 The 
constant activation of sub-clinical levels 
of pro-inflammatory cytokines can lead 
to the expression of high levels of several 
markers involved in the acute immune 
response such as CRP, IL-1?, TNF?, 
IL-8, MCP-1,14 and to disease develop-
ment through activation of the classical 
apoptotic machinery including activa-
tion of caspases and c-jun terminal kinase 
(JNK).15
Besides that, acute or chronic viral 
infection can be a contributing factor to 
T1DM and T2DM through the activation 
of the inflammatory cascade,16 specifi-
cally, viral infection causes high levels of 
one member of the chemokine family, the 
Interferon-?-inducible protein (IP-10),17 
also known as chemokine (C-X-C motif) 
ligand 10 (CXCL10).
Increased CXCL10 serum levels have 
been found present in both T1DM18,19 
and T2DM patients20 as well as in patients 
with high risk to develop T1DM18 and 
T2DM.21 It acts as a potent chemo-attrac-
tant for mononuclear cells, T-cells, B-cells 
and NK-cells. Particularly, the production 
of the chemokine CXCL10 is present prior 
to the onset or at least at an early stage of 
the disease development.22,23
In our recent study we point out that 
CXCL10 is able by itself to trigger apop-
tosis in isolated human islets. Detailed 
analysis of CXCL10-induced apoptosis in 
CXCL10
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activity by its natural receptor CXCR3.38-
40 In our study we demonstrate that the 
pro-apoptotic CXCL10 effect is CXCR3-
independent.24 Instead, Toll like receptor 
4 (TLR4) signaling mediated such pro-
apoptotic machinery (Fig. 1).
TLR 4 signaling is able to trigger the 
expression of JNK.41 Given that, CXCL10 
activates JNK, induces caspase 3 cleavage 
which in turn cleaves the protein activated 
kinase 2 PAK-2 and ends in reversing the 
Akt signal from proliferation to apoptosis 
(Fig. 1).
JNK activation could have a different 
starting point, either via a direct or indi-
rect activation by TLR4,41 or through a 
crosstalk with PI3K/Akt.42 CXCL10 may 
give the initial burst and triggers a down-
stream activation of the apoptotic signal 
that involves both PI3K/Akt and JNK 
pathways (Fig. 1).
with aging.33,34 Nevertheless, the impor-
tant capacity to adapt insulin secretion to 
the metabolic demand through increasing 
?-cell mass is maintained at older age.1,35 
Logically, this could be achieved by ?-cell 
replication, which was observed in human 
?-cells in obesity1 and pregnancy,36 but to 
a much lesser extend than in rodents.31
Given that the switch from ?-cell 
proliferation and adaptation to apoptosis 
and ?-cell failure may occur as a general 
mechanism in diabetes progression, we 
further investigated CXCL10 signaling 
as a model for such deleterious activity 
in ?-cells. One signal which is essential 
for ?-cell survival is the PI3K/Akt path-
way.37 Despite the pre-apoptotic effect of 
CXCL10, Akt is highly and prolonged 
activated. Why does apoptosis occur in 
the presence of such protective factor? It 
is well established that CXCL10 exerts its 
islets identified apoptotic cells frequently 
in doublets, which suggests that proliferat-
ing cells are vulnerable to apoptosis.24 This 
observation is in line with earlier studies 
from diabetic mouse models.25-27
In obese state, there is an increase in 
?-cell mass due to replication of already 
existing ?-cells.28 Mice fed a high fat diet 
adapt to the higher insulin demand by 
increasing their functional ?-cell mass 
due to ?-cell hyperplasia rather than 
hypertrophy.28 Also, ?-cell replication is 
the primary mechanism for maintaining 
postnatal ?-cell mass shown in mice29 as 
well as in humans.30 ?-cell replication 
rapidly decreases with age, shown in mice 
at the age of around 6 months31 and in 
humans as early as at the age of ~1 year30 
and further decreases to almost undetect-
able levels.1,32 The capacity of the ?-cell to 
adapt to a higher insulin demand declines 
Figure 1. Our hypothetical model how CXCL10 signaling and production leads to ?-cell apoptosis. Binding of CXCL10 to TLR4, TNF? to TNFR1, 
IFN? to IFNyR1 result in their own gene upregulation. FFA may enhance such proinflammatory target gene production. Expression and secretion of 
CXCL10, IFN? and TNF? lead to a feedback signaling ending in an ampligied self induction and apoptosis. We hypothesize that binding of CXCL10 on 
TLR4 results in MyD88-dependent activation of P13K and AKT followed by a possible crosstalk between JNK and AKT. Activated JNK leads to cleav-
age of Caspase 3 and cleavage of PAK2 ending in a switch from survival of ?-cell apoptosis.
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pathways with IL-1? signaling.53 Similar 
to our study, IL-1? expression has been 
found in islets from patients with T2DM.54 
Antagonizing IL-1? signaling by the nat-
urally occurring interleukin-1receptor 
antagonist (IL-1Ra) showed that IL-1Ra 
treatment could improve ?-cell function 
in patients with T2DM in a recent trial55 
and improved glycemia and ?-cell survival 
in mouse models of T1DM & T2DM.56-62 
It is therefore possible that the use of neu-
tralizing antibodies to CXCL10 alone or 
in combination with antagonizing IL-1?63 
provides a potent new strategy for the 
therapy of T1DM and T2DM to rescue 
the ?-cell.
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